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A Toxicological Profile for Cresols, Draft for Public Comment was released in October 2006.  This
edition supersedes any previously released draft or final profile.  
Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at:
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
 
















































    




   





   








This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the hazardous substance described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a hazardous substance’s toxicologic properties.  Other pertinent
literature is also presented, but is described in less detail than the key studies.  The profile is not intended 
to be an exhaustive document; however, more comprehensive sources of specialty information are 
referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile
begins with a public health statement that describes, in nontechnical language, a substance’s relevant
toxicological properties.  Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance’s health effects is described in a health effects summary.  Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance 
is available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or 
levels of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and 
local levels; interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed.  Staff of the Centers for Disease Control and Prevention and other Federal scientists have 





























   
 
   








and was made available for public review.  Final responsibility for the contents and views expressed in 
this toxicological profile resides with ATSDR.
Howard Frumkin M.D., Dr.P.H. Julie Louise Gerberding, M.D., M.P.H.
Director Administrator
National Center for Environmental Health/ Agency for Toxic Substances and
Agency for Toxic Substances and Disease Registry
Disease Registry
*Legislative Background
The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization 
Act (SARA) of 1986 (Public Law 99 499) which amended the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980 (CERCLA or Superfund).  This public law directed ATSDR to 
prepare toxicological profiles for hazardous substances most commonly found at facilities on the
CERCLA National Priorities List and that pose the most significant potential threat to human health, as
determined by ATSDR and the EPA.  The availability of the revised priority list of 275 hazardous 
substances was announced in the Federal Register on December 7, 2005 (70 FR 72840).  For prior
versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866);
October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17,1990 (55 FR 42067);
October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); February 28, 1994 (59 FR 9486);
April 29, 1996 (61 FR 18744); November 17, 1997 (62 FR 61332); October 21, 1999(64 FR 56792);
October 25, 2001 (66 FR 54014) and November 7, 2003 (68 FR 63098).  Section 104(i)(3) of CERCLA, 














   
 






     
  















   
    
   
   
 
 
   




           






   




QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
 
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
 
Section 3.7 Children’s Susceptibility
 
Section 6.6 Exposures of Children
 
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure
history is provided.  Other case studies of interest include Reproductive and Developmental
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide











   
 
   














   

















   
   
 
   
viiiCRESOLS
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk




























































Syracuse Research Corporation, North Syracuse, New York
 
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1.	 Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2.	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs.
3.	 Data Needs Review.  The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance.













































   
     
   
 
 




A peer review panel was assembled for cresols.  The panel consisted of the following members:
1.	 David Kalman, Ph.D., Chair and Professor, Department of Environmental and Occupational
Health Sciences, University of Washington, Health Sciences Building, F-463, Seattle,
Washington;
2.	 John R. Balmes, M.D., Professor, Pulmonary and Critical Care Division, University of California
San Francisco, San Francisco General Hospital, San Francisco, California; and
3.	 Rolf Hartung, Ph.D., DABT, Consultant in Environmental Toxicology, Professor of
Environmental Toxicology (Retired), University of Michigan, 3125 Fernwood Avenue, Ann 
Arbor, Michigan.
These experts collectively have knowledge of cresol's physical and chemical properties, toxicokinetics,
key health end points, mechanisms of action, human and animal exposure, and quantification of risk to 
humans.  All reviewers were selected in conformity with the conditions for peer review specified in 
Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as
amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
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1.  PUBLIC HEALTH STATEMENT 
 
This public health statement tells you about cresols and the effects of exposure to these substances. 
 
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation.  These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities.  o-Cresol, m-cresol, p-cresol, and mixed cresols have been identified in at least 
210, 22, 310, and 70 of the 1,678 current or former NPL sites, respectively.  Although the total number of 
NPL sites evaluated for these substances is not known, the possibility exists that the number of sites at 
which cresols are found may increase in the future as more sites are evaluated.  This information is 
important because these sites may be sources of exposure, and exposure to these substances may be 
harmful. 
 
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  Such a release does not always lead to exposure.  You 
can be exposed to a substance only when you come in contact with it.  You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact. 
 
If you are exposed to cresols, many factors will determine whether you will be harmed.  These factors 
include the dose (how much), the duration (how long), and how you come in contact with it.  You must 
also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and 
state of health. 
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1.1   WHAT ARE CRESOLS? 
 
Description  Three types (or isomers) of cresols exist: ortho-cresol, meta -cresol, and 
para-cresol; abbreviated as o-cresol, m-cresol, and p-cresol.  
 
Pure cresols are solid, while mixtures tend to be liquid. 
 
Cresols have a medicinal smell. 
 
Uses 





 • Consumer 
products 
 
Cresols are both manufactured chemicals and natural components in many 
foods.  Large amounts of cresols are produced in the United States. 
 
Cresols are used to manufacture other chemicals and as solvents. 
 
Cresols kill microorganisms and are added to soaps as disinfectants. 
 
 
For more information on the physical and chemical properties of cresols, and their production, disposal 
and use, see Chapters 4 and 5. 
 
1.2   WHAT HAPPENS TO CRESOLS WHEN THEY ENTER THE ENVIRONMENT? 
 
Sources  Cresols are released to the environment during the burning of wood, coal, 





 • Air 
 
 
 • Water 
 
 • Soil 
 
 
Cresols are quickly broken down in the air, usually within 1–2 days.  They can 
also be removed from the air by rain. 
 
Cresols in water are degraded within days by microorganisms. 
 
Cresols are degraded rapidly in soil by microorganisms, but a portion may 
move into groundwater. 
 
 
For more information on cresols in the environment, see Chapter 6. 
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The primary way you can be exposed to cresols is by breathing air 
containing them.  Releases of cresols into the air occur from:  
 • industries using or manufacturing cresols 
 • automobile exhaust 
 • cigarette smoke 
 • wood and trash burning 
 
A national emissions study conducted from 1990 to 1998 reported an 
average county-level concentration of 31.7 nanograms per cubic meter 
(ng/m3) for all cresol isomers combined. 
 
Water Cresols have been detected in surface waters and groundwater, but 
generally at low levels (approximately 1 microgram per liter [µg/L] or less). 
 
Higher levels have been detected: 
 • where petroleum spills have occurred 
 • near hazardous waste sites 
 • in industrial effluents 
 
Workplace A large number of workers are potentially exposed to cresols.  Potential 
exposures occur in: 
 • manufacture of cresols 
 • chemical laboratories 
 • coal gasification facilities 
 • paint and varnish application 
 • application of insulation lacquers to copper wires 
 • wood-preserving facilities 
 
Exposure may occur through breathing and dermal contact with 
contaminated air and/or liquid cresols or products containing cresols. 
 
Food Low levels of cresols have been found in some foods such as tomatoes, 
tomato ketchup, asparagus, cheeses, butter, bacon, and smoked foods. 
 
Some drinks also contain cresols (coffee, black tea, wine, Scotch whisky, 




Exposure may occur through accidental or intentional ingestion or contact of 
the skin with cleaners or disinfectants containing cresols.   
 
 
For more information on human exposure to cresols, see Chapter 6. 
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1.4   HOW CAN CRESOLS ENTER AND LEAVE MY BODY? 
 
Enter your body  




 • Ingestion 
 
 
 • Dermal contact 
 
There is no information to determine whether cresols can enter the 
bloodstream through your lungs if you breathe air contaminated with these 
substances.   
 
Cresols in food or water may rapidly enter your body through the digestive 
tract.   
 
Cresols may enter through your skin when you come into contact with 
liquids containing cresols. 
 
Leave your body  Once in your body, cresols are transformed into other chemicals called 
metabolites.  Most of these metabolites leave your body in the urine within 
1 day.   
 
 
For more information on how cresols enter and leave the body, see Chapter 3. 
 
1.5   HOW CAN CRESOLS AFFECT MY HEALTH? 
 
This section looks at studies concerning potential health effects in animal and human studies.  
 
Humans 
 • Inhalation 
 
 • Oral 
 
 
 • Dermal 
 
Brief exposures to 6 mg/m3 o-cresol in the air caused nose and throat irritation. 
 
Ingestion of liquid products containing cresols can cause serious 
gastrointestinal damage and even death. 
 
Application of concentrated cresols to the skin can cause severe skin damage 
and even death. 
Laboratory 
animals  
 • Inhalation 
 







 • Dermal 
 
Short-term exposure to cresols in air has caused irritation of the respiratory 
tract and muscle twitching. 
 
 
Placing cresols in the stomach of animals by means of a feeding tube has 
caused muscle twitching and loss of coordination. 
 
Eating food contaminated mostly with p-cresol or with a mixture of m- and 
p-cresol for 28 days or longer has caused lesions inside the nose of rats and 
mice; mice also developed lesions in the lungs and in the thyroid gland. 
 
Short-term application of cresols to the skin of animals has produced skin 
irritation. 
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Cancer The EPA has determined that cresols are possible human carcinogens.  The 
International Agency for Research on Cancer (IARC) has not classified cresols 
as to their carcinogenicity. 
 
 
Further information on the health effects of cresols in humans and animals can be found in 
Chapters 2 and 3. 
 
1.6   HOW CAN CRESOLS AFFECT CHILDREN? 
 
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age. 
 
Effects in children  There are no studies of children exposed to cresols, but it is expected that 
children exposed to cresols will suffer the same effects observed in exposed 
adults. 
 
There is a report of a baby who suffered serious damage to the skin, liver, 
and kidneys, went into a coma, and eventually died 4 hours after liquid 
cresol was accidentally spilled on his head. 
 
Birth defects Fetal toxicity and birth defects have been reported in animals given cresols. 




There is no information on levels of cresols in breast milk. 
 
1.7   HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO CRESOLS? 
 
Tobacco smoke Cresols are components of tobacco smoke.  Avoid smoking in enclosed 
spaces like inside the home or car in order to limit exposure to children and 




Household cleaners and disinfectants containing cresols should be stored 
out of the reach of young children to prevent accidental poisonings and skin 
burns and follow manufacturer’s directions on the label. 
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Cresols can be measured in blood and urine.  Cresols are normal 




A higher-than-normal concentration of cresols in the urine may suggest 
recent exposure to these substances or to substances that are converted to 
cresols in the body. 
 
The detection of cresol and/or its metabolites in your urine cannot be used 
to predict the kind of health effects that might develop from that exposure.  
 
 
Information about tests for detecting cresols in the body is given in Chapters 3 and 7. 
 
1.9   WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
 
The federal government develops regulations and recommendations to protect public health.  Regulations 
can be enforced by law.  The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances.  Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law.  The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances. 
 
Regulations and recommendations can be expressed as “not-to-exceed” levels.  These are levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value.  This critical value is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans.  Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors. 
 
Recommendations and regulations are also updated periodically as more information becomes available.  
For the most current information, check with the federal agency or organization that provides it. 
 
CRESOLS  7 
 








Some regulations and recommendations for cresols include the following: 
 
Drinking water  EPA has not established drinking water standards and health advisories for 
cresols.  
 
Workplace air OSHA set a legal limit of 5 parts per million (ppm) cresols (all isomers) in air 
averaged over an 8-hour work day. 
 
 
For more information on regulations and advisories, see Chapter 8. 
 
1.10   WHERE CAN I GET MORE INFORMATION? 
 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
 
ATSDR can also tell you the location of occupational and environmental health clinics.  These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances. 
 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You may 
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical 
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to:  
 
  Agency for Toxic Substances and Disease Registry 
  Division of Toxicology and Environmental Medicine 
  1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
 
Organizations for-profit may request copies of final Toxicological Profiles from the following: 
 
  National Technical Information Service (NTIS) 
  5285 Port Royal Road 
  Springfield, VA 22161 
  Phone: 1-800-553-6847 or 1-703-605-6000 
  Web site: http://www.ntis.gov/ 
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9CRESOLS
2. RELEVANCE TO PUBLIC HEALTH
 
2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO CRESOLS IN THE UNITED 
STATES 
Cresols are widely distributed in the environment and the general population may be exposed to low
levels of cresols mainly through the inhalation of contaminated air.  Cresols are readily degraded in the
atmosphere; atmospheric concentrations outside of source-dominated areas are typically low.  Since
cresols are released via automobile exhaust, areas of high traffic and gas stations are likely to have 
increased atmospheric levels of cresols.  Cresols are also the product of combustion of coal, wood, and 
municipal solid waste; therefore, residents near coal and petroleum fueled facilities, as well as residents 
near municipal waste incinerators, may have increased exposure to cresols.  There are limited air
monitoring data for cresols; a median concentration of 1.5 μg/m3 o-cresol was detected in air samples 
from 3 locations, the range of p-cresol at 11 locations was 0.5–20 μg/m3, and m-cresol was not detected in 
air samples from 2 locations.  A national emissions study conducted from 1990 to 1998 reported a
county-level estimated ambient average concentration of 31.7 ng/m3 for all cresol isomers combined.
Cresol levels in soil and water are usually low.  When detected in surface water, cresol levels are typically
around 1 μg/L or less.  Higher levels are occasionally observed in groundwater or surface water where
petroleum spills have occurred or near hazardous waste sites.  In a study of public groundwater at
superfund sites, o-cresol and p-cresol were detected at maximum concentrations of 390 and 150 μg/L, 
respectively; however, neither was detected in well fields or finished water from treatment plants (no data 
were provided for m-cresol).  Due to their relatively rapid rate of biodegradation, cresols are only
occasionally detected in soils, primarily in areas where petroleum products were spilled or produced.  
o-Cresol was detected at maximum concentrations of 12,000–34,000 µg/kg in soil samples obtained from
an abandoned pine tar manufacturing plant in Gainesville, Florida.  
Employees in occupations that routinely involve the combustion of coal or wood may be exposed to 
higher levels of cresols than the general population.  Environmental tobacco smoke is also a source of
cresol exposure.  Depending on the brand and type of cigarette, the average cresol concentration in a
45 cubic meter chamber after six cigarettes had been smoked ranged from 0.17 to 3.9 μg/m3.
Although low levels of cresol have been detected in certain foods and tap water, these do not constitute
major sources of exposure for most people.  Cresols have been reported in tea leaves, tomatoes, and 
ketchup as well as butter, oil, and various cheeses, but levels are not available.  People with contaminated 
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tap water can be exposed from drinking the water or eating foods prepared with it.  In addition, inhalation 
can occur from volatilized cresol during showering, bathing, and cooking activities with contaminated 
water.  Dermal exposure to cresols may also occur due to bathing or showering with contaminated water.
Exposure to children occurs by the same routes that affect adults.  There are no known specific sources of 
exposure to children.  Cresol has not been reported in breast milk or baby foods.  Children are likely to be
exposed to cresols through inhalation of contaminated air from automobile exhaust, waste incineration, 
and second-hand smoke.  
2.2  SUMMARY OF HEALTH EFFECTS 
Information about the effects of cresols in humans is derived mainly from case reports of accidental or
intentional ingestion of cresol solutions or from accidental contact of cresol with the skin.  Cresols
produce corrosive damage at sites of contact; therefore, the skin and mucosal membranes are targets for
cresols toxicity.  In a single study of controlled exposures in volunteers, brief exposures to 6 mg/m3 
o-cresol caused 8 out of 10 subjects to complain of respiratory irritation.  Fatalities due to ingestion and
dermal exposure to cresols have been described.  Other effects reported in these acute high oral and/or
dermal exposure scenarios include respiratory failure, tachycardia and ventricular fibrillation, abdominal
pain, vomiting, and corrosive lesions of the gastrointestinal tract, methemoglobinemia, leukocytosis and 
hemolysis, hepatocellular injury, renal alterations, skin damage, metabolic acidosis, and unconsciousness.  
Many of these effects may not have been caused directly by cresols, but may be a result of secondary
reactions to shock caused by external and internal burns. 
Inhalation or dermal exposure of animals to cresols has produced irritation and corrosion at the site of
contact.  Animals exposed acutely to cresol vapors and aerosols showed signs of respiratory irritation, 
although the levels associated with irritation have not been reliably documented.  Inflammation and 
irritation of the upper respiratory tract, pulmonary edema, and hemorrhage and perivascular sclerosis in 
the lungs were seen in a variety of animal species exposed intermittently to 9–50 mg/m3 of o-cresol for 
≥1 month; other isomers were not tested.  White mice exposed acutely to commercial mixtures of cresol
isomers exhibited irritation and inflammation of the eyes and nose.  Also noticed in these inhalation 
studies were effects on the nervous system (excitation, fatigue, convulsions).  Animals that died had fatty
degeneration and necrosis of the liver, degeneration of the tubular epithelium in the kidneys, bronchitis,
pulmonary hemorrhage, and dystrophic changes in the heart and in nerve cells and glia in the brain.  All
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three cresol isomers, either alone or in combination, severely irritated the skin of rabbits, producing
visible and irreversible tissue destruction.  
From a limited number of intermediate oral studies, nasal epithelial lesions appear to be a particularly
sensitive target for cresols’ toxicity.  Dietary exposure of rats and mice to p-cresol or to a mixture of
m/p-cresol (58.5% m-cresol, 40.9% p-cresol) for 28 days or 13 weeks induced dose-related alterations in
the nasal respiratory epithelium at doses of 95 mg/kg/day and higher.  The severity of the lesions also was 
dose-related.  The lesions were located at the most anterior portions of the nasal septum, dorsal arch, and
medial aspect of the nasal turbinates.  No such lesions were seen with o- or m-cresol in the 28-day study
or with o-cresol in the 13-week study (neither m-cresol nor p-cresol alone were tested in the 13-week
study).  Nasal lesions were also observed in male rats and female mice exposed to a mixture of m/p-cresol
in the feed for 2 years; the results suggested that the lesions already had developed by week 13 and did 
not increase in severity during the remainder of the dosing period.  Intermediate-duration oral gavage
studies and two multi-generation reproductive dietary studies in mice did not examine the nasal
respiratory epithelium of the animals.  It is also relevant to note that in the inhalation studies discussed
above, there is no specific mention of evaluation of the nasal cavity.  Additional studies may be necessary 
to rule out the possibility that the nasal lesions are due to direct contact of cresol with the nasal epithelium
(see Section 2.3 for a more detailed discussion on this particular issue). 
The nervous system also appears to be a sensitive target of cresols toxicity in oral studies, although this
seems to be limited to oral gavage studies.  Rodents administered cresols by oral gavage for acute or
intermediate durations showed neurological signs such as hypoactivity, excessive salivation, labored 
respiration, and tremors, in addition to decreased body weight gain.  Some neurological signs were
observed in rats dosed by gavage with as low as 50 mg/kg/day of cresol isomers.  None of these effects 
have been seen in dietary studies, or if seen, they have occurred at much higher dose levels than in oral
gavage studies.  The reason for this difference is unknown, but it probably is related to toxicokinetic
differences between the two modes of oral dosing.
Dietary exposure to higher doses of cresols, generally >240 mg/kg/day, caused increases in liver weight;
thresholds for these changes in liver weight were comparable among cresol isomers.  Kidney weight was 
only increased in rats dosed with ≥861 mg/kg/day o-cresol for 28 days.  Clinical chemistry tests gave no 
indication of altered function in these organs and no gross and microscopic alterations were seen, even at
the highest doses administered (>1,000 mg/kg/day).  Other systemic effects observed in rats and mice 
treated with relatively high doses of cresols (>1,000 mg/kg/day) in the diet for 13 weeks included 
   
 









   
 
  
   
   
   
   
  
   
 
 
   
     
   
  
 






    
   








2. RELEVANCE TO PUBLIC HEALTH
decreased weight gain (all isomers).  A 2-year study also provided evidence of kidney toxicity in rats
(720 mg/kg/day m/p-cresol) and thyroid gland toxicity in mice (≥100 mg/kg/day m/p-cresol).
Reproductive effects of cresols isomers administered to rats and mice in the diet were limited to mild to 
moderate uterine atrophy and lengthening of the estrous cycle, generally at the highest dose levels tested 
(>2,000 mg/kg/day).  Dietary multi-generation studies in mice with o-cresol and m/p-cresol found no 
significant effects with o-cresol; m/p-cresol at the highest level tested (1,682 mg/kg/day) caused minor
maternal toxicity (reduced body weight gain), decreased number of pups/litter, and increased cumulative
days to litter (delay in producing additional F1 offspring).  Developmental studies that treated rats and 
rabbits by oral gavage during gestation observed fetal effects (skeletal variations and delayed ossification)
at dose levels that also caused maternal toxicity.
A 2-year bioassay found equivocal evidence of carcinogenetic activity of m/p-cresol (60%/40%) in male
Fischer-344 rats based on a nonsignificant increase in the incidence of renal tubule adenoma.  The same
study found some evidence of carcinogenetic activity in female B6C3F1 mice based on an increased 
incidence of forestomach squamous cell papilloma.  Cresols gave indications of promotion potential in a
dermal skin promotion assay; p-cresol was the least potent isomer, o-cresol was approximately 3 times 
more potent than p-cresol, and m-cresol was in between. The EPA has determined that cresols are 
possible human carcinogens (Group C) based on inadequate data in humans and limited data in animals
(the assessment is dated 10/89).  According to EPA’s updated criteria for classifying chemicals, cresols
fall in the category of chemicals for which there is “inadequate information to assess carcinogenic
potential.” 
The database in animals is insufficient to propose a toxicity ranking for cresol isomers, even though 
p-cresol seemed to be the most potent for induction of the critical effect, nasal respiratory lesions, in rats 
and mice in the National Toxicology Program (NTP) study.  The human database is inadequate to propose
a toxicity ranking for cresol isomers.
2.3  MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for cresols.  An 
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure.  MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
   
 








    
   











   
   
    
    
 
    
   
  
 
    




2. RELEVANCE TO PUBLIC HEALTH
health effect(s) for a specific duration within a given route of exposure.  MRLs are based on 
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs
The available health effects data for humans or animals exposed to cresols by inhalation are inadequate to 
establish concentration-response relationships, which are needed to identify adverse effects levels.  
Therefore, inhalation MRLs were not derived for cresols.  In an experiment in humans, brief exposures to 
6 mg/m3 o-cresol caused 8 out of 10 subjects to complain of respiratory irritation (Uzhdavini et al. 1972).  
No information was provided on how the cresol vapor was generated or sampled.  Two animal studies
were available in which exposure involved mixtures of vapors and aerosols that provided insufficient
information to reliable estimate exposure levels (Campbell 1941; Uzhdavini et al. 1972).  o-Cresol (9– 
50 mg/m3) was tested in the studies of Uzhdavini et al. (1972) in a variety of species, whereas Campbell
(1941) tested commercial mixtures of cresol isomers in white mice.  These studies provided data on 
lethality, as well as information on effects on the respiratory system (irritation, inflammation, edema, 
hemorrhage), and nervous system (excitation, fatigue, convulsions).  Animals that died had fatty
degeneration and necrosis of the liver, degeneration of the tubular epithelium in the kidneys, bronchitis, 
pulmonary hemorrhage, and dystrophic changes in the heart and in nerve cells and glia in the brain.
Because of limitations in study design (mainly in the methodology for generating and monitoring the
vapor concentrations) and reporting, these studies are not useful for risk assessment.
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Oral MRLs
As mentioned in Section 2.2, effects of cresol administered by oral gavage are markedly different than 
those observed in dietary studies.  Administration of cresols by oral gavage to animals results in lowest­
observed-adverse-effect levels (LOAELs) much lower than LOAELs defined in dietary studies.  For 
example, LD50 values for undiluted cresols in rats ranged from 121 to 242 mg/kg/day (EI du Pont 1969), 
whereas dietary doses in the range of 1,000–2,000 mg/kg/day for intermediate durations caused little or
no toxicity in rats and mice (NTP 1992b).  Serious neurological effects (i.e., lethargy, tremors, 
convulsions) were seen in rats dosed by oral gavage with doses ranging from 450 to 600 mg/kg/day for
90 days (EPA 1988b, 1988c, 1988d; TRL 1986; Tyl 1988a, 1988b), but no such effects were observed in 
the dietary studies at much higher dose levels (NTP 1992a, 1992b, 1992c, 2008).  The reason for this
difference is not known, but it is most likely related to differences in toxicokinetics between the two
methods of cresol administration.  There are no studies that compared the toxicokinetics of cresols 
following dietary and gavage administration, but there is information for a related chemical, phenol.  
Phenol toxicity following oral gavage dosing is different than following administration in the drinking
water.  In the case of phenol, there are data that suggest that toxicity is correlated with peak blood 
concentration rather than with total dose, such as the area under the blood concentration curve (AUC)
following a single gavage dose or repeated daily doses.  This is consistent with data from Bray et al. 
(1950), who observed that p-cresol was more toxic when given by stomach tube to fasting rabbits than 
when the rabbits were given their daily food 1–2 hours before dosing with p-cresol; the assumption is that
p-cresol became mixed with the food, which delayed its absorption.  Also relevant is a recent study by
Morinaga et al. (2004), which found concentrations of free cresols in liver and spleen from rats given a
single oral gavage dose much higher than in blood at all times after dosing (up to 8 hours).  Based on 
these observations and the fact that an oral gavage exposure protocol does not resemble human 
environmental exposure scenarios to cresols, only dietary studies are considered for MRL derivation, 
even though some LOAELs by gavage are lower than dietary LOAELs.
No acute-duration oral MRL was derived for cresols due to lack of acute dietary exposure studies.
•	 An MRL of 0.1 mg/kg/day has been derived for intermediate-duration oral exposure (15–
 
364 days) to cresols.
 
Almost all of the information available on health effects from intermediate-duration oral exposure is
derived from a comprehensive study in rats and mice administered o-, m-, or p-cresol or a cresol mixture 
of m- and p-cresol for 28 days or 13 weeks (NTP 1992b).  There are also two multigeneration 
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reproductive toxicity studies in mice dosed with o-cresol (NTP 1992a) and a mixture of m- and p-cresol
(NTP 1992c).  In the NTP (1992b) study, rats and mice dosed with p-cresol or an m/p-cresol mixture
showed lesions in the nasal respiratory epithelium.  The nasal lesions occurred in rats dosed with p-cresol
for 28 days (≥770 mg/kg/day), in rats exposed to m/p-cresol for 28 days (≥95 mg/kg/day), in mice
exposed to p-cresol for 28 days (≥163 mg/kg/day), in mice exposed to m/p-cresol for 28 days 
(≥604 mg/kg/day), in rats exposed to m/p-cresol for 13 weeks (≥123 mg/kg/day), and in mice exposed to 
m/p-cresol for 13 weeks (≥472 mg/kg/day).  The lesions were located at the most anterior portions of the
nasal septum, dorsal arch, and medial aspect of the nasal turbinates.  The hyperplasia was characterized 
by increased number of goblet cells and pseudogland formation due to the infolding of the hyperplastic
cells.  The hyperplastic areas were associated with single cell necrosis.  The intermediate-duration oral
gavage studies (EPA 1988b, 1988d) and two multi-generation reproductive dietary studies in mice (NTP
1992a, 1992c) did not examine the nasal respiratory epithelium of the animals.  Small increases in liver
weight were observed in rats and mice at higher doses (≥242 mg/kg/day) in both the 28-day and 13-week
studies; kidney weight was only increased in rats dosed with ≥861 mg/kg/dayo-cresol for 28 days.  
However, the changes in organ weight were not associated with alterations in clinical tests of liver and 
kidney function or gross and microscopic alterations (NTP 1992b).  Decreased weight gain was also 
observed in rats and mice at relatively high doses (>1,000 mg/kg/day).  
In addition to the systemic effects observed in the 28-day and 13-week studies (NTP 1992b), exposure to 
high doses of cresols has resulted in reproductive and developmental effects.  Mild to moderate uterine
atrophy and lengthening of the estrous cycle were generally observed at the highest dose levels tested 
(>2,000 mg/kg/day) for all three isomers.  Exposure of mice to 1,682 mg/kg/day m/p-cresol caused minor
maternal toxicity (reduced body weight gain), decreased number of pups/litter, and increased cumulative
days to litter (delay in producing additional F1 offspring).  These effects were not observed in mice 
exposed to 660 mg/kg/day o-cresol (NTP 1992a).  
Evaluation of the results of the available intermediate-duration dietary studies indicates that the most 
sensitive end point was the nasal respiratory epithelium of rats and mice dosed with p-cresol or a mixture
of m- and p-cresol (NTP 1992b).  The effects occurred in male and female rats and mice dosed for 
28 days or 13 weeks.  The data sets considered for MRL derivation were the 28-day experiment in female 
rats and the 13-week experiment in male rats based on the lowest effect levels identified in both sets, 
95 mg/kg/day in the 28-day experiment and 123 mg/kg/day in the 13-week experiment.  In the 28-day 
study, the incidences of hyperplasia of the nasal respiratory epithelium in female rats dosed with 0, 27, 
95, 268, 886, and 2,570 mg/kg/day of m/p-cresol were 0/5, 0/5, 3/4, 5/5, 5/5, and 5/5, respectively.  In the
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13-week study, the incidences in male rats dosed with 0, 123, 241, 486, 991, and 2,014 mg/kg/day 
m/p-cresol were 0/10, 3/10, 8/10, 10/10, 8/10, and 10/10, respectively.  The latter series is preferred 
because of the longer duration of exposure and because of the increased reliability of a dose-response
curve based on 10 rats per group rather than on only 5 rats per group in the 28-day study.  
An issue that has to be considered is the possibility that the nasal lesions were caused by evaporation of
the cresol from the food (even though cresols have relatively low vapor pressure, particularly p-cresol)
and thus due to direct contact of the airborne chemical with the nasal respiratory epithelium.  The
inhalation database consists of a study by Uzhdavini et al. (1972) who exposed various animal species to 
o-cresol (o-cresol did not induce nasal lesions in the NTP study) for various periods of time.  Acute
exposures of mice produced irritation of mucous membranes and higher concentrations induced 
pulmonary edema and histopathological changes in the lungs.  Repeated exposures of mice also induced 
symptoms of irritation of the respiratory tract, but there is no specific mention of the nasal cavity.  
Exposures of rats and guinea pigs for 4 months produced symptoms of irritation and inflammation in the
upper respiratory tract, local edema, and perivascular sclerosis in the lungs.  Because of limitations in 
study design and reporting, few conclusions can be drawn from the experiments of Uzhdavini et al. 
(1972) other than that o-cresol is a respiratory irritant at the concentrations tested. NTP (1992b)
conducted preliminary studies to assess the stability of the various cresol isomer-feed mixtures and
detected losses due to evaporation from 10 to 12% after storage for 7 days under simulated cage 
conditions.  Therefore, fresh chemical-diet mixtures were supplied twice weekly during the studies.  
Estimating the concentration of cresol in the air from such losses from food is virtually impossible due to 
numerous uncertainties.  The threshold for nasal lesions in rats was about 2,000 mg/kg of m/p-cresol in 
the food.  A loss of 10% per week represents 200 mg of cresol/kg of food per week or about 1.2 mg/kg 
feed per hour.  However, a concentration of cresol in air cannot be estimated because of many unknown 
factors such as volume of distribution, air flow speed, etc.  A somewhat related possibility is that cresol
evaporates inside the mouth of the animal aided by the higher temperature (about 38 °C) and reaches the
nasal cavity from inside the mouth.  There is also the possibility of nasal exposures due to exhalation of
the cresols previously ingested, although there is no indication from toxicokinetics studies that this may
occur.  Until it can be demonstrated with some certainty that the nasal lesions are not caused by a 
systemic effect of cresol and in the interest of protecting humans potentially exposed under similar
conditions, the MRL was based on the increased incidence of the nasal lesions in rats.
In the principal study for the MRL, groups of Fischer 344 rats (20/sex/group) were administered 
m/p-cresol (58.5% m-cresol, 40.9% p-cresol) in the diet at levels of 0, 1,880, 3,750, 7,500, 15,000, or
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30,000 ppm for 13 weeks (NTP 1992b).  The corresponding doses of test compound estimated by the
investigators were 0, 123, 241, 486, 991, and 2,014 mg/kg/day for males and 0, 131, 254, 509, 1,024, and 
2,050 mg/kg/day for females.  End points evaluated included clinical signs, food consumption, organ 
weights, clinical chemistry and hematology, and gross and microscopic appearance of organs and tissues.  
Although the dose groups consisted of 20 rats of each sex, 10 males and 10 females were used for clinical
chemistry, hematology, and urinalysis studies and the remaining 10 rats/sex/group were used in gross
pathology, organ weight, and histopathological studies.  There were no deaths during the study.  Final
body weight in the 2,014/2,050 mg/kg/day males and females was reduced 17 and 12%, respectively, 
relative to controls.  Food consumption was also reduced (about 10%) in this group during the first week
of the study.  Additionally, males and females in this group exhibited rough hair coat; females also had a
thin appearance.  Absolute and relative liver weights were significantly increased (11–12%) in males at
486 mg/kg/day and in females at 1,024 mg/kg/day.  Absolute and relative kidney weight was increased in 
males at 991 mg/kg/day.  In general, hematology findings were unremarkable, although there was a
tendency to hemoconcentration at 2,014/2,050 mg/kg/day early in the study.  Clinical chemistry tests
showed an increase in serum alanine aminotransferase (ALT) in males and females exposed to 
2,014/2,050 mg/kg/day and in sorbitol dehydrogenase (SDH) in males at 2,014 mg/kg/day only on day 5.  
Bile acids in serum were increased in females at 2,050 mg/kg/day on day 90 and at 241 and 
991 mg/kg/day in males also on day 90.  There was no indication of renal injury as judged by the results
of urinalyses.  Significant histopathological changes included minimal bone marrow hypocellularity in 
males and females (likely secondary to decreased weight gain) at 2,014/2,050 mg/kg/day, and increased 
colloid (minimal) in thyroid follicular cells in females at 509 mg/kg/day and in males at 15,000 ppm
(991 mg/kg/day).  An increased dose-related incidence and severity of hyperplasia and glandular
hyperplasia of the nasal respiratory epithelium was observed in male and female rats.  Severity was 
minimal at 123/131 mg/kg/day, mild at 486/509 mg/kg/day, and moderate at 2,014/2,050 mg/kg/day.  The
lesions were located at the most anterior portions of the nasal septum, dorsal arch, and medial aspect of 
the nasal turbinates. The hyperplasia was characterized by increased number of goblet cells and 
pseudogland formation due to the infolding of the hyperplastic cells. The hyperplastic areas were
associated with single cell necrosis.  The incidences in males dosed with 0, 123, 241, 486, 991, and
2,014 mg/kg/day were 0/10, 3/10, 8/10, 10/10, 8/10, and 10/10, respectively.  A similar trend was seen in 
female rats, but 3/10 control females also exhibited hyperplasia (3/10, 1/10, 5/10, 9/10, 8/10, and 10/10 at
0, 131, 254, 509, 1,024, and 2,050 mg/kg/day, respectively).  
Data from the NTP (1992b) were considered adequate for analysis using the benchmark dose approach 
for MRL derivation.  Benchmark dose models in the EPA Benchmark Dose Software (BMDS)
   
 








     
   
    






   
 
     
   
    
   
    
 
    
 
 






   
  
  
    






2. RELEVANCE TO PUBLIC HEALTH
(version 2.0) were fit to the incidence data for nasal lesions in male and female rats exposed to m/p-cresol
in the diet for 13 weeks in order to determine potential points of departure for the MRL (details of the
modeling are presented in Appendix A).  Comparing fits across nine different models, the log-logistic
model was determined to be the best-fitting model for the male rat data set, whereas the quantal linear
model was the best-fitting model for the female rat data set.  Following EPA’s Benchmark Dose 
Guidance (EPA 2000a) to select a point of departure, a benchmark response (BMR) of 10% was selected
for the benchmark analysis of nasal lesion incidence data in the 13-week NTP (1992b) study.  The
benchmark dose (BMD) corresponding to a BMR of 10% extra risk is 55.89 mg/kg/day.  BMDL10s (i.e., 
95% lower confidence limits on the model-estimated dose associated with a 10% extra risk for nasal
lesions) calculated with the best-fitting models for each data set were 13.9 mg/kg/day for males and 
30.8 mg/kg/day for females.  While this difference in benchmark dose may indicate that male rats are 
more sensitive than females, it also can be just a statistical artifact in a rather small sample size, only
10 rats per group. The male rat data set was selected for determining the point of departure for MRL
derivation in order to be public health protective.  Applying an uncertainty factor of 100 (10 for
extrapolation from animals to humans and 10 for human variability) to the BMDL10 of 13.9 mg/kg/day
yields an intermediate-duration oral MRL of 0.1 mg/kg/day for m/p-cresol.
•	 An MRL of 0.1 mg/kg/day has been derived for chronic-duration oral exposure (365 days or
more) to cresols.
The only chronic-duration dietary study with cresols is the NTP (2008) toxicology and carcinogenesis
studies in male Fischer-344/N rats and female B6C3F1 mice.  Although the report has not yet been 
finalized by the NTP, a draft technical report has been reviewed by the NTP Board of Scientific
Counselors Technical Reports Review Subcommittee, and a draft abstract, pathology tables, and survival
and growth curves are available on the NTP web site.  In the study, the male Fischer-344/N rats were fed
diets that provided mean time-weighted average (TWA) doses of m/p-cresol of approximately 0, 70, 
230, or 720 mg/kg/day for 2 years.  Survival rates were not affected by treatment with m/p-cresol.  
Inspection of the data shows that the most sensitive end point in rats was the nasal respiratory epithelium, 
as in the shorter-term studies (NTP 1992b).  Other less sensitive effects observed in rats included 
hyperplasia of the transitional epithelium of the renal pelvis, squamous metaplasia in the nasal respiratory
epithelium, inflammation of the nose, and eosinophilic foci in the liver.  Incidences of respiratory
epithelium hyperplasia of minimal to mild severity were 3/50, 17/50, 31/50, and 47/50 in the control, 
low-, mid-, and high-dose groups, respectively.  During the first 13 weeks of the 2-year study, the mean 
dose in the low-dose group was 123 mg/kg/day (calculated from weekly averages provided in the report), 
the same as in the earlier 13-week study (NTP 1992b), and the incidence of respiratory hyperplasia in this
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group at termination was 17/50 (34%), almost the same as in the earlier 13-week study, 3/10 (30%).  This
suggests that, over the range of doses used in these studies, exposure beyond 13 weeks (i.e., duration of
exposure) had little or no effect on the incidence or severity of the lesions, indicating that the
intermediate-duration MRL is protective of nasal lesions for a 2-year exposure period. This is supported 
by the fact that fitting the incidence data for nasal respiratory epithelium hyperplasia from the 2-year
study to the same BMDS model (Log-Logistic) that provided the BMDL10 used to derive the
intermediate-duration oral MRL yields a BMDL10 for chronic exposure to m/p-cresol of 
13.9017 mg/kg/day, essentially the same as the BMDL10 of 13.9381 mg/kg/day used to derive the
intermediate-duration oral MRL for m/p-cresol.  Thus, the intermediate-duration oral MRL should be
protective of nasal respiratory lesions in rats induced by chronic-duration exposure.
The female B6C3F1 mice were fed diets that provided TWA doses of approximately 0, 100, 300, or
1,040 mg m/p-cresol/kg/day for 2 years.  Survival rates were comparable among dose groups.  Significant
treatment-related, non-neoplastic effects occurred in the lung (bronchiole hyperplasia), nose (respiratory
epithelium hyperplasia), thyroid gland (follicular degeneration), and liver (eosinophilic foci).  In the lung, 
the incidences of minimal to moderate bronchiole hyperplasia were 0/50, 42/50, 44/49, and 47/50 in the
control, low-, mid-, and high-dose groups, respectively.  In the nose, the corresponding incidences of
minimal to mild respiratory epithelium hyperplasia were 0/50, 0/50, 28/49, and 45/49.  In the thyroid, the
corresponding incidences of mild follicular degeneration were 7/48, 24/48, 24/49, and 21/50.  The
corresponding incidences of eosinophilic foci in the liver were 1/50, 0/50, 2/49, and 12/50.  Clearly, the
thresholds for thyroid follicular degeneration and bronchiole hyperplasia were lower than those for nasal
epithelial hyperplasia and liver foci; therefore, the incidence data for the former two lesions were
considered for derivation of a chronic-duration oral MRL for m/p-cresol.  After inspection of the dose 
response data, the use of a LOAEL/NOAEL approach for MRL derivation was considered to be more 
appropriate than the use of benchmark dose analysis because of the steep increase in the response rates 
between the control groups and the first exposure levels.  It should be noted that neither bronchiole
hyperplasia nor thyroid follicular degeneration were present in female mice in the 13-week study with 
m/p-cresol (NTP 1992b), suggesting that longer periods of exposure were necessary for these lesions to 
develop.  Applying an uncertainty factor of 1,000 (10 for use of a LOAEL, 10 for extrapolation from
animals to humans, and 10 for human variability) to the LOAEL of 100 mg/kg/day for bronchiole
hyperplasia of the lung and follicular degeneration of the thyroid gland in female mice, yields an chronic-
duration oral MRL of 0.1 mg/kg/day for m/p-cresol. 
   
 











     
  
   
  
    
    
    




2. RELEVANCE TO PUBLIC HEALTH
The most comprehensive study of cresols by dietary exposure is the NTP (1992b) study.  In that study,
each individual isomer and an m/p-cresol mixture were tested in rats and mice for 28 days; in addition, 
o-cresol and m/p-cresol were tested in rats and mice for 13 weeks.  Assessing the comparative toxicity of 
the cresol isomers, NTP (1992b) noted that: “In general, there were no significant indications of distinct
toxicities between the three isomers.”  However, nasal lesions only occurred in rats and mice dosed with 
p-cresol and m/p-cresol in the 28-day studies and in rats and mice dosed with m/p-cresol in the 13-week
studies.  Since m-cresol alone was not tested in the 13-week studies, it is unknown whether longer dietary
exposure to this isomer would produce similar lesions.  Thus, it would appear that p-cresol is the most
toxic of the isomers with regard to inducing nasal lesions and, since no other significant toxicities were
observed in these dietary studies, the MRL for m/p-cresol should also be protective for exposures to the
individual cresol isomers.  Therefore, the intermediate- and chronic-duration oral MRLs for m/p-cresol
also can be adopted for o-, m-, and p-cresol.














   
    
   
  
 
   
 
   
 
   
   















3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of cresols.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.  
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
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the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
Studies of the inhalation toxicity of cresols have not been adequately detailed.  The exposures involved 
mixtures of vapors and aerosols that were not characterized sufficiently to estimate exposure levels 
reliably.  Furthermore, methods for evaluating the toxicological end points were not adequately described.  
In addition, it is very likely that dermal exposure, and thus dermal absorption, also occurred.  Therefore,
no LSE table or figure containing levels of significant exposure was constructed for this route.  
Nevertheless, certain general conclusions can be drawn from the reports regarding the toxic potential of
inhaled cresols.  These are discussed below.
3.2.1.1  Death 
No studies were located regarding death in humans following inhalation exposure to cresols.
Cresols may be lethal to animals when inhaled (Campbell 1941; Uzhdavini et al. 1972).  The inhalation 
exposure levels and durations that kill animals have not been reliably documented.  Lethality has been 
reported in mice exposed to approximately 178 mg/m3 of o-cresol aerosol for an unspecified acute 
duration, suggesting that the minimal lethal exposure level for cresol aerosols may be <178 mg/m3 
(Uzhdavini et al. 1972).  For longer-term exposure, the minimal lethal level may exceed 50 mg/m3, since 
exposure to this concentration of o-cresol for 1 month had no effect on mouse mortality (Uzhdavini et al. 
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1972).  Clinical signs that preceded death in acute experiments included irritation of mucous membranes
and neuromuscular excitation that progressed from tremors to clonic convulsions. 
3.2.1.2  Systemic Effects
No studies were located regarding gastrointestinal, hematological, musculoskeletal, or dermal effects in 
humans or animals following inhalation exposure to cresols.
Respiratory Effects. When inhaled as a concentrated aerosol, o-cresol is a respiratory irritant in 
humans; however, the minimal exposure level and duration associated with irritation have not been 
reliably documented.  Following brief exposures to 6 mg/m3, 8 out of 10 subjects complained of mucosal
irritation symptoms including dryness, nasal constriction, and throat irritation (Uzhdavini et al. 1972).
Signs of respiratory irritation have been reported in animals acutely exposed to cresol vapors and 
aerosols, although the levels associated with irritation have not been reliably documented (Campbell
1941; Uzhdavini et al. 1972).  Mucosal irritation, as shown by parotid gland secretions, occurred in cats
during 30-minute exposures to 5–9 mg/m3 of o-cresol (Uzhdavini et al. 1972).  An assortment of
respiratory effects, including inflammation and irritation of the upper respiratory tract, pulmonary edema, 
and hemorrhage and perivascular sclerosis in the lungs were seen in animals exposed to 9–50 mg/m3 of
o-cresol 2–6 hours/day for ≥1 month (Uzhdavini et al. 1972).
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans
following inhalation exposure to cresols.
Heart muscle degeneration was reported in mice exposed to 50 mg/m3 of o-cresol 2 hours/day for 1 month 
(Uzhdavini et al. 1972).  Mice were probably exposed to an aerosol.  Exposure levels were not reliably
documented.
Hepatic Effects. No studies were located regarding hepatic effects in humans following inhalation 
exposure to cresols.
Fatty degeneration and centrilobular necrosis were observed in the livers of mice that died following
acute exposure to o-cresol; the mean lethal concentration was 178 mg/m3. Exposure to 9 mg/m3 for
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4 months interfered with liver function in rats, as shown by increased susceptibility to hexanol narcosis
(Uzhdavini et al. 1972).
Renal Effects. No studies were located regarding renal effects in humans following inhalation
exposure to cresols.
Blood was found in the urine of mice acutely exposed to o-cresol; the mean lethal concentration was 
178 mg/m3 (Uzhdavini et al. 1972).  Necropsy and histopathologic examination of the mice that died 
following exposure revealed edema and swelling of the glomeruli, degeneration of the tubular epithelium, 
and perivascular hemorrhage.
Ocular Effects. No studies were located regarding ocular effects in humans following inhalation 
exposure to cresols.
Eye irritation was noted in mice briefly exposed to highly concentrated cresylic acid (a mixture of cresol
isomers and other phenolic solvents that boils above 204 C) vapors; however, the exact exposure 
concentrations associated with irritation were not documented (Campbell 1941).
3.2.1.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans or animals following inhalation 
exposure to cresols.
3.2.1.4  Neurological Effects 
No studies were located regarding neurological effects in humans following inhalation exposure to 
cresols.
Neurologic effects in animals acutely exposed to cresol aerosols have been reported (Uzhdavini et al. 
1972).  The effects include mild nervous excitation, muscle twitching accompanied by general fatigue, 
and clonic convulsions.  The exposure concentrations associated with these effects have not been reliably
documented; however, they may occur at levels approximating 178 mg/m3 during a single exposure.  
Prolonged exposure (2 hours/day for 1 month) to a lower concentration of o-cresol aerosol (50 mg/m3) 
reportedly produced degeneration of nerve cells and glial elements in mice (Uzhdavini et al. 1972).  The
   
 














   
  
   
 
     
  
 





   
     
   
   
    
  
    
    
    
  
    
 
   




severity of these changes was not discussed, however, and no further details were provided.  The
exposure concentration associated with this effect was not reliably documented.
No information was located regarding the following effects of cresols in humans following inhalation 
exposure:
3.2.1.5  Reproductive Effects
3.2.1.6  Developmental Effects 
3.2.1.7  Cancer
3.2.2 Oral Exposure
3.2.2.1  Death 
Ingestion of cresols can be fatal to humans.  Fatalities were described in several case reports involving
ingestion of cresol-containing disinfectants.  A 37-year-old woman died 4 days after swallowing about
250 mL of a disinfectant described as 50% cresols in a mixture of linseed oil, potassium hydroxide, and 
water.  Death was caused by acute intravascular hemolysis, which resulted in multiple thrombosis and 
renal failure (Chan et al. 1971).  The lethal dose was roughly 2 g/kg of cresols (only about one-half of 
which was actually absorbed).  The same report described the case of a woman who recovered after
drinking a smaller amount of the same disinfectant (approximately 100 mL).  The urine of both women 
contained glucuronides of cresol metabolism.  A woman who swallowed between 500 and 750 mL of a
concentrated cresol mixture died from cardiac arrest 26 hours later (Labram and Gervais 1968).  Among
the 52 cases of cresol poisoning reported by Isaacs (1922), two patients died, both within 0.5 hours of
drinking a disinfectant purported to contain 25–50% cresols.  Similarly, Monma-Ohtaki et al. (2002)
reported that ingestion of a large volume of a saponated cresol solution caused the death of a man in about
15 minutes.  A woman who drank a disinfectant suspected of containing cresols died 5 days later (Dellal
1931).  There was little corrosion in the throat so it is probable that not much disinfectant was swallowed.  
The cause of death was thought to be acute hemorrhagic degeneration of the pancreas, which may or may
not have been related to cresol consumption.  Bruce et al. (1976) also described two cases of ingestion of
cresols that ended in death; in both cases, there was significant injury to the gastrointestinal tract.
LD50 values in rats were 1,350, 1,800, and 2,020 mg/kg for o-, p-, and m-cresol, respectively, for 10%
solutions in olive oil (Deichmann and Witherup 1944).  LD50 values of 121, 242, and 207 mg/kg were
reported for undiluted o-, m-, and p-cresol, respectively, in rats (EI du Pont 1969).  Hypoactivity, tremors, 
   
 














    
 
     
     
     
     
   







    
 
   
 










convulsions, salivation, and dyspnea were signs commonly seen preceding death (EI du Pont 1969).  
Acute LD50 values for various cresylic acid formulations in mice ranged from 500 to 2,050 mg/kg
(Campbell 1941).  Although LD50 values were not determined in other species, minimum lethal values 
were available for a few species; the small number of animals in these studies, however, limits the
reliability of these data.  In rabbits, minimum lethal values from ingestion ranged from 620 to 
1,400 mg/kg for the three isomers (Deichmann and Witherup 1944).  In mink, the minimum lethal value
of o-cresol by gavage was 200 mg/kg, and in ferrets, it was 400 mg/kg (Hornshaw et al. 1986).
Dietary administration of 4,480 mg/kg/day of o-cresol to male mice or 5,000 mg/kg/day to female mice 
for 10 days resulted in the death of 2/5 males and 1/5 females (NTP 1992b).  Doses of 4,710 or
4,940 mg/kg/day of m-cresol killed 2/5 males and 2/5 female mice, respectively, in a 6-day period (NTP
1992b).  A diet containing 30,000 ppm of p-cresol (The National Toxicology Program [NTP] did not
estimate doses, but were probably 4,000–5,000 mg/kg/day) caused the death of 4/5 male and 5/5 female 
mice within 1 week in this diet.  In the cases of o- and m-cresol, necropsy of the dead animals did not
reveal any notable histopathological changes.  In the case of p-cresol, lesions were considered secondary
to moribund condition or stress, except for liver and kidney necrosis and bone marrow hypocellularity, 
which could have been related to p-cresol (NTP 1992b).  Exposure of male F-344 rats or female B6C3F1 
mice to up to 720 and 1,040 mg/kg/day, respectively, in the diet for 2 years did not affect survival rates 
(NTP 2008). 
Mortality data were also available for pregnant rats (Tyl 1988a) and rabbits (Tyl 1988b) given cresols by
gavage repeatedly during gestation in studies of developmental toxicity.  Both o- and p-cresol produced 
mortality among rats given 450 mg/kg/day, whereas m-cresol did not (Tyl 1988a).  In rabbits, p-cresol
appeared to produce a dose-related increase in mortality at 50–100 mg/kg/day.  No deaths occurred in 
rabbits exposed to o- or m-cresol (Tyl 1988b).
Exposure to o-, p-, or m-cresol at 450 mg/kg/day by oral gavage produced 12–60% mortality in adult 
male and female rats in two-generation reproduction studies.  The elevated mortality occurred in both the
F0 and F1 generation adults (Neeper-Bradley and Tyl 1989a, 1989b; Tyl and Neeper-Bradley 1989).  In 
13-week oral gavage studies of systemic toxicity in rats, elevated mortality resulted only from exposure to 
o-cresol at 600 mg/kg/day (EPA 1988b); in these studies, p- and m-cresol failed to produce mortality at
450–600 mg/kg/day (EPA 1988c, 1988d).
   
 









   
 
   
 
 
   
 
     
    
  
   
   
 
  
   
     
    
     
     
    
    
    
  
      
    
  






All reliable LD50 and LOAEL values for death in each species and duration category are recorded in 
Table 3-1 and plotted in Figure 3-1.
3.2.2.2  Systemic Effects
The highest NOAEL values and all reliable LOAEL values for systemic effects of each type in each 
species and duration category are recorded in Tables 3-1 and plotted in Figure 3-1.
Respiratory Effects. Diffuse necrosis of the bronchial epithelium was noted in a woman who died 
after drinking 500–750 mL of a concentrated cresol mixture (Labram and Gervais 1968).  This effect was
thought to have occurred prior to death.  Edema and hemorrhage were also observed, but may have
occurred secondary to death.  Adhesions and fluid were found in the lungs of a woman who died after
drinking a disinfectant suspected of containing cresols (Dellal 1931).
Hyperplastic or metaplastic lesions in the respiratory epithelium have been observed in rats orally
exposed to cresols for intermediate durations.  Epithelial metaplasia of the trachea has been reported to 
occur in Sprague-Dawley male and female rats treated by gavage with 600 mg/kg/day of p-cresol for 
13 weeks (EPA 1988c).  Fischer-344 rats exposed to doses of up to approximately 2,600 mg/kg/day of
o-cresol or m-cresol in the diet for 28 days had no noticeable histological alterations in tissues of the 
respiratory tract, including nasal tissues (NTP 1992b).  However, exposure of males to ≥835 mg/kg/day or
females to ≥770 mg/kg/day of p-cresol, or of males to ≥261 mg/kg/day or females to ≥95 mg/kg/day of a
mixture of m- and p-cresol (58/41%) induced dose-related (incidence and severity) hyperplasia of the
nasal respiratory epithelium (NTP 1992b).  This suggests that p-cresol is more potent than the other
isomers in inducing this type of lesion.  The corresponding NOAELs were 256 and 242 mg/kg/day for
p-cresol and 90 and 27 mg/kg/day for the mixture.  In a 13-week dietary study in rats, similar lesions were 
seen in males at ≥123 mg/kg/day of the cresol mixture and in females at ≥254 mg/kg/day (NTP 1992b).  
A NOAEL for males was not identified; the NOAEL for females was 131 mg/kg/day.  Neither m-cresol
nor p-cresol alone was tested in the 13-week study.  The lesions were observed at the most anterior
portions of the nasal septum, dorsal arch, and medial aspect of the nasal turbinates.  The hyperplasia was
characterized by increased number of goblet cells and pseudogland formation due to the infolding of the
hyperplastic cells.  The incidence data for nasal lesions in male and female rats exposed for 13 weeks 
were analyzed via a benchmark dose approach to derive points of departure for deriving an intermediate-






























1 Rat once 
(Wistar) (GO) 
2	 Rat once 
(Wistar) (GO) 
3	 Rat once 
(Wistar) (GO) 
4	 Rat once 
(albino) (G) 
5	 Rat once 
(albino) (G) 
6	 Rat once 
(albino) (G) 
7	 Mouse once 
(NS) (GW) 











(LD50, 10% solution in 
olive oil) 
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(2/5 males and 1/5 
females died before day 
10) 
Reference 
Chemical Form Comments 
Deichmann and Witherup 1944 
ortho 
Deichmann and Witherup 1944 
meta 
Deichmann and Witherup 1944 
para 
EI du Pont 1969 
meta 
EI du Pont 1969 
ortho 



























































4710 M (2/5 males and 2/5 















450 F (audible respiration) 
175 F (12% decreased body 
weight gain) 
450 F (47% decreased body 
weight gain during 
treatment) 
Other 450 F (15% reduced food 
intake during treatment) 
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175 F 450 F (46% decreased body 
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Other 450 F (13% reduced food 












175 F 450 F (40% decreased body 
weight gain during 
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Other 175 F 450 F (25% decreased food 









































































































50 F (ocular discharge) 
















































































































NOAEL is for uterine 





450 Tyl 1988a 
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NOAEL is for uterine 
weight and corpora 
lutea. 
NOAEL is for uterine 
weight and number of 
corpora lutea. 
NOAEL is for uterine 
weight and number of 
corpora lutea. 
NOAEL is for uterine 
weight and number of 
corpora lutea. 
NOAEL is for 
postimplantation loss, 
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600 (death of 19 females and 














450 (death of 8/25 males and 
5/25 females) 
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Key to Species Frequency NOAEL Less Serious Serious Reference 




































(epithelial metaplasia in 
trachea) 
(6-8% decreased red 
blood cell count and 
hemoglobin) 
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450 EPA 1988d 
meta 











50 M 150 M (22% decreased body 
weight gain) 
1000 Koizumi et al. 2003 
meta 
NOAELs are for 
histopathology of liver 
and kidney and a 



























































Bd Wt 175 M 450 M (13% reduced final body 
weight) 







Bd Wt 175 M 450 M (15% decreased final 
body weight) 







Resp 2610 M NTP 1992b 
ortho 
NOAELs are for organ 
weights and 
histopathology. 
Cardio 2610 M 




266 M 861 M (25% increase absolute 
liver weight and 23% in 
relative) 
Renal 266 M 861 M (15% increase in 
absolute kidney weight 
and 13% in relative) 
Endocr 2610 M 
Dermal 2610 M 






















































Resp 2470 M NTP 1992b 
meta 
NOAELs are for organ 
weights and 
histopathology. 
Cardio 2470 M 




252 M 870 M (16% increase in 
absolute and relative liver 
weight) 
Renal 2470 M 
Endocr 2470 M 
Dermal 2470 M 




















































Resp 242 F 770 F (respiratory nasal 
epithelium hyperplasia) 
Cardio 2180 M 
Gastro 2180 M 
Hemato 770 F 2060 F (bone marrow 
hypocellularity) 
Musc/skel 2180 M 
Hepatic 83 F 242 F (16% increase absolute 
liver weight) 
Renal 2180 M 
Endocr 2180 M 
Dermal 2180 M 
Bd Wt 835 M 2060 F (16% reduced final body 
weight) 
Serious Reference 
(mg/kg/day) Chemical Form Comments 
NTP 1992b 
para 
NOAELs are for organ 
weights and 
histopathology. 
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Chemical Form Comments 
NOAELs are for organ27 F 95 F	 (hyperplasia in NTP 1992b 
weights andrespiratory nasal	 mix histopathology.epithelium) 
2600 M 
90 M 261 F	 (hyperplasia and 
hyperkeratosis of 
esophageal epithelium) 
886 M 2570 M (bone marrow 
hypocellularity) 
2600 M 
261 M 877 M (16-20% increase in 
absolute and relative liver 
weight) 
2600 M 
90 M 261 M (increased colloid in 
thyroid follicular cell) 
2600 M 


















































Resp 2028 M NTP 1992b 
ortho 
NOAELs are for organ 
weights and 
histopathology. 
Cardio 2028 M 
Gastro 2028 M 





247 M 510 M (10-12% increase in 
absolute and relative liver 
weight) 
Renal 2028 M 
Endocr 2028 M 
Dermal 2028 M 







































Key to Species Frequency 







55 Rat	 13 wk 
ad lib(Fischer- 344) 
(F) 























Chemical Form Comments 
b 
123 M (3/10 with minimal 
hyperplasia in the nasal 
respiratory epithelium vs. 
0/10 in controls) 
NTP 1992b 
mix 





991 M 2014 M (bone marrow 
hypocellularity) 
2050 F 
241 M 486 M (11-12% increase in 
absolute and relative liver 
weight) 
2050 F 
254 F 509 F (increased colloid in 
thyroid follicular cells) 
2050 F 
991 M 2014 M (17% reduced final body 
weight) 
175 M 450 M (10% decreased final 
body weight) 















































Resp 1650 M 4480 M (rapid breathing) NTP 1992b 
ortho 
NOAELs are for organ 
weights and 
histopathology. 
Cardio 5000 F 







Endocr 5000 F 
Dermal 5000 F 





















































Resp 651 F 2080 F (labored respiration) NTP 1992b 
meta 
NOAELs are for organ 
weights and 
histopathology. 
Cardio 4940 F 







Endocr 4940 F 
Dermal 4940 F 








































































NOAELs are for organ50 M 163 M (3/5 with minimal	 NTP 1992b 
weights andhyperplasia of nasal	 para histopathology.respiratory epithelium vs. 





564 F 1590 F	 (15-20% increase in 








































































NTP 1992b	 NOAELs are for organ200 F 604 F	 (3/5 with minimal 
weights andhyperplasia of the nasal	 mix histopathology.respiratory epithelium vs. 
0/5 in controls) 
4730 F 
4730 F 
1490 M 4530 M (bone marrow 
hypocellularity) 
4730 F 
604 F 1880 F	 (30% increase in 




1490 M 4530 M (alopecia) 


































































NTP 1992b NOAELs are for organ3205 F 
weights andortho histopathology. 
3205 F 




794 M 1723 M (17-19% increase in 




































Key to Species Frequency 







































Chemical Form Comments 
402 M 776 M (4/10 with minimal 
hyperplasia of the nasal 
respiratory epithelium vs. 
1/10 in controls) 
NTP 1992b 
mix 







402 M 776 M (12% increase in 






1415 M (mild to moderate 
forestomach hyperplasia) 




















































Resp 400 Hornshaw et al. 1986 
ortho 
NOAELs are for organ 















Resp 320 Hornshaw et al. 1986 
ortho 
NOAELs are for organ 




















320 F (weight loss) 
EPA 1988b 
ortho 
NOAEL is for weight 
and histopathology of 






































































































NOAEL is for changes 
in histopathology of 
spleen, thymus, and 
lymph nodes. 
NOAEL is for changes 
in weight and 
histopathology of 
spleen, thymus, and 
lymph nodes. 
NOAEL is for weight 
and histopathology of 
lymphoreticular organs. 








NOAELs are for weight 




























































































NOAEL is for weight 
and histopathology of 
lymphoreticular organs. 
NOAEL is for weight 
and histopathology of 
lymphoreticular organs. 
NOAELs are for weight 
and histopathology of 
lymphoreticular organs. 
NOAELs are for weight 
and histopathology of 
lymphoreticular organs. 
NOAEL is for weight 
and histopathology of 
lymphoreticular organs. 
NOAEL is for weights 



































































3205 F NTP 1992b 
ortho 
NOAEL is for weight 





1693 F NTP 1992b 
mix 
NOAEL is for weight 




























































































































NOAEL is for 
histopathology of the 
brain and clinical signs. 
NOAEL is for weight 
and histopathology of 
the brain and clinical 
signs. 
NOAEL is for weight 
and histopathology of 
the brain and clinical 
signs. 
NOAEL is for weight 
and histopathology of 
the brain and clinical 
signs. 
NOAEL is for weight 
and histopathology of 





















































































Tyl and Neeper-Bradley 1989 
ortho 
Comments 
NOAEL is for 
histopathology of the 
brain and clinical signs. 
Behavioral tests done 
throughout the study 




Behavioral tests done 
throughout the study 




Behavioral tests done 
throughout the study 

























































































3205 F NTP 1992b 
ortho 
NOAEL is for weight 





1693 F NTP 1992b 
mix 
NOAEL is for weight 





















































































450 Neeper-Bradley and Tyl 1989b 
meta 
Comments 
NOAEL is for weight 
and histopathology of 
reproductive organs. 
Fertility was not 
assessed. 
NOAEL is for 
histopathology of 
reproductive organs. 
Fertility was not 
assessed. 
NOAEL is for changes 
in weight and 
histopathology of 
reproductive organs. 
The NOAEL is for 
reproductive function 
end points in both 
sexes. 
The NOAEL is for 
reproductive function 













































































































Less Serious	 Serious 
(mg/kg/day)	 (mg/kg/day) 
2310 F	 (mild uterine atrophy in 
4/5 females) 
2060 F	 (mild to moderate uterine 
atrophy) 



















NOAEL is for weight 
and histopathology of 
reproductive organs; 
fertility was not 
assessed. 
Fertility was not 
assessed. 
Fertility was not 
assessed. 
NOAEL is for weight 
and histopathology of 
reproductive organs, 
sperm effects, and 




















































450 Tyl and Neeper-Bradley 1989 
ortho 
The NOAEL is for 
reproductive function 







660 NTP 1992a 
ortho 
NOAEL is for 
reproductive functional 
end points in a study 










1670 F (mild atrophy of the 
uterus in 5/5 mice) 
NTP 1992b 
ortho 










4940 F (mild to moderate 
atrophy of mammary 











1590 F NTP 1992b 
para 
NOAEL is for weight 
and histopathology of 
reproductive organs; 























































































1390 1682 (increased cumulative 





105 Hornshaw et al. 1986 
ortho 
Comments 
NOAEL is for weight 
and histopathology of 
reproductive organs; 
fertility was not 
assessed. 
Fertility was not 
assessed. 
NOAEL is for weight 
and histopathology of 
reproductive organs, 
sperm effects, and 
estrous cycle length. 
No histopathology in 
reproductive organs 
from males or females. 
Fertility of F1 not 
altered. 
NOAEL is for 
reproductive function 



















































































1390 1682 (decreased number of 
live pups/litter) 
Reference 
Chemical Form Comments 
Koizumi et al. 2003 Tremors observed in 
newborn rats but not in meta 5-week old exposed for 
28 days. 
Neeper-Bradley and Tyl 1989a 
para 
Neeper-Bradley and Tyl 1989b 
meta 











































The LOAEL for123 M (17/50 with minimal NTP 2008 
respiratory is listed ashyperplasia of the nasal mixed 123 mg/kg/day, whichrespiratory epithelium, 
was the mean dose3/50 in controls) 
during the first 13 






230 M 720 M (increased incidence of 
eosinophilic foci) 
230 M 720 M (transitional epithelial 










Key to Species Frequency 
Figure (Strain) (Route) 
CHRONIC EXPOSURE 
Systemic 
129 Rat 2 yr 









































Key to Species Frequency 











131 Rat 2 yr 





















Chemical Form Comments 
d 
100 F (42/50 with minimal 
bronchiolar hyperplasia, 
0/50 in controls) 
NTP 2008 
mixed 
NOAELs are for 
histopathology of 




300 F 1040 F (increased eosinophilic 
foci) 
1040 F 




100 F 300 F (11% reducton in final 
body weight) 
1040 F (24% reduction in final 
body weight) 
720 M NTP 2008 
mixed 























































































NOAEL is for 
histopathology of 
lymphoreticular organs. 
NOAEL is for 
histopathology of the 
brain. 
NOAEL is for 
histopathology of the 
brain. 
NOAEL is for 
histopathology of the 
reproductive organs. 










































1040 F (CEL: squamous cell 
papilloma in 








a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate-duration oral minimal risk level (MRL) of 0.1 mg/kg/day; the MRL was derived by dividing the BMDL10 of 13.94 mg/kg/day by an uncertainty factor of 
100 (10 for animal to human extrapolation and 10 to protect sensitive subpopulations). 
c Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-1. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
d Used to derive a chronic-duration oral minimal risk level (MRL) of 0.1 mg/kg/day; the MRL was derived by dividing the LOAEL of 100 mg/kg/day by an uncertainty factor of 1000 (10 
for animal to human extrapolation, 10 for use of a LOAEL, and 10 for human variability). 
ad lib = ad libitum; Bd Wt = body weight; BMDL = below minimum detectable limits; Cardio = cardiovascular; CNS = central nervous system; d = day(s); Endocr = endocrine; (F) = 
feed; F = Female; (G) = gavage; Gastro = gastrointestinal; gd = gestational day; (GO) = gavage in oil; (GW) = gavage in water; hemato = hematological; hr = hour(s); 
Immuno/Lymphoret = immunological/lymphoreticular; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); Musc/skel = 
musculo/skeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; occup = occupational; pnd = post-natal day; Resp = respiratory; SGOT = serum glutamic 
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 LOAEL, More Serious-Animals
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NOAEL - Animals
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Figure 3-1 Levels of Significant Exposure to Cresols - Oral (Continued) 
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Figure 3-1 Levels of Significant Exposure to Cresols - Oral (Continued) 
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Figure 3-1 Levels of Significant Exposure to Cresols - Oral (Continued) 
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B6C3F1 mice also exhibited nasal changes following dietary treatment with p-cresol or the m/p-cresol
mixture for 28 days (NTP 1992b).  For p-cresol, the LOAEL in males and females was 163 and 
207 mg/kg/day, respectively, with corresponding NOAELs of 50 and 60 mg/kg/day.  For the mixture, the
respective LOAELs in males and females were 4,530 and 604 with corresponding NOAELs of 1,490 and 
200 mg/kg/day.  Male mice dosed with 4,530 mg/kg/day of the cresol mixture also exhibited a significant
increase in bronchiolar hyperplasia.  In the 13-week study in mice with o-cresol and the cresol mixture, 
hyperplasia of the respiratory nasal epithelium was seen in males treated with 776 mg/kg/day, but not
402 mg/kg/day, and in females at 1,693 mg/kg/day, but not 923 mg/kg/day of the cresol mixture.  No 
such lesions were seen in mice dosed with o-cresol in doses of up to 2,700–3,200 mg/kg/day for
13 weeks. 
The respiratory system was also a target for m/p-cresol in male Fischer rats (females not tested) and 
female B6C3F1 mice (males not tested) in a 2-year dietary study (NTP 2008).  In rats, the response with 
the lowest threshold appeared to be hyperplasia of the respiratory epithelium of the nose, which occurred 
with an incidence of 3/50, 17/50, 31/50, and 47/50 in rats dosed with mean time-weighted average (TWA)
doses of 0, 70, 320, and 720 mg/kg/day, respectively; severity was minimal to mild.  The incidence in the
low-dose group (17/50, 34%) was very similar to that reported in the 13-week study (NTP 1992b) (3/10, 
30%) in male rats that received mean daily doses of 123 mg/kg/day during the 13 weeks of the study.  
Since the mean dose received by the low-dose rats during the first 13 weeks of the 2-year study was 
123 mg/kg/day (from a table in the NTP report providing mean weekly doses during the first 13 weeks), it
means that the lesions were already established by week 13 of the 2-year study and did not increase in 
severity.  Therefore, the value listed as a LOAEL in the LSE table is 123 mg/kg/day, the true mean dose
during the first 13 weeks, rather than the low TWA dose of 70 mg/kg/day for the entire duration of the
chronic study.  Other nasal lesions observed in rat included squamous metaplasia of the nasal epithelium, 
hyperplasia of the goblet cell, and inflammation of the nose.  In mice, the most sensitive response was
hyperplasia of the bronchiole of the lung, occurring with incidences of 0/50, 42/50, 44/49, and 47/50 in 
mice dosed with mean TWA doses of 0, 100, 300, and 1,040 mg/kg/day, respectively.  Hyperplasia of the
bronchiole of the lung was not a lesion reported in mice in the 13-week NTP (1992b) study.  Dose-related 
elevated incidences of respiratory epithelium hyperplasia were also reported at 300 and 1,040 mg/kg/day
in mice (NTP 2008).  The LOAEL of 100 mg/kg/day for bronchiole hyperplasia in female mice exposed
for 2 years was used to derive a chronic-duration oral MRL for cresols.
   
 








     
    
  
 




    
   
      
    
     
  
 
    
   
  







     








Pregnant rats (Tyl 1988b) and rabbits (Tyl 1988a) exposed to o-, p-, and m-cresol were reported to have
audible respiration and labored breathing.  These effects may be of a neurologic origin, rather than a
direct effect on the respiratory system (Section 3.2.2.4).  
Cardiovascular Effects. A woman who swallowed 500–750 mL of a concentrated cresol mixture 
exhibited tachycardia with polymorphic ventricular extra-systoles shortly after exposure (Labram and 
Gervais 1968).  This was followed within 26 hours by ventricular fibrillation and cardiac arrest.
In rats exposed to o-cresol (EPA 1988b), p-cresol (EPA 1988c), or m-cresol (EPA 1988d) at levels up to 
600 mg/kg/day for 13 weeks by gavage, histological examination of the heart revealed no changes that
indicated an adverse effect on the heart.  A 28-day dietary study reported no significant histopathological
effects in the heart or aorta of rats dosed with up to approximately 2,600 mg/kg/day of each cresol isomer
or with a mixture (58/41%) of m- and p-cresol (NTP 1992b).  A similar lack of effects was reported in 
rats following 13 weeks of treatment with approximately 2,000 mg/kg/day of o-cresol or the cresol
mixture in the diet (NTP 1992b).
In mice, treatment for 28 days with up to approximately 5,000 mg/kg/day of o-cresol, m-cresol, or the
m/p-cresol mixture or 1,590 mg/kg/day of p-cresol had no significant effect on the gross or microscopic 
appearance of the heart or aorta (NTP 1992b).  Similar effects were reported in mice dosed with up to 
3,200 mg/kg/day of o-cresol or 1,693 mg/kg/day of the m/p-cresol mixture for 13 weeks (NTP 1992b).  
The data available suggest that the cardiovascular system is not a sensitive target for cresol toxicity.
No gross or microscopic alterations were observed in the heart of male rats and female mice administered 
mean doses of up to 720 and 1,040 mg/kg/day m/p-cresol, respectively, via the diet for 2 years (NTP
2008).
Gastrointestinal Effects. Mouth and throat burns, abdominal pain, and vomiting were common 
symptoms of cresol poisoning among 52 patients who drank between 4 and 120 mL of a disinfectant 
containing 25–50% mixed cresols (Isaacs 1922).  These effects were also seen in a man who swallowed
approximately 250 mL of a concentrated cresol mixture in a suicide attempt (Jouglard et al. 1971).  
Hemorrhagic degeneration of the pancreas was the cause of death in a woman who swallowed a 
disinfectant suspected of containing cresols.  It was not clear, however, if this effect was actually
produced by the disinfectant or was due to a pre-existing condition (little disinfectant was taken) (Dellal
1931).  In a man who ingested an unknown amount of cresol, gastrointestinal endoscopy performed 
   
 








   
  
     
 
 
     
   
   
   
   
  
 
   
     
  
 
   
 
       
     
  
   
  
 
   
 
 
      
    
    
       




10 hours later revealed dark red corrosive injuries on the esophagus and stomach wall (Hayakawa 2002). 
Diffuse erosions in the gastrointestinal tract have been observed in subjects who drank saponated cresol
solutions containing about 50% cresol (Bruce et al. 1976; Kamijo et al. 2003; Wu et al. 1998; Yashiki et
al. 1990).
Rats exposed to cresols in doses up to 600 mg/kg/day for 13 weeks by gavage in corn oil did not have
gastrointestinal lesions (EPA 1988b, 1988c, 1988d). However, dietary administration of p-cresol in doses 
of approximately 1,415 mg/kg/day for 20 weeks produced an increased incidence of mild and moderate
hyperplasia of the forestomach of hamsters (Hirose et al. 1986).  Rats treated for 28 days with up to 
approximately 2,200–2,400 mg/kg/day of each cresol isomer in the diet showed no significant alterations 
in the gastrointestinal tract.  However, doses ≥260 mg/kg/day of m/p-cresol mixture (58/41%) induced 
hyperplasia and hyperkeratosis of the esophageal epithelium in male and female rats (NTP 1992b); the 
NOAEL was 90–95 mg/kg/day.  Higher doses (2,500–2,600 mg/kg/day) also induced hyperplasia in the
epithelium of the forestomach.  Longer treatments (13 weeks) with approximately 2,000 mg/kg/day of
o-cresol or the cresol mixture had no significant effect on the gastrointestinal tract of rats (NTP 1992b).
In mice, doses of up to near 5,000 mg/kg/day of o-, m-, or an m/p-cresol mixture had no significant effect
on the gastrointestinal tract (NTP 1992b).  Similarly, no increased incidence of gastrointestinal tract 
lesions occurred with up to 1,590 mg/kg/day of p-cresol; the highest dietary dose of p-cresol was not
estimated by NTP (1992b) since it killed all the mice, but was probably near 5,000 mg/kg/day.  The
13-week studies in mice provided no evidence of gastrointestinal alterations following doses of
approximately 1,500–1,700 mg/kg/day of the cresol mixture, but doses of 2,700–3,200 mg/kg/day of
o-cresol induced minimal forestomach epithelial hyperplasia (NTP 1992b).  
No gross or microscopic alterations were observed in the gastrointestinal tract of male rats and female 
mice administered mean doses of up to 720 and 1,040 mg/kg/day m/p-cresol, respectively, via the diet for
2 years (NTP 2008).
Hematological Effects. Hematological effects were described in four people who ingested cresol­
containing products.  One woman swallowed 100 mL of a disinfectant containing 50% mixed cresols, 
receiving a dose of approximately 1 g/kg (Chan et al. 1971).  Methemoglobin was seen in the blood after
1.5 hours, but was no longer detected after 6 hours.  Some Heinz bodies were observed after 6 hours, but
these disappeared after 2 days.  A second woman who drank 250 mL of disinfectant (roughly 2 g/kg)
experienced more serious effects.  Methemoglobinemia and markedly reduced glutathione levels were 
   
 














   
 




   





      
    
     
 
     
  
     








seen after 7 hours.  After 3 days, the patient developed severe hemoglobinemia and hemoglobinuria, 
indicating that massive intravascular hemolysis had occurred; extensive Heinz body formation had also 
taken place.  The patient died the next day, apparently from thrombus formation and kidney failure
secondary to acute intravascular hemolysis (Chan et al. 1971).  A marked increased in methemoglobin 
also was observed in a man 15 hours after he swallowed a cresol solution of unknown concentration 
(Minami et al. 1990).  Heinz body formation, hemoglobinemia, hemoglobinuria, and hemolytic anemia
were also seen in a man who drank 100 mL of penetrating oil containing 12% mixed cresols, receiving a 
dose of about 170 mg/kg (Cote et al. 1984).  In addition, a man who swallowed approximately 250 mL of
a concentrated cresol mixture developed severe hemolytic anemia during the second week following
ingestion (Jouglard et al. 1971).  Isaacs (1922) did not find abnormalities in the blood of any of
52 patients who had ingested cresols, but the specific analyses performed were not reported.  Low platelet
count, which could have been due to disseminated intravascular congestion, was described in a man who 
drank an undetermined amount of cresol (Hayakawa 2002).  Leukocytosis and hemolysis were reported in 
a man who drank 300 mL of a 50% saponated solution of cresols (Wu et al. 1998).  The hematological
effects of cresols appear to be due to both an oxidant effect on the cell contents and a direct effect on the
red cell membrane (Chan et al. 1971).
Severe hematological effects, such as those reported in humans, were not observed in animals exposed to 
cresols possibly because acute high-dose studies in animals did not investigate hematological effects.  
Mild decreases in red blood cells, blood hemoglobin concentrations, and hematocrit were reported in rats 
dosed by gavage with 175 mg/kg of p-cresol for 13 weeks (EPA 1988c), but the effects were not
produced by the other isomers (EPA 1988b, 1988d).  Mild and inconsistent changes in red blood cell
count seen in mink were of questionable significance (Hornshaw et al. 1986).  A study in rats reported 
increased incidence of moderate bone marrow hypocellularity following 28 days of a diet that provided 
approximately 2,000–2,200 mg/kg/day of p-cresol or 2,500–2,600 mg/kg/day of an m/p-cresol mixture
(NTP 1992b); the NOAELs were near 800 mg/kg/day.  Blood parameters were not monitored in this
28-day study.  Bone marrow hypocellularity also was reported in female rats treated with 
≥1,021 mg/kg/day of o-cresol for 13 weeks and in male and female rats treated with approximately
2,100 mg/kg/day of m/p-cresol (NTP 1992b).  Hematological parameters in the 13-week studies with both 
o-cresol and m/p-cresol were unremarkable, although there was a tendency to hemoconcentration in 
animals receiving the highest doses (>2,000 mg/kg/day) early in the study. 
Male mice treated for 28 days with 4,530 mg/kg/day of m/p-cresol showed mild to moderate bone marrow
hypocellularity, but no such effect was seen at 1,490 mg/kg/day or in females treated with up to 
   
 











   
  
 
       
 
 
   
    
 
  







       




   
  






4,730 mg/kg/day (NTP 1992b).  Bone marrow hypocellularity also was observed in all mice treated with 
the highest dietary level of p-cresol, 30,000 ppm (NTP did not estimate daily doses at this level since all 
mice died), but not at estimated doses near 1,500 mg/kg/day (NTP 1992b).  No significant hematological
effects were reported in mice in the 13-week study with o-cresol (2,700–3,200 mg/kg/day) or m/p-cresol
(1,500–1,700 mg/kg/day). 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans
following oral exposure to cresols.
Cresols had no effect on the incidence of gross or microscopic lesions in the muscle or bone of rats given 
doses up to 600 mg/kg/day by gavage for 13 weeks (EPA 1988b, 1988c, 1988d).  The NTP (1992b)
dietary studies examined sternebrae and femurs of rats and mice and found no significant gross or
microscopic alterations in these tissues.  Maximal doses of all the cresols tested were approximately
2,000–2,600 mg/kg/day in rats (28-day and 13-week studies), 4,500–5,000 mg/kg/day (28-day study in 
mice), 2,700–3,200 mg/kg/day (13-week in mice with o-cresol), and 1,500–1,600 mg/kg/day (13-week in 
mice with m/p-cresol).  Skeletal muscle was not examined in the NTP (1992b) study.  No gross or 
microscopic alterations were observed in bone (not specified) of male rats and female mice administered 
mean doses of up to 720 and 1,040 mg/kg/day m/p-cresol, respectively, via the diet for 2 years (NTP
2008).
Hepatic Effects. Moderate fatty degeneration was found in the liver of a woman who died after
drinking 250 mL of a disinfectant, which contained 50% mixed cresols (Chan et al. 1971).  The liver
appeared normal in another woman who died after ingesting a disinfectant suspected of containing cresols 
(Dellal 1931).  In a more recent case report, a woman who ingested 70 mL of a 50% cresol solution 
experienced a marked increase in serum aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) activities (more than 100-fold increase) after a 24-hour asymptomatic period (Hashimoto et al. 
1998).  The hepatocellular injury was not severe enough to cause liver descompensation and there was no 
evidence of hepatic encephalopathy.  Blood work done 22 days after the poisoning episode revealed 
normal serum AST and ALT values.  Similar results have been reported in other cases of acute oral
intoxication with cresols (Bruce et al. 1976; Hayakawa 2002; Kamijo et al. 2003).  
Following oral exposure of animals to cresols by gavage, increased relative liver weight and increased 
serum transaminase levels were reported.  Relative liver weights in rats increased following gavage 
exposure to doses of 450 mg/kg/day of cresols during pregnancy (Tyl 1988a).  Longer-term exposure to 
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levels as low as 5 mg/kg/day had the same effect in mink and ferrets (Hornshaw et al. 1986).  However, in 
these studies, changes in liver weight were not accompanied by histological changes and may not have 
indicated adverse effects.  Increased levels of serum AST and ALT were seen in female rats given 
600 mg/kg/day of p-cresol by gavage for 13 weeks and appeared to be correlated with the presence of 
hepatic inflammation (EPA 1988c).
Dietary administration of approximately ≥700–800 mg/kg/day of o-, m-, or m/p-cresol to rats for 28 days 
resulted in increases (>10%) in absolute and relative liver weight (NTP 1992b). The NOAELs were 
approximately 260–270 mg/kg/day.  For p-cresol, doses of 242 mg/kg/day caused a 16% increase in 
absolute liver weight, whereas 83 mg/kg/day produced an increase of only 6%.  No significant gross or
microscopic changes were seen in the liver in this series of experiments.  In the 13-week rat study with 
o-cresol, absolute and relative liver weights were increased in males and females at ≥510 mg/kg/day.  
Clinical chemistry tests showed an increase in serum bile acids in females at ≥1,021mg/kg/day and in 
males at 2,028 mg/kg/day.  However, there was no indication of liver necrosis or cholestasis, as serum
ALT, 5'-nucleosidase, and alkaline phosphatase activities were not significantly affected.  Furthermore, 
there were no gross or histological alterations in the liver even with the highest doses of 2,028 mg/kg/day.  
Similar results were reported for the m/p-cresol mixture.  Clinical chemistry tests showed some alterations 
in enzymes activities, but no clear pattern or dose-relationships.  Bile acids in serum were increased at
study termination in females at 2,050 mg/kg/day and in males at 241 and 991 mg/kg/day.  Gross necropsy 
and histopathology of the liver did not reveal any significant treatment-related alterations.  Administration 
of mean doses of 720 mg m/p-cresol mixture/kg/day for 2 years male Fisher rats produced a significant
increase in the incidence of eosinophilic foci in the liver of (NTP 2008).  In rats dosed with 
≤230 mg/kg/day, the incidences were comparable to controls.  
In mice, treatment in the diet with up to 5,000 mg/kg/day (the highest dose tested) of o- or m-cresol for
28 days caused mortality but did not induce significant histopathological effects on the liver (NTP
1992b).  Doses of 1,590 mg/kg/day of p-cresol increased absolute and relative liver weight (15–20%) in 
female mice, but caused no histopathology; no significant changes were seen at 564 mg/kg/day.  Mice 
treated with a higher dose level of p-cresol (30,000 ppm in food, but doses were not estimated by NTP)
that killed 9/10 mice by day 5 showed liver necrosis.  The m/p-cresol mixture, at ≥1,880 mg/kg/day, 
increased absolute and relative liver weight in female mice, but there were no histological alterations even 
at the higher dose level of 4,730 mg/kg/day.  In the 13-week study, o-cresol increased liver weight in 
males at ≥1,723 mg/kg/day, whereas the m/p-cresol mixture had the same effect at ≥776 mg/kg/day (NTP
1992b).  There were no treatment-related alterations in liver morphology in the 13-week study or in 
   
 








   
   
    
 
   
 
     
    
   
    
  
     
  
      
   
  
  
    
 
     
   
   
       
    
   




      




clinical chemistry tests that would have indicated alterations in liver function.  The only effect reported in 
female mice in the 2-year NTP (2008) bioassay with m/p-cresol was an increased incidence of
eosinophilic foci in the liver at the 1,040 mg/kg/day dose level, but not at ≤300 mg/kg/day. 
While some hepatic parameters were affected by treatment with some cresol isomers, the overall database 
does not suggest that the liver is a particularly sensitive target for cresol toxicity.
Renal Effects. Massive eosinophilic necrosis was found in the proximal tubule of a woman who died 
after drinking 500–750 mL of a concentrated cresol mixture (Labram and Gervais 1968).  This effect was
considered by the investigators to have occurred before death, and may have been due to the toxic action
of cresol.  Renal effects in a woman who drank 250 mL of a disinfectant (50% mixed cresols), and later
died, consisted of fibrin clumps in the glomeruli and a moderate level of tubular degeneration, which 
could have been due to intravascular thrombosis (Chan et al. 1971).  Mild congestion of the kidney was
reported in a second woman who died following consumption of a disinfectant suspected of containing
cresols (Dellal 1931).  Greatly elevated blood urea nitrogen (BUN) and serum creatinine were reported in 
another case of ingestion of a saponated cresol solution (Wu et al. 1998).  Among 52 patients with 
diagnosed cresol poisoning, there were signs of renal toxicity, including darkly colored urine, renal
irritation, and in a few cases, reduced phenolsulphonephthalein output (Isaacs 1922).  Bruce et al. (1976)
observed lipofuscin deposits in the cells of many of the proximal convoluted tubules in a woman who 
died 2 hours after ingestion of an unknown quantity of Lysol®. 
Exposure of male rats to 600 mg/kg/day by gavage for 13 weeks induced a slight increase, which did not
appear to be dose related, in the incidence of histological changes characteristic of chronic nephropathy
(EPA 1988c).  No such changes were seen in rats treated with comparable doses of o- or m-cresol and 
urinalyses provided no evidence for altered kidney function with any of the cresol isomers.  Exposure of
rats to m-, p-, or an m/p-cresol mixture in the diet for 28 days in doses of up to 2,200–2,600 mg/kg/day 
did not induce treatment-related alterations in gross or microscopic appearance of the kidneys (NTP
1992b).  Doses of ≥861 mg/kg/day of o-cresol increased absolute and relative kidney weight (13–15%) in 
male rats, whereas 266 mg/kg/day produced changes in kidney weight of ≤5% relative to controls.  
Kidney weight in females was not significantly altered.  Histological examination of the kidneys did not 
reveal lesions.  The 13-week study found no renal alterations in rats dosed with up to approximately
2,000 mg/kg/day of o-cresol or the m/p-cresol mixture (NTP 1992b).  In both cases, urinalyses provided 
no evidence of renal injury.  Increased incidence of transitional epithelium hyperplasia (minimal to mild 
severity) of the renal pelvis (8/50 compared with 0/50 in controls) was reported in male rats that received 
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mean doses of 720 mg m/p-cresol/kg/day for 2 years through the diet (NTP 2008); the NOAEL was
230 mg/kg/day.  
Renal effects in mice in the NTP (1992b) studies were limited to kidney necrosis, which was observed in 
mice that died after being exposed to a diet containing 30,000 ppm p-cresol (dosed were not calculated by
NTP, but were probably in the range of 4,000–5,000 mg/kg/day).  p-Cresol in doses of 1,590 mg/kg/day 
had no significant effect on the kidneys in the 28-day study.  The other isomers and the m/p-cresol
mixture did not induce adverse kidney effects in doses of up to 4,000–4,500 mg/kg/day and neither did 
o-cresol (2,700–3,200 mg/kg/day) or m/p-cresol (1,500–1,700 mg/kg/day) in the 13-week study.  No 
significant gross or microscopic alterations were reported in the kidneys from female mice dosed with up 
to 1,040 mg m/p-cresol in the diet for 2 years (NTP 2008).
The available studies in animals do not suggest that the kidneys are a sensitive target for cresol toxicity.
Endocrine Effects. No studies were located regarding endocrine effects in humans following oral
exposure to cresols.
Studies in animals do not suggest that endocrine organs are susceptible targets for cresol toxicity.  A
13-week gavage study with the three cresol isomers reported no treatment-related gross or microscopic 
alterations in the pituitary, thyroid, adrenals, and pancreas of rats treated with doses of up to 
450 mg/kg/day of m-cresol or 600 mg/kg/day of o- and p-cresol (EPA 1988b, 1988c, 1988d). 
Both the 28-day and 13-week dietary studies with cresol isomers and a cresol mixture conducted by NTP
(1992b) examined the adrenals, pancreas, thyroid, parathyroid, and pituitary of rats and mice.  The only
treatment-related effect observed was an increase in colloid within the thyroid gland follicles in rats
treated with an m/p-cresol mixture for 28 days and 13 weeks.  The LOAEL and NOAEL in the 28-day 
were approximately 270 and 90 mg/kg/day, respectively, in males and females.  In the 13-week study, the
LOAEL for females was 509 mg/kg/day and for males 991 mg/kg/day; the corresponding NOAELs were
254 and 486 mg/kg/day.  NTP (1992b) noted that the biological significance of the lesions is uncertain 
because it was not seen with the individual isomers, nor was it associated with follicular cell hypertrophy
and/or hyperplasia. The highest doses of the individual isomers tested in the rats were in the range of 
2,000–2,400 mg/kg/day.  Mice treated for 28 days received doses of up to 5,000 mg/kg/day of cresols.  
Mice treated for 13 weeks received up to 3,200 mg/kg/day of o-cresol and 1,700 mg/kg/day of m/p-cresol.  
Administration of up to 720 mg m/p-cresol/kg/day to male rats via the diet for 2 years did not cause any
   
 









    
 
   
  
 
     
 
 
    
    
   
    










        
  
    
 
 







significant alteration in gross or microscopic appearance of the pancreas or of the adrenal, pituitary, 
parathyroid, and thyroid glands (NTP 2008).  In female mice, administration of m/p-cresol for 2 years 
induced a significant increase in the incidence of mild follicular degeneration of the thyroid in all dosed 
groups (7/48, 24/48, 24/49, and 21/50 in the 0, 100, 300, and 1,040 mg/kg/day dose groups, respectively)
(NTP 2008).  The LOAEL of 100 mg/kg/day for mild follicular degeneration of the thyroid gland in 
female mice was used to derive a chronic oral MRL for cresols.
Dermal Effects. No studies were located regarding dermal effects in humans following oral exposure 
to cresols.
There were no gross or histological alterations in the skin of rats treated with cresol isomers for 28 days
or 13 weeks in doses of 2,100–2,600 mg/kg/day (NTP 1992b).  In mice, the only significant treatment-
related effect was alopecia in males and females treated with 4,530 and 4,730 mg/kg/day, respectively, of
m/p-cresol for 28 days.  No such effect occurred in mice treated with up to 3,205 mg/kg/day of o-cresol or
1,693 mg/kg/day of m/p-cresol for 13 weeks.  No exposure-related histopathological changes in the skin 
were observed in rats and mice exposed up to 720 or 1,040 mg/kg/day, respectively, m/p-cresol in the diet 
for 2 years (NTP 2008).
Ocular Effects. No studies were located regarding ocular effects in humans following oral exposure
to cresols.
Pregnant rabbits repeatedly given ≥50 mg/kg/day of the cresol isomers during gestation were found to 
have significant amounts of ocular discharge, some of which may have been due to hemorrhaging (Tyl
1988b), but no gross or microscopic lesions of the eye were found in rats given cresols in doses of up to 
450 mg/kg/day of m-cresol or 600 mg/kg/day of o- or p-cresol by oral gavage for 13 weeks (EPA 1988b,
1988c, 1988d; TRL 1986).  No exposure-related histopathological changes in the eye were observed in 
rats and mice exposed up to 720 or 1,040 mg/kg/day, respectively, m/p-cresol in the diet for 2 years (NTP
2008).
Body Weight Effects. No studies were located regarding body weight effects in humans following
oral exposure to cresols.  
In animals, a common response to oral exposure to cresols, particularly in oral gavage studies, was 
decreased growth, often associated with decreased food consumption (EPA 1988b, 1988c, 1988d;
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Hornshaw et al. 1986; Koizumi et al. 2003; Neeper-Bradley and Tyl 1989a, 1989b; TRL 1986; Tyl 1988a;
Tyl and Neeper-Bradley 1989).  The effects were usually more pronounced during the early stages of the 
studies and, in almost all cases, were associated with significant reductions in food consumption.  It
should be mentioned also that the dose levels that reduced food consumption and body weight gain 
induced neurological effects such as hypoactivity, incoordination, and tremors.  Reduced body weight
gain was also observed in the dietary studies in rats and mice, generally at the highest dose levels tested 
(i.e., ≥2,000 mg/kg/day) and was almost always associated with reduced food consumption (NTP 1992b).  
Whether the latter is due to poor palatability or other reason is unknown since pair-fed groups were not
utilized.
Final body weight in male rats treated with 720 mg m/p-cresol/kg/day in the diet for 2 years was 15%
lower than in controls (NTP 2008), the NOAEL was 230 mg/kg/day.  In the same study, final body
weight of female mice dosed with 300 and 1,040 mg m/p-cresol/kg/day was reduced 11 and 24%, 
respectively, relative to controls.  Food consumption was not significantly affected in either species 
throughout the study.   
Metabolic Effects. Marked metabolic acidosis (pH 7.058) was reported in a man who drank an 
undetermined amount of cresol (Hayakawa 2002).  Similar observations were made by Kamijo et al. 
(2003) in a man who drank about 150 mL of a saponated cresol solution containing about 50% cresol.  No 
explicit mention of adverse metabolic effects was made in other reports of ingestion of cresols.
There is no evidence that cresols induced metabolic effects at the doses tested in the animal studies 
available. 
3.2.2.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans following oral exposure to cresols.
The only immunological end points examined in animal studies were weight and gross and microscopic 
appearance of the spleen and thymus and occasionally, lymph nodes.  Spleen weight was unaffected by
28-day exposure to o-cresol in the feed at doses up to 400–720 mg/kg/day in ferrets and 320– 
480 mg/kg/day in mink (Hornshaw et al. 1986).  Similarly, no effect was seen on spleen weight in a
reproduction study in which mink were exposed to 105–190 mg/kg/day of o-cresol in the feed for
6 months (Hornshaw et al. 1986).  Absolute spleen weight was decreased (approximately 18%) in male
   
 








    
  
 
     
     
 
    







   
   
  
     
   
 
 
   
 
  











rats given 600 mg/kg/day of p-cresol by gavage for 13 weeks, but relative spleen weight was unaffected 
and no lesions were found; neither weight nor morphological appearance of the thymus or mandibular
lymph nodes was significantly altered (EPA 1988c).  No significant alterations were seen in these tissues 
in rats given similar doses of o- or m-cresol (EPA 1988b, 1988d).  Studies in rats and mice exposed to 
cresol isomers and a mixture of m- and p-cresol for 28 days or 13 weeks also found no significant
histological alterations in lymphoreticular organs and tissues (NTP 1992b).  Maximal doses in mice were 
near 5,000 mg/kg/day and in rats near 2,600 mg/kg/day.  Similar results were reported in the 2-year study
with maximal doses of m/p-cresol of 720 mg/kg/day in male rats and 1,040 mg/kg/day in female mice
(NTP 2008).  None of the studies mentioned above conducted tests of immunocompetence.
These NOAELs for lymphoreticular effects are presented in Table 3-1 and plotted in Figure 3-1.
3.2.2.4  Neurological Effects 
Neurological effects have frequently been noted following oral exposure to cresols.  A woman who drank
approximately 100 mL of a disinfectant, which consisted of roughly 50% mixed cresols, was
semiconscious after 2 hours.  A second woman, who swallowed about 250 mL of the same disinfectant, 
was in a deep coma after 2 hours.  She regained consciousness 10 hours later (Chan et al. 1971). A
woman who swallowed 500–750 mL of a concentrated cresol mixture fell into a deep coma within 1 hour
(Labram and Gervais 1968).  Coma was a common feature of cresol poisoning among 52 patients studied 
by Isaacs (1922).  The author noted that unconsciousness could occur very soon after exposure and could 
last 14 hours or more.
A series of neurological effects, including hypoactivity and lethargy, excess salivation, dyspnea, 
incoordination, muscle twitches and tremors, convulsions, and coma, have been reported in animals
acutely exposed to cresols by gavage (Deichmann and Witherup 1944; Hornshaw et al. 1986; TRL 1986;
Tyl 1988a, 1988b).  The lowest dose at which neurological effects were reported was 50 mg/kg/day, 
which produced hypoactivity and labored respiration in pregnant female rabbits repeatedly dosed with 
o- or p-cresol during gestation (Tyl 1988b).  In rats, effects such as hypoactivity and rapid labored 
respiration were seen at 50 mg/kg/day for all three isomers (TRL 1986).  More serious effects, such as 
convulsions, were seen at 450 mg/kg/day or higher (TRL 1986).
A detailed oral neurotoxicity study of intermediate duration was performed on rats using all three cresol
isomers administered by gavage for 13 weeks (TRL 1986).  A host of clinical observations indicative of
   
 








    
   
   
  
    
 













    
   
  
    
 
 
   
 
  




neurotoxicity (including hypoactivity, rapid labored respiration, excessive salivation, and tremors) was 
reported at doses of 50 mg/kg/day or higher for all three isomers.  However, the results of a number of
neurobehavioral tests designed to assess demeanor and motor and reflex activity (testing was done 6 times 
throughout the 13 weeks prior to dosing) showed only sporadic differences with controls and/or
alterations were not dose-related.  No brain weight changes or histopathologic lesions in the brain or other
nervous tissues were found for any isomer.  Convulsions were reported at 450 mg/kg/day or higher (TRL
1986).  More recently, salivation and tremors were reported in young rats treated by gavage with 
1,000 mg/kg/day m-cresol, but not 300 mg/kg/day, for 28 days (Koizumi et al. 2003).  Other studies of
prolonged oral exposure to cresols by gavage had similar findings (EPA 1988b, 1988c, 1988d; Hornshaw
et al. 1986; Neeper-Bradley and Tyl 1989a, 1989b; Tyl and Neeper-Bradley 1989).  The only 
intermediate-duration gavage studies to determine NOAEL values for neurological effects were the
two-generation reproduction studies in rats (Neeper-Bradley and Tyl 1989a, 1989b; Tyl and Neeper-
Bradley 1989).  Neurological NOAEL values of 30 mg/kg/day were reported for all three cresol isomers 
in these studies.  However, tests for neurobehavioral effects were not performed.  None of the studies
mentioned above observed treatment-related gross or microscopic alterations in the brain, spinal cord, or
sciatic nerve. 
In the intermediate-duration dietary studies in rats and mice conducted by NTP (1992b), the most
common adverse clinical signs of neurological impairment observed were lethargy and occasionally
tremors, and were seen only in mice.  Male and female mice dosed with 4,400–5,000 mg/kg/day of
o-cresol for 28 days showed lethargy and tremors; these signs were not seen at 1,700 mg/kg/day.  Female 
mice, but not males, exposed to 2,080 mg/kg/day of m-cresol for 28 days also exhibited lethargy.  
Lethargy was also seen in male mice dosed with 1,410 mg/kg/day of p-cresol and in male and female 
mice dosed with 4,530–4,730 mg/kg/day of the m/p-cresol mixture. These results indicate that, at least 
for the end points of lethargy and tremors, mice are more sensitive than rats.  Gross and microscopic 
examination of the brain of rats and mice in the NTP (1992b) study did not reveal any treatment-related 
lesions.  Similar negative observations were reported in male rats and female mice dosed with up to 
720 and 1,040 mg/kg/day m/p-cresol, respectively, in the diet for 2 years (NTP 2008). 
The highest NOAEL values and all reliable LOAEL values for neurological effects in each species and 
duration category are recorded in Table 3-1 and plotted in Figure 3-1.
   
 








   
 
   
 
    
 
   
   
   
    
  
     
   
   
 
    
 
       
 
    
    
 
     




     
  







3.2.2.5  Reproductive Effects
No studies were located regarding reproductive effects in humans following oral exposure to cresols.
Developmental toxicity studies in which pregnant rats (Tyl 1988a) and rabbits (Tyl 1988b) were exposed 
to cresols by gavage during gestation reported no effects on the reproductive parameters investigated 
(e.g., number of ovarian corpora lutea, number of implantation sites, number of viable fetuses), even at
maternally toxic doses.  Two-generation reproduction studies in rats (up to 450 mg/kg/day of each isomer
by gavage) and mink (up to 105 mg/kg/day dietary o-cresol for 6 months) also failed to detect adverse 
effects on reproductive function or lesions in reproductive tissues (Hornshaw et al. 1986; Neeper-Bradley
and Tyl 1989a, 1989b; Tyl and Neeper-Bradley 1989).  These studies also included doses producing
maternal toxicity.  No histopathological lesions and only mild organ weight changes of doubtful
significance were reported in the reproductive organs of animals exposed to up to 600 mg/kg/day of
cresols by gavage for 13 weeks (EPA 1988b, 1988c, 1988d). 
The NTP (1992b) study evaluated changes in weight and histopathology of reproductive organs of males
and females, as well as sperm parameters and duration of the estrous cycle, of Fisher-344 rats and 
B6C3F1 mice exposed via the diet to cresol isomers and to a mixture of m- and p-cresol.  The only
significant effects observed in rats in 28-day experiments included mild to moderate uterine atrophy in 
females dosed with 2,310 mg/kg/day of m-cresol or 2,060 mg/kg/day of p-cresol.  In the 13-week study, 
doses of ≥509 of m/p-cresol lengthened the estrous cycle in females and doses of 1,024 and 
2,050 mg/kg/day induced minimal to mild uterine atrophy.  No significant effects were seen in male rats 
dosed with up to 2,200–2,600 mg/kg/day of cresols.  In mice, 28 days of dosing with 1,670 mg/kg/day of
o-cresol produced mild atrophy of the uterus, whereas 4,940 mg/kg/day of m-cresol induced mild to 
moderate atrophy of the mammary glands, uterus, and ovaries.  Neither p-cresol nor the m/p-cresol
mixture adversely affected the reproductive end points in mice in the 28-day study.  A 13-week regimen 
of 3,205 mg/kg/day of o-cresol lengthened the estrous cycle in mice, and doses of up to 1,500– 
1,700 mg/kg/day of m/p-cresol did not induce any significant alterations in males or females.  Treatment
of male rats and female mice with up to 720 and 1,040 m/p-cresol/kg/day, respectively, in the diet for
2 years did not induce any significant alterations in the gross or microscopic morphology of reproductive
organs (NTP 2008).  
Two studies have evaluated the effects of o-cresol and a mixture of m/p-cresol on reproductive function 
end points in CD-1 mice using a continuous breeding protocol (NTP 1992a, 1992c).  End points evaluated 
   
 

























    
 
    
   
   
     
  
  
   
  
    
  
  




included fertility, mean number of litters per pair, live litter size, weight and histopathology of
reproductive organs, vaginal cytology, and sperm parameters.  Both studies started with a 14-week
cohabitation period in which males and females received the test material in the diet.  The highest doses 
during this period were 660 mg/kg/day for o-cresol and 1,682 mg/kg/day for m/p-cresol.  No significant
alterations were observed with o-cresol at any stage of the study.  However, the highest dose of
m/p-cresol significantly decreased the number of live pups/litter and increased the cumulative days to 
litter; a dose level of 1,390 mg/kg/day was a NOAEL.  To determine which sex was the affected sex 
during the cohabitation period, a 1-week crossover mating trial was conducted, but the results indicated 
that either sex could have been affected.  In neither study was fertility affected.  In addition, sperm
parameters and gross and microscopic morphology of reproductive organs were not affected by treatment
with the cresols.
NOAEL and LOAEL values for reproductive effects derived from these studies are recorded in Table 3-1 
and plotted in Figure 3-1.
3.2.2.6  Developmental Effects 
No studies were located regarding developmental effects in humans following oral exposure to cresols.
Developmental effects have been reported in animals given cresols, but only at maternally toxic doses.  
Maternal effects in rats dosed by gavage on gestation days 6–15 (audible respiration, reduced body weight
gain, reduced food consumption, ataxia, tremors, and hypoactivity) occurred at 450 mg/kg/day (Tyl
1988a).  At this dose, both o- and p-cresol produced slight fetotoxicity (increased incidences of dilated 
lateral ventricles in the brain and minor skeletal variations, respectively), but had no effect on 
malformation incidence or gestation parameters (e.g., the number of implantations per litter or fetal body
weight per litter).  No effects of any kind were seen at lower doses.  m-Cresol had no effect on gestation 
parameters, fetotoxicity, or the incidence of malformations, even at maternally toxic doses (Tyl 1988a).  
An additional study in which rats were dosed only on gestation day 11 with up to 1,000 mg/kg of p-cresol
reported no significant effects on post-implantation loss, litter size, viability, or postnatal weight of the
offspring, even when maternal toxicity was evident at doses ≥410 mg/kg (Kavlock 1990).  Slight maternal
toxicity in the form of decreased weight gain was also observed at the 1,682 mg/kg/day dose level.  In 
rabbits dosed on gestation days 6–18 with up to 100 mg/kg/day of each isomer, maternal effects, such as 
audible respiration, ocular discharge, and hypoactivity, were seen following exposure to o- or p-cresol at
50 mg/kg/day (Tyl 1988b).  At 100 mg/kg/day, o-cresol produced slight fetotoxicity (increased incidences 
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of subepidermal hematoma on the head and poorly ossified sternebrae), but no other effects at any dose. 
Neither p- nor m-cresol produced any developmental effects in this study (Tyl 1988b).
Fetotoxicity was also observed at parentally-toxic doses in two-generation reproduction studies.  Rats
treated by gavage with 450 mg/kg/day of o- and p-cresol for 10 weeks before mating produced F1 
offspring that had reduced body weight 4–6 weeks after birth.  This dose also produced overt toxicity in 
the parents (Neeper-Bradley and Tyl 1989a; Tyl and Neeper-Bradley 1989).  In contrast to the results of
the developmental toxicity studies discussed above, m-cresol was the most potent developmental toxicant
among the cresols in the two-generation studies.  This isomer reduced pup survival during lactation when 
administered by gavage at the high dose of 450 mg/kg/day (Neeper-Bradley and Tyl 1989b).  Parental
toxicity manifested as reduced body weight gain was reported at the low dose of 30 mg/kg/day.  
Decreased number of live pups/litter (F1) was reported in a 2-generation reproductive study in mice
exposed to 1,682 mg/kg/day of an m/p-cresol mixture for 14 weeks, but not at 1,390 mg/kg/day (NTP
1992c).  
The comparative susceptibility of newborn and young rats to m-cresol was studied by Koizumi et al. 
(2003).  Neonates were treated by gavage with up to 300 mg/kg/day m-cresol from postnatal day 4 to 21, 
whereas 5-week-old rats were dosed with up to 1,000 mg/kg/day for 28 days.  Most neonates exhibited 
deep respiration, hypersensitivity on handling, and tremors under contact stimulus at 300 mg/kg/day.  
Final body weight also was significantly reduced at this dose level. Tremors also occurred in few
neonates at 100 mg/kg/day, but no clinical signs were seen at 30 mg/kg/day.  No significant alterations
were reported in clinical chemistry, hematology, gross or microscopic pathology (major organs and 
tissues), or physical development and sexual maturation.  In the young rats, clinical signs such as
salivation, tremors, and reduced weight gain were observed at 1,000 mg/kg/day, but there were no 
significant alterations in clinical chemistry, hematology, or histopathological changes at this dose level. 
A dose level of 300 mg/kg/day m-cresol was a NOAEL in 5-week-old rats, whereas 30 mg/kg/day was a 
NOAEL in neonates. 
NOAEL and LOAEL values derived from these studies are recorded in Table 3-1 and plotted in 
Figure 3-1.
3.2.2.7  Cancer
No studies were located regarding cancer in humans following oral exposure to cresols.
   
 









   
 
 
   
   
    
      
 
 
   
 
  
   
     
   
    
 
   
 
 










In an intermediate-duration study, a diet that provided approximately 1,415 mg/kg/day of p-cresol for
20 weeks produced an increased incidence of mild to moderate forestomach hyperplasia in hamsters, 
suggesting that this cresol isomer may have the potential to act as a promoter of forestomach 
carcinogenesis in this species (Hirose et al. 1986).  However, promotion potential was not tested directly.  
However, p-cresol did not produce forestomach hyperplasia in rats treated with the chemical in the diet
(2% or approximately 2,140 mg/kg/day) for an unspecified period of time (Altmann et al. 1986), but rats
are generally less sensitive than hamsters to inducers of forestomach lesions.  In mice, simultaneous 
administration of 1 mg of o-cresol and 1 mg of benzo[a]pyrene twice daily by gavage for up to 30 weeks 
increased the incidence and malignancy of forestomach tumors and shortened their latency relative to 
benzo[a]pyrene alone (Yanysheva et al. 1993).  However, administration of o-cresol before or after 
benzo[a]pyrene decreased the carcinogenicity of the latter substance. 
A recently conducted 2-year feeding study with a mixture of m- and p-cresol (60%/40%) found no 
evidence of neoplastic effects in male Fischer-344 rats (females were not tested) that received mean doses
of up to 720 mg/kg/day of the test material (NTP 2008).  However, NTP (2008) determined that a slight
nonstatistically significant increase (p=0.121) in the incidence of renal tubule adenoma constituted an 
equivocal finding.  In female B6C3F1 mice (males were not tested) that received mean doses of
approximately 0, 100, 300, or 1,040 mg/kg/day, the incidence of squamous cell papilloma of the
forestomach was significantly increased (p<0.001) in the high dose group (0/50, 1/50, 1/49, 10/50).  No 
other significant neoplastic effect was reported in mice.
The EPA (IRIS 2008) has classified the three cresol isomers in Group C, “possible human carcinogens,”
based on inadequate human data and limited data in animals (the assessment is dated 10/89).  The
assessment was based on an increased incidence of skin papillomas in mice in an initiation-promotion 
study and on the fact that the cresol isomers produced positive results in genetic toxicity studies both 
alone and in combination.  Based on updated guidelines for carcinogen assessment (EPA 2005c), cresols
fall in the category of chemicals for which there is “inadequate information to assess carcinogenic
potential.”  EPA did not derive quantitative estimates of carcinogenic risk for cresols (IRIS 2008). EPA’s
assessment of cresols’ carcinogenicity was conducted before the results of the NTP (2008) study became 
available.
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3.2.3 Dermal Exposure 
3.2.3.1  Death 
There are two case reports of people who died following dermal exposure to cresols.  In one case, a
1-year-old baby had 20 mL of a cresol derivative (90% mixed cresols in water) spilled on his head, 
covering about 7% of his body surface.  The baby died in coma within 4 hours (Green 1975).  Assuming
the baby weighed approximately 10 kg, the lethal dose in this case can be estimated to have been roughly
2 g/kg if all the cresol was absorbed, but was probably less since the infant’s head was washed with soap 
and water 5 minutes after the spill.  In the other case, a man fell into a vat of a cresylic acid derivative 
(cresol content unknown) and suffered burns on 15% of the body surface.  Anuria was evident after
36 hours and blood urea content rose steadily during the following days.  The patient fell into a coma on 
the 9th day, and death occurred on the 10th day (Cason 1959).  Dermal absorption of cresol also appears
to have been responsible for the death of a man who worked with an antiseptic solution containing
concentrated mixed cresols for 2 days prior to becoming ill (Larcan et al. 1974).
In rabbits, dermal LD50 values for cresols were 890, 300, 2,830, and 2,000 mg/kg for o-, p-, m-, and mixed 
cresols, respectively (Vernot et al. 1977).  These values are recorded in Table 3-2.  Based on these 
LD50 values, p-cresol appears to be more toxic dermally than o-cresol, with m-cresol being the least toxic
of the three isomers.
3.2.3.2  Systemic Effects
No studies were located regarding cardiovascular or musculoskeletal effects in humans or animals 
following dermal exposure to cresols.
Respiratory Effects. Hemorrhagic pulmonary edema was found at necropsy in a 1-year-old baby
who died after having 20 mL of a cresol-containing product spilled on his head (Green 1975).  Liu et al. 
(1999) reported a case of a woman who suffered acute respiratory failure following chemical burns 
caused by skin contact with a saponated solution of mixed cresols.  
No studies were located regarding respiratory effects in animals following dermal exposure to cresols.
Gastrointestinal Effects. No lesions were found in the gastrointestinal tract of a 1-year-old baby
























(Route) System NOAEL Less Serious Serious 
Reference 
Chemical Form Comments 
ACUTE EXPOSURE 
Death 
Rabbit 1 d 
24 hr/d 2000 
mg/kg/day 
(LD50) 
Vernot et al. 1977 
mix 
Rabbit 1 d 
24 hr/d 890 
mg/kg/day 
(LD50) 
Vernot et al. 1977 
ortho 
Rabbit 1 d 
24 hr/d 2830 
mg/kg/day 
(LD50) 
Vernot et al. 1977 
meta 
Rabbit 1 d 
24 hr/d 300 
mg/kg/day 
(LD50) 
Vernot et al. 1977 
para 
Systemic 
Rabbit 1 d 
4 hr/d Dermal 147 
mg/kg/day 
(skin corrosion) 
Vernot et al. 1977 
mix 
Rabbit 1 d 
4 hr/d Dermal 147 
mg/kg/day 
(skin corrosion) 
Vernot et al. 1977 
ortho 
Rabbit 1 d 
4 hr/d Dermal 147 
mg/kg/day 
(skin corrosion) 
Vernot et al. 1977 
meta 
Rabbit 1 d 
4 hr/d Dermal 147 
mg/kg/day 
(skin corrosion) 

















d = day(s); hr = hour(s); LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; NOAEL = no-observed-adverse-effect level 
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No studies were located regarding gastrointestinal effects in animals following dermal exposure to
cresols.
Hematological Effects. Hematological effects in a man apparently exposed to cresol dermally while 
working with an antiseptic solution containing concentrated mixed cresols, included methemoglobinemia
with massive hemolysis and the presence of numerous large Heinz bodies in the blood (Larcan et al. 
1974).  Similar effects have been reported following oral exposure to cresols (see Section 3.2.2.2).
No studies were located regarding hematological effects in animals following dermal exposure to cresols.
Hepatic Effects. Necropsy revealed extensive centrilobular to mid-zonal liver necrosis in a 1-year-old 
baby who had 20 mL of a cresol derivative spilled on his head (Green 1975).
No studies were located regarding hepatic effects in animals following dermal exposure to cresols.
Renal Effects. A 1-year-old baby who died after a cresol derivative was spilled on his head had
congested and swollen kidneys that were damaged by tubular necrosis (Green 1975).  A man who fell into 
a vat containing a cresylic acid derivative developed anuria after 36 hours and experienced a steady
increase in blood urea levels for 10 days until he died (Cason 1959).  Anuria was also seen in a man who 
apparently absorbed cresol through the skin while working with an antiseptic solution containing
concentrated mixed cresols (Larcan et al. 1974).  Acute polyuric renal failure was described in a man who
accidentally spilled with m-cresol onto both legs and face (Evers et al. 1994).
No studies were located regarding renal effects in animals following dermal exposure to cresols.
Dermal Effects. Corrosive damage to the skin has been reported in humans dermally exposed to 
cresols (Cason 1959; Green 1975; Herwick and Treweek 1933; Klinger and Norton 1945; Pegg and 
Campbell 1985).  In one patient, disfiguring scars remained visible 1 year after exposure (Herwick and 
Treweek 1933).  However, no reaction to cresol was noted when it was applied to the skin as a 1% 
solution in alcohol (Reimann 1933).
Cresols are also strong skin irritants in animals.  All three cresol isomers, either alone or in combination, 
are severely irritating to rabbit skin, producing visible and irreversible tissue destruction (Vernot et al. 
   
 











    
 




    
 







   
   











1977).  Some cresylic acids produced induration and discoloration of the skin in rats (Campbell 1941).  
All reliable LOAEL values for acute dermal effects in rabbits are recorded in Table 3-2.
In a study of intermediate duration, dermal application of 0.5% p-cresol for 6 weeks produced permanent
depigmentation of the skin and hair of mice (Shelley 1974).  A caustic effect on the skin was noted in one
strain of mouse, but not another.  Neither o- nor m-cresol produced any color change in the mice.  The
investigator suggested that only p-cresol was active because it mimics the structure of tyrosine, the amino 
acid present in melanin, so that tyrosinase acts on it, liberating free radicals that damage melanocytes.  
NOAEL and LOAEL values were not derived from this study because the applied dose was not reported.
3.2.3.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological effects in humans or animals following dermal
exposure to cresols.
3.2.3.4  Neurological Effects 
Neurological effects were seen in two people who were accidentally exposed to mixed cresols on the skin 
and later died.  A 1-year-old baby who had 20 mL of a cresol derivative spilled on his head was 
unconscious within 5 minutes; autopsy revealed swelling and congestion of the brain (Green 1975).  A
man who fell into a vat containing a cresylic acid derivative and received burns on 15% of his body fell
into a coma 9 days later (Cason 1959).  A man who survived a 5–6-hour immersion of his hands in a
concentrated cresylic acid solution experienced persistent eye watering, followed by pain on the side of
his face and, ultimately, marked facial paralysis (Klinger and Norton 1945).
Only one study reported neurological effects in animals following dermal exposure to cresols.  Rapid, 
shallow breathing and convulsions were observed in rats 5–30 minutes after covered dermal application 
of 1.0–3.5 mL/kg of certain cresylic acid formulations (Campbell 1941).  Other formulations had no 
effect. These convulsions stopped after a few hours in the rats that survived.
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No studies were located regarding the following health effects in humans or animals after dermal
exposure to cresols:
3.2.3.5  Reproductive Effects
3.2.3.6  Developmental Effects 
3.2.3.7  Cancer
No studies were located regarding cancer in humans following dermal exposure to cresols.
Cresols have not been evaluated for ability to induce cancer when applied to the skin of animals.  
However, a study of skin tumor promotion by cresols was located (Boutwell and Bosch 1959).  Mice
were given a single dermal application of 9,10-dimethyl-1,2-benzanthracene (DMBA), a cancer initiator,
followed by application of 20% solutions of o-, p-, or m-cresol in benzene twice a week for 12 weeks.  
This level of cresols exposure proved to be acutely toxic, producing relatively high nontumor-related 
mortality.  Consequently, all tumor results were based on number of survivors (14–20 per group).  
Promotion with cresols led to increases in the average number of skin papillomas per mouse and the
percentage of exposed mice with at least one papilloma.  o-Cresol was the most potent isomer, and 
p-cresol the least.  Carcinomas were not observed following cresols exposure, although the observed 
papillomas have the potential to develop into carcinomas.  A problem with the study was use of benzene, 
a known carcinogen, as the solvent for the cresols.  However, benzene controls in the cresols experiment
did not develop papillomas, and neither did benzene controls in four parallel series of experiments (a few
papillomas were observed in a fifth benzene control group).  Therefore, the results of this study showing
that all three cresol isomers are capable of promoting skin tumors initiated by DMBA appear to be valid.  
3.3 GENOTOXICITY
The genotoxic effects of cresols have been well studied.  In vitro genotoxicity assays on o-, p-, and 
m-cresol are shown in Table 3-3.  Results were uniformly negative in Salmonella assays with or without
metabolic activation (Douglas et al. 1980; Florin et al. 1980; Haworth et al. 1983; Kubo et al. 2002; NTP
1992b; Pepper, Hamilton & Scheetz 1981; Pool and Lin 1982) and mixed in in vitro studies using
mammalian cells (Brusick 1988a, 1988b, 1988c; Cifone 1988a, 1988b, Gaikwad and Bodell 2001;
Hamaguchi and Tsutsui 2000; Hikiba et al. 2005; Li et al. 2005; Miyachi and Tsutsui 2005; Murli 1988, 
Pepper, Hamilton & Scheetz 1980, 1981).  Positive results were reported in assays for chromosomal
   
 
































       
     
  
    
    
 
    
   
 
   




    
   
  
 
     
  
 






    
   
  
  




        




   
 
 
    
 







    





   
 
     
    
 















Salmonella Reverse mutation – – Douglas et al. 1980; o, p, m, 1:1:1
typhimurium on Florin et al. 1980; mixture of o,
plates Haworth et al. 1983; p, m
Kubo et al. 2002;
Pepper, Hamilton &
Scheetz 1980, 1981;
Pool and Lin 1982
Eukaryotic organisms:
Mammalian cells:
CHO cells Chromosomal + + Murli 1988 o, p
aberrations
CHO cells Chromosomal – – Murli 1988 m
aberrations
CHO cells Sister chromatid + + Pepper, Hamilton & o, 1:1:1 
exchange Scheetz 1980, 1981 mixture of o,
p, m
Mouse Cell transformation + No data	 Pepper, Hamilton & 1:1:1 mixture 
BALB/C-313 cells Scheetz 1980 of o, p, m
Mouse Cell transformation No data + Brusick 1988b p
BALB/C-313 cells
Mouse Cell transformation – –	 Brusick 1988a, o, m
BALB/C-313 cells	 1988b, Pepper ,
 




L5178Y mouse Forward mutation + (+)	 Pepper, Hamilton & 1:1:1 mixture 
lymphoma cells Scheetz 1980 of o, p, m
L5178Y mouse Forward mutation – – Cifone 1988a; o, p, m
lymphoma cells Pepper, Hamilton &
Scheetz 1981
 
Mouse spermatid DNA damage No data + Li et al. 2005 o
 
Primary rat Unscheduled DNA No data – Pepper, Hamilton & o
 
hepatocytes synthesis Scheetz 1981 









Human peripheral Semiconservative/ No data (+) Daugherty and p
 
lymphocytes repair DNA	 Franks 1986




HL-60 cells DNA adduct – + Gaikwad and Bodell p
 
formation	 2001
   
 


















   
 
    
 
 
    
 
     





   
 









         























































– = negative result; + = positive result; (+) = weakly positive; CHO = Chinese hamster ovary;
DNA = deoxyribonucleic acid; SHE = Syrian hamster embryo
   
 








     
   
      
   
    
  
   
    
   
 
    
     
 
    
  
 
     
   
    
  
 
     
    
  
  
   
 
   
   
   





aberrations for o- and p- cresol, but not for m-cresol in Chinese hamster cells (Murli 1988), while 
m-cresol produced positive results for chromosomal aberrations in Syrian hamster embryo cells (Hikiba et 
al. 2005).  There was a positive result for sister chromatid exchange for o-cresol and for a mixture of o-, 
p-, and m-cresol in Chinese hamster ovary cells (Pepper, Hamilton & Scheetz 1980, 1981), and Syrian 
hamster embryo cells (Miyachi and Tsutsui 2005), which is in contrast to negative results for sister
chromatid exchange in human fibroblasts for the o-, p-, and m-isomers (Cheng and Kligerman 1984). 
p-Cresol, and a mixture of the o-, p-, and m-cresol, also produced cell transformation in mouse
BALB/C-3T3 cells (Brusick 1988b; Pepper, Hamilton & Scheetz 1980), while o- and m-cresol did not
(Brusick 1988a, 1988b; Pepper, Hamilton & Scheetz 1981; Sernav 1989b).  
A 1:1:1 mixture of the three cresol isomers was positive in tests for forward mutation in mouse lymphoma
cells (Pepper, Hamilton & Scheetz 1980), but negative for each isomer tested individually (Cifone 1988a;
Pepper, Hamilton & Scheetz 1981).  Assays were negative for increased DNA synthesis in rat hepatocytes 
for o- and m-cresols (Cifone 1988b; Pepper, Hamilton & Scheetz 1981), and positive in Syrian hamster
embryo cells with activation for m-cresol (Hamaguchi and Tsutsui 2000) and in human peripheral
lymphocytes for p-cresol (Daugherty and Franks 1986).  DNA damage was found in mouse spermatid and 
human peripheral lymphocytes in assays testing o-cresol (Li et al. 2005), as was DNA adduct formation in
rat hepatocytes and HL-60 cells incubated with p-cresol (Gaikwad and Bodell 2001).  A weak positive
result was reported for SV40 induction in Syrian hamster kidney cells (Moore and Coohill 1983).  
Positive results obtained in some human and animal in vitro tests suggest that cresols have some ability to 
react with DNA, and may be clastogenic under certain circumstances.  
Results from in vivo genotoxicity assays on o-, p-, and m-cresol are shown in Table 3-4.  Studies of the
genotoxicity of cresols in animals in vivo reported negative results for dominant lethal, chromosomal
aberrations and mouse bone marrow, alveolar macrophages, and regenerating liver cells in vivo (Cheng
and Kligerman 1984; Ivett 1989a, 1989b, 1989c; Sernav 1989a, 1989b).  Treatment of male and female
B6C3F1 mice with up to 2,723 or 3,205 mg/kg/day o-cresol, respectively, for 13 weeks did not increase 
the incidence of micronuclei in peripheral blood erythrocytes (NTP 1992b).  Similar negative results were
reported in male and female mice dosed with up to 1,513 or 1,693 mg/kg/day m/p-cresol, respectively
(NTP 1992b).  However, micronucleus frequency was increased in bone marrow from male mice injected 
twice intraperitoneally with 20, 40, or 80 mg/kg o-cresol (Li et al. 2005).  Although o-, p-, and m-cresol
and a 1:1:1 mixture of the three cresol isomers gave some indication of genotoxic activity in in vitro
assays with mammalian cells, most in vivo assays were negative, with one exception.  Overall, cresols do 
not seem to pose a genotoxic threat to humans under normal environmental exposure conditions.
   
 




















       
   
 







       
       
  
  








Table 3-4.  Genotoxicity of Cresols In Vivo
Results
Species (test With Without
system) End point activation activation References Isomer
Eukaryotic organisms (in vivo):
Mouse Dominant lethal No data – Ivett 1989a, 1989b o, p
Mouse Chromosomal aberrations (bone No data – Ivett 1989b m
marrow)
Mouse Sister chromatid exchange (bone No data – Cheng and o, p, m
marrow, alveolar macrophages, Kligerman 1984
and regenerating liver cells)
Mouse Micronucleus frequency No data + Li et al. 2005 o
Mouse Micronucleus frequency No data – NTP 1992b o, m/p
Drosophila Sex-linked recessive lethal No data – Sernav 1989a, o, p
melanogaster 1989b
– = negative result; + = positive result
   
 








   
 
  
   
      
   
  






    
 
  
     
    
  
   







     





Cresols can be absorbed following inhalation, oral, and dermal exposure by humans and animals.  Most of
the evidence of absorption in humans is indirect, derived from cases of accidental dermal contact with 
these substances or accidental or intentional ingestion.  Limited data from workers exposed to airborne
cresols provide evidence of absorption by inhalation, although dermal absorption could have also 
occurred.  Quantitative data are not available.  Little is known about distribution of cresols in humans.  In 
a fatal case of dermal intoxication, cresols were found in the brain and liver.  Studies in animals dosed by
oral gavage with a single dose of m- or p-cresol indicate that cresols can distribute rapidly into many
organs and tissues.  Cresols undergo oxidative metabolism in the liver and are rapidly eliminated, mostly
in the urine, as sulfate or glucuronide conjugates.  A study showed that human and rat liver microsomes in 
vitro metabolized p-cresol in a similar manner.  However, the relevance of the available toxicokinetics 
information in animals to toxicokinetics of cresols in humans is unknown.
3.4.1 Absorption 
p-Cresol is normally found in the body where it is generated from protein breakdown.  p-Cresol is one of
the metabolites of the amino acid tyrosine and of phenylalanine.  Tyrosine and phenylalanine are
converted to 4-hydroxyphenylacetic acid by intestinal bacteria.  4-Hydroxyphenylacetic acid is further
decarboxylated to p-cresol, which is absorbed from the intestine and excreted in the urine as conjugates 
(De Smet et al. 1997; Vanholder et al. 1999).  De Smet et al. (1998a) reported a mean concentration of
8.6 µmol/L of p-cresol (0.93 mg/L) in serum from healthy subjects.  
3.4.1.1  Inhalation Exposure 
No studies were located regarding the rate and extent of absorption in humans following inhalation 
exposure to cresols.
The absorption of cresols following inhalation exposure in animals has not been quantified, but can be
assumed to occur, since mortality and other effects have been reported in animals following exposure 
(Campbell 1941; Kurlyandskiy et al. 1975; Uzhdavini et al. 1972).
   
 








   
 
   
  
  
   
 
  
    
   
    
  
      
       
 
    
   
   
  









   
  
  





3.4.1.2  Oral Exposure
No studies were located regarding the rate and extent of absorption in humans following oral exposure to 
cresols.  However, it can be assumed that cresol are absorbed orally based on the many reports of adverse 
effects in subjects who ingested cresols accidentally or intentionally (i.e., Chan et al. 1971; Hashimoto et
al. 1998; Kamijo et al. 2003; Labram and Gervais 1968).
In a study in rabbits administered all three cresol isomers by oral gavage under fasting conditions, from
65 to 84% of the administered dose was recovered in the urine within 24 hours, indicating that at least that
amount had been absorbed (Bray et al. 1950).  When p-cresol was administered 1–2 hours after the
rabbits were fed, the rabbits exhibited less toxic effects than when given the compound under fasting
conditions, indicating that the gastrointestinal contents retarded the absorption of p-cresol (Bray et al. 
1950).  A recent study showed that after a single gavage dose of a cresol soap solution (p- and m-cresol)
to rats, 50% of the administered dose disappeared from the gastric contents in 15 minutes, and almost all
of the administered cresol disappeared within 8 hours (Morinaga et al. 2004).  In blood, the unconjugated 
concentrations of p- and m-cresol decreased rapidly for 2 hours after peaking 30 minutes after dosing.  No 
unconjugated cresols could be detected after 4 hours.  The p-cresol glucuronide in blood was always
higher than the p-cresol sulfate, whereas the concentration of m-cresol sulfate was consistently higher
than the m-cresol glucuronide.  Based on the fact that the concentrations of the unconjugated cresols in 
liver and spleen were much higher than those in blood over a monitoring period of 8 hours, Morinaga et
al. (2004) suggested that cresol administered by oral gavage diffuses directly through the gastric and 
small intestinal walls.  
3.4.1.3 Dermal Exposure 
The occurrence of coma, death, and systemic effects in two humans dermally exposed to cresols (Cason
1959; Green 1975) indicates that these compounds can be absorbed through the skin.  In another case of
accidental dermal exposure to cresols, Fuke et al. (1998) reported that the concentrations of unconjugated
p-cresol, sulfate, and glucuronide in the serum collected 2 hours after exposure were 15.7, 21.3, and 
38.6 µg/mL, respectively.  The respective concentrations of m-cresol were 31.4, 17.0, and 82.9 µg/mL; 
the exposure amount was unknown so that the extent of absorption could not be estimated.  An in vitro
study of the permeability of human skin to cresols found that these substances had permeability
coefficients greater than that for phenol, which is known to be readily absorbed across the skin in humans
(Roberts et al. 1977).
   
 





















     
       
   
    
  
   
  




    
 
   







No studies were located regarding the rate and extent of absorption in animals following dermal exposure 
to cresols.
3.4.2 Distribution 
3.4.2.1  Inhalation Exposure 
No studies were located regarding the extent of distribution in humans or animals following inhalation 
exposure to cresols.
3.4.2.2  Oral Exposure
No studies were located regarding the distribution of cresols in humans following oral exposure.
The distribution of m- and p-cresol has been studied in rats (Morinaga et al. 2004).  Rats received a single 
gavage dose of a mixture of m- and p-cresol soap solution (100 mg p-cresol, 160 mg m-cresol/kg) and 
conjugated and unconjugated cresols were determined in tissues at various times up to 8 hours after
dosing.  The concentrations of unconjugated m- and p-cresol in liver and spleen were always much higher
than in blood and higher than the sulfate or glucuronide metabolites in those organs.  The unconjugated
concentrations of both cresols in brain, lung, and muscle were similar to those in blood.  The
concentration of glucuronidated cresols were always highest in the kidney followed by the liver.  
Comparison of the concentration of glucuronide and sulfate conjugates in tissues showed that the
glucuronide was always higher than the sulfate for both p- and m-cresol, particularly in the liver and 
kidneys.  In all tissues, m-cresol sulfate was always higher than p-cresol sulfate, suggesting a slightly
different metabolic disposition for these two isomers.  
3.4.2.3 Dermal Exposure 
Cresols were identified in the blood (12 mg/100 mL), liver, and brain of a 1-year-old baby who died 
4 hours after 20 mL of a cresol derivative was spilled on his head (Green 1975). 
No studies were located regarding the extent of distribution in animals following dermal exposure to 
cresols.
   
 








    
 
    
      
  
    
       
     
 
 









     
   
  
     
    
 
   
  
   
  






3.4.2.4 Other Routes of Exposure 
In rats administered a single intravenous dose of 3 mg/kg of p-cresol, the concentration of p-cresol in 
blood 5 minutes after dosing was 6.7 mg/L and decreased gradually to 0.6 mg/L near 240 minutes after
dosing (Lesaffer et al. 2001).  The half-life of p-cresol in serum was 1.5 hours (twice as long as 
creatinine) and its total clearance was 23.2 mL/minute/kg (3 times that of creatinine).  Also, the volume of
distribution of p-cresol was 5 times that of creatinine; however, renal clearance of p-cresol
(4.8 mL/minute/kg) was about half that of creatinine.  Similar results were reported in a subsequent paper
from the same group of investigators (Lesaffer et al. 2003a).
3.4.3 Metabolism
No studies were located regarding metabolism in humans following exposure to cresols.
A few studies reported on the metabolism of cresols in animals.  Cresols in the urine are found primarily
as sulfate and glucuronide conjugates.  In the urine of rabbits, 60–72% of the orally administered dose
was recovered as ether glucuronide, and 10–15% was recovered as ethereal sulfate (Bray et al. 1950).  A
similar result was obtained in an earlier study in rabbits in which 14.5–23.5% of the orally administered 
dose was found conjugated with sulfate in the urine (Williams 1938).  For simple phenols such as cresols, 
the proportions of the conjugates are known to vary with dose and to differ from one species to the next.  
In the study by Bray et al. (1950), hydroxylation of a small percentage (3%) of the administered dose to 
2,5-dihydroxytoluene (conjugated) occurred for both o- and m-cresol.  No hydroxylation occurred for
p-cresol, but p-hydroxybenzoic acid (both free and conjugated) was detected in the urine.  Only 1–2% of
the administered dose was found as unconjugated free cresol in the urine.  A study in rats showed that
m-cresol is preferentially metabolized to sulfate, and p-cresol to glucuronide (Morinaga et al. 2004).
Studies by Thompson and coworkers (Thompson et al. 1994, 1995, 1996) and Yan et al. (2005) have
provided more detailed information on the metabolism of cresols and the role of metabolism in 
hepatotoxicity (the role of metabolism on hepatotoxicity is discussed in Section 3.5.2).  Using rat liver
microsomes and precision-cut liver slices, Thompson et al. (1995) demonstrated that p-cresol formed 
monoglutathione conjugates with a structure consistent with the formation of a quinone methide
intermediate.  The latter may be formed in two successive one electron oxidation steps by cytochrome
P-450 (Koymans et al. 1993).  Using human liver microsomes Yan et al. (2005) confirmed that the
activation of p-cresol by oxidation forms a reactive quinone methide which formed a conjugate, 
   
 















   
   
 




   
    
      
   
   
  
 
   
 
   
 
  
    
 





glutationyl-4-methyphenol.  In addition, a new pathway was identified consisting of aromatic oxidation 
leading to the formation of 4-methyl-o-hydroquinone which is further oxidized to 4-methyl[1,2]benzo­
quinone.  The latter formed three adducts with glutathione, but the predominant was found to be
3-(glutathione-S-yl)-5-methyl o-hydroquinone.  It was also found that 4-hydroxybenzylalcohol, a major
metabolite formed by oxidation of the methyl group in liver microsomes, was further converted to 
4-hydroxybenzaldehyde.  Experiments with recombinant P-450s demonstrated that the formation of the
quinone methide intermediate was mediated by several P-450s including CYP2D6, 2C19, 1A2, 1A1, and 
2E1.  The ring oxidation pathway was found to be mediated primarily by the CYP2E1 and to a lesser
extent by CYP1A1, 1A2, and 2D6.  Formation of 4-hydroxybenzaldehyde was catalyzed by 1A2 and also 
1A1 and 2D6.  Human liver microsomes formed the same adducts as rat liver microsomes suggesting that
the metabolism of p-cresol is similar in humans and rats.  The metabolic pathway for p-cresol proposed
by Yan et al. (2005) is shown in Figure-3-2.
3.4.4 Elimination and Excretion 
3.4.4.1  Inhalation Exposure 
Studies of subjects occupationally exposed to cresols have demonstrated that cresols are eliminated in the
urine.  Workers employed in the distillation of the high temperature phenolic fraction of tar excreted 
p-and o-cresol in the urine at rates of 2.4 and 3.3 mg/hour, respectively (Bieniek 1994).  The highest
concentrations in urine were found during the first 2 hours after the end of the work shift.  A study of
76 men working at a coke plant where the geometric mean concentrations of o-, m-, and p-cresol in the
breathing zone air were 0.09, 0.13, and 0.13 mg/m3, respectively, reported that the corresponding
concentrations in hydrolyzed urine were 16.74, 16.74, and 0.53 mg/g creatinine (Bieniek 1997).  
3.4.4.2  Oral Exposure
No studies were located regarding excretion in humans following oral exposure to cresols.
Following oral exposure to cresols in rabbits, 65–84% of the dose was excreted in the urine within 
24 hours, mostly as ethereal glucuronides and sulfates (Bray et al. 1950).
3.4.4.3 Dermal Exposure 
No studies were located regarding excretion in humans or animals following dermal exposure to cresols.
   
 
















Figure 3-2.  Bioactivation Pathways of p-Cresol in Human Liver Microsomes
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Source:  adapted from Yan et al. 2005
   
 














   
  
   




    
 
  









   
   
 







3.4.4.4  Other Routes of Exposure 
Intravenous injection of a single dose of p-cresol to rats resulted in approximately 23% of the injected 
dose being excreted in the urine as parent compound within 240 minutes, the duration of the experiment
(Lesaffer et al. 2001).  As indicated in Section 3.4.2.4, the total clearance of p-cresol largely exceeded its 
renal clearance, which led Lesaffer et al. (2001) to suggest the presence of extra-renal elimination routes
for p-cresol, namely, exsorption from the blood compartment into the gastrointestinal tract, biotrans­
formation, or excretion via the bile.  A subsequent study from the same group of investigators showed 
that in rats, 64% of an intravenous dose of p-cresol (9.6 mg/kg) was excreted as p-cresylglucuronide 
(Lesaffer et al. 2003b).  When the glucuronide and the unconjugated p-cresol were combined, 
approximately 85% of the injected dose was recovered in the urine.  
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.  
   
 








       
  
   
 
   
 
      
 
 




















The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-3 shows a conceptualized representation of a PBPK model.
If PBPK models for cresols exist, the overall results and individual models are discussed in this section in 
terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.
No PBPK models have been developed for cresols.
   
 























Figure 3-3.  Conceptual Representation of a Physiologically Based
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Note:  This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source:  adapted from Krishnan et al. 1994
   
 








   
     
 
    
    
   
     
 




       
     
  
   
     
 
      
 










   
   




3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
Absorption. No specific information was located regarding the mechanism of absorption of cresols.  
However, in a study in rats administered a cresol soap solution (m- and p-cresol) via a gastric tube, the
concentration of free cresols in liver and spleen were much higher than those in blood at all times after
dosing (up to 8 hours) (Morinaga et al. 2004).  This led the investigators to suggest that cresol
administered via a stomach tube diffuses directly though the gastric and small intestinal walls, which 
according to Morinaga et al. (2004), would explain the very high concentration of unconjugated cresols
found in the liver and also in the spleen, which is adjacent to the stomach.  Whether this also happens
following ingestion of cresols mixed in food or in water is not known. 
Distribution. No specific information was located regarding how cresols are transported in blood, but
it is reasonable to assume that they may be bound to albumin, the most important binding protein for
many acidic and basic drugs (Mabuchi and Nakahashi 1988).  In a study of healthy subjects and patients
with chronic renal failure, no free p-cresol could be detected in the blood of healthy subjects, 100% was
protein-bound (De Smet et al. 1998a).  No information was located for o- or m-cresol. 
Metabolism. The limited information available summarized in Section 3.4.3 indicates that cresols
undergo conjugation with sulfate and glucuronic acid and also form oxidative metabolites.  However, 
there is virtually no information on possible shifts between these reactions that could be dose-dependent,
dependent on the availability of co-substrates in the conjugation reactions, or related to different enzyme 
activity levels across areas of the liver, as occurs with structurally similar chemicals (i.e., phenol).  The
role of metabolism on the toxicity of cresols is discussed in Section 3.5.2.
Excretion. Cresols are excreted in the urine as glucuronides and sulfates.  However, based on the
observation that the total clearance of p-cresol largely exceeded its renal clearance in rats administered 
p-cresol intravenously, Lesaffer et al. (2001) suggested the presence of extra-renal elimination routes for
p-cresol, namely, exsorption (reverse absorption or secretion) from the blood compartment into the
gastrointestinal tract, biotransformation, or excretion via the bile.  Exsorption from the blood 
compartment into the gastrointestinal tract may be plausible for unbound p-cresol, a relatively small 
molecule, but not for protein-bound p-cresol, which is how 100% of p-cresol is normally found in the
blood (De Smet et al. 1998a).  No pertinent information was located for o- or m-cresol.
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3.5.2 Mechanisms of Toxicity
Limited information is available regarding the mechanism(s) of toxicity of cresols.  Cresols are irritant
and corrosive at high concentrations as evidenced by numerous cases of accidental dermal exposure or
accidental or intentional ingestion of cresols.  Much like phenol, cresols impair the stratum corneum and 
produce coagulation necrosis by denaturating and precipitating proteins. 
The role of metabolism in the toxicity of cresol has been studied by Thompson and coworkers (Thompson 
et al. 1994, 1995, 1996). Using lactate dehydrogenase (LDH) leakage or intracellular potassium as 
indices of toxicity in precision-cut rat liver slices as a test system, they showed that p-cresol was the most
toxic of the three isomers.  Similar results were obtained in liver slices from rats pretreated with 
phenobarbital, an inducer of cytochrome P-450; however, in this case, the toxicity of each isomer relative
to control was increased compared to untreated slices.  On a molar basis, p-cresol was 5–10 times more 
toxic than o- or m-cresol in the LDH leakage test.  Incubation with the thiol precursor N-acetylcysteine or
inhibition of cytochrome P-450 with metyrapone inhibited the toxicity of p-cresol, whereas depletion of
glutathione increased the toxicity of p-cresol.  These treatments had little effect on the toxicity of o- or
m-cresol, suggesting a somewhat different mechanism of action, at least in the test system used.  
Furthermore, p-cresol rapidly depleted intracellular levels of glutathione, while the other isomers did it to
a lesser extent.  In the absence of glutathione, the major metabolite of p-cresol was p-hydroxybenzyl
alcohol, which caused no observable toxicity to the liver slices.  In the presence of glutathione, the 
amount of p-hydroxybenzyl alcohol was reduced by about 30% and the new product formed was
confirmed to be a glutathione conjugate formed via the formation of a reactive quinone methide 
intermediate.  The reactive intermediate bound covalently to protein in slices and in microsomal
preparations.  A metabolic pathway for p-cresol proposed by Yan et al. (2005) is shown in Figure 3-2.
A study by Kitagawa (2001) suggested that liver mitochondria may be a target for the liver toxicity of
cresols based on results that indicated that these compounds inhibited mitochondrial respiration and 
induced or accelerated swelling of the mitochondria.  However, it is difficult to relate the results from
these studies in vitro to the observations of little or no alterations in the liver of animals dosed with 
cresols for extended periods of time (NTP 1992b).  
Many studies in which the animals were dosed with cresols by oral gavage reported adverse neurological
signs ranging from lethargy to tremors and convulsions (EPA 1988b, 1988c; TRL 1986; Tyl 1988a, 
1988b).  Dietary studies reported occasional tremors only at the highest doses administered.  The 
   
 











    
     
 
   
 
   
 




   
  
    
 




    
 
   
 
  





mechanism by which cresols induced these effects is unknown.  Studies in rats have reported that cresols 
induce changes in neurotransmitter levels in the brain (Calderón-Guzmán et al. 2005) and in activities of
some enzymes (DeWolf et al. 1988; Savolainen 1979).  Calderón-Guzmán et al. (2005) also suggested 
that cresols may increase lipid peroxidation and change membrane fluidity in rat brain.  Studies have also 
reported neurophysiological changes in animals exposed to cresols.  Mattsson et al. (1989) observed 
excitation of somatosensory evoked potentials and changes in the EEG in rats following intravenous
administration of o-cresol.  Mohammadi et al. (2001) reported that o-cresol, but not m-cresol, activated
GABAA receptors expressed in transformed human embryonic kidney cells.  If such an effect were to 
occur in the intact animal, it may result in decreased activity and sedation since GABA normally mediates 
inhibitory neural activity.  Whether any of these putative mechanisms of neurological effects are involved 
in the effects observed following oral dosing of animals, particularly by gavage, is unknown.  Cresols
could be acting at multiple sites including sites at the periphery.
3.5.3 Animal-to-Human Extrapolations 
Cresols are irritants and corrosive in high concentrations and will produce similar effects on the skin and 
mucosal surfaces of humans and animals.  Other than death and neurological effects, which have been 
reported both in humans and animals exposed to high amounts of cresols, it is difficult to predict other
health outcomes in humans based on observations in animals.  The metabolism of cresols seems to be
similar in humans and rats based on the fact that both species excrete sulfate and glucuronide conjugation 
products in the urine.  Furthermore, Yan et al. (2005) showed that bioactivation patterns for p-cresol in
human and rat liver microsomes lead to the same reactive intermediates and glutathione adducts.  While 
this and other studies (Thompson et al. 1994, 1995) served to construct a toxicity ranking for cresol
isomers in hepatocytes in vitro, extrapolation to other toxicities would be pure speculation and
inappropriate.  
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
   
 





















   
 






   
 
      
  
    
 
    
    
   
 
  




naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
Based on the available information, there is no evidence that cresols are endocrine disruptors in humans
and little evidence in animals.  A 28-day dietary study reported mild uterine atrophy in female rats dosed 
with 2,310 mg/kg/day of m-cresol or 2,060 mg/kg/day of p-cresol (NTP 1992b).  Comparable doses of
o-cresol or an m/p-cresol mixture were without significant effect.  A 13-week treatment with the
≥509 mg/kg/day m/p-cresol in the diet significantly lengthened the estrous cycle of rats, and doses of
1,024 and 2,050 mg/kg/day induced minimal to mild uterine atrophy (NTP 1992b).  In mice, exposure to 
≥1,670 mg/kg/day of o-cresol for 28 days also induced mild atrophy of the uterus, and 4,940 mg/kg/day 
of m-cresol induced mild to moderate atrophy of the mammary gland, uterus, and ovaries (NTP 1992b).  
In addition, doses of 3,205 mg/kg/day of o-cresol for 13 weeks lengthened the estrous cycle in female 
mice.  In these studies, there was no biologically significant effect on males’ reproductive organs or on 
sperm parameters.  In the 2-year bioassay, doses of up to 720 and 1,040 mg/kg/day m/p-cresol, 
respectively, did not induce and significant alterations in gross or microscopic morphology of
reproductive organs (NTP 2008).
   
 














    
   
 
 
   
     
   
    
   









   
 
  
    
 





Multiple-generation reproductive studies that administered cresols by oral gavage (Neeper-Bradley and 
Tyl 1989a, 1989b; Tyl and Neeper-Bradley 1989) or through the diet (NTP 1992a, 1992c) have provided 
no evidence of endocrine-mediated alterations on reproduction or development.
In standard developmental toxicity studies in rats and rabbits, cresols have induced slight fetotoxicity, but
only at maternally toxic doses (Tyl 1988a, 1988b).  A study that treated newborn rats with m-cresol by
gavage from postnatal day 4 through 21 reported noticeable clinical signs (tremors, hypersensitivity) with
the highest dose tested, 300 mg/kg/day, but there were no alterations in the physical development or
sexual maturation of the pups (Koizumi et al. 2003).
A study in which embryos of rats were incubated in vitro with p-cresol observed increased incidence of
structural abnormalities such as hind limb bud absence and tail defects, but there is no evidence that this
was endocrine-mediated (Oglesby et al. 1992).  Additional information from studies in vitro is limited.  
Nishihara et al. (2000) reported that p-cresol tested positive and o-cresol negative for estrogenic activity
in a reporter gene expression assay using yeast cells (Nishihara et al. 2000).  A substance was considered
positive when its activity was more than 10% of the activity of 10-7 M 17β-estradiol.  Neither o-cresol nor
p-cresol showed androgenic activity (agonist or antagonist) in stably transfected CHO-K1 cell lines, 
which expressed the androgen receptor (AR) and a AR-responsive luciferase gene reporter (Araki et al. 
2005; Satoh et al. 2005).  
Collectively, the available evidence does not suggest that cresols represent a hazard due to properties of
endocrine disrupters, although a few cases of mild atrophy of female reproductive organs and lengthening
of estrous cycle in rats and mice were reported for cresols, but generally at relatively high doses.
3.7  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
   
 

















   
 
  
   
   
 
  
   
     
 
  
   
       
   
  
  
   
  







Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage
may not be evident until a later stage of development.  There are often differences in pharmacokinetics
and metabolism between children and adults.  For example, absorption may be different in neonates
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
   
 


















      
  






   





   
 
  
      
      
  
   
     
    
CRESOLS 116
3. HEALTH EFFECTS
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
There are no studies that specifically address the health effects of exposure to cresols in children;
therefore, it is unknown whether children differ from adults in their susceptibility to health effects from
cresols.  Only one study was located that compared the effects of m-cresol administered by gavage in 
newborn rats and young rats (Koizumi et al. 2003).  Newborn rats exhibited adverse neurological signs at
approximately one third the doses that affected young rats.  It is unknown whether this reflects differences 
in pharmacokinetics or on other aspects of m-cresol action.  Data on the effects of cresols in adults are 
derived almost exclusively from cases of accidental or intentional ingestion of cresol solutions (i.e., Chan 
et al. 1971; Hayakawa 2002; Isaacs 1922; Jouglard et al. 1971; Kamijo et al. 2003; Minami et al. 1990;
Wu et al. 1998) or accidental dermal exposure (i.e., Cason 1959; Pegg and Campbell 1985).  In some of
these cases, death occurred.  Exposure to these amounts of cresols produced corrosion at the points of
contact including the skin and gastrointestinal tract.  Similar effects would be expected in children 
exposed to high amounts of cresols.  In fact, Green (1975) reported the death of a child after a cresol
mixture was spilled on his head. 
There is no information regarding possible adverse developmental effects in humans exposed to cresols.  
Some studies in animals have reported fetotoxicity at dose levels that also produced maternal toxicity
(Neeper-Bradley and Tyl 1989a, 1989b; Tyl 1988a, 1988b; Tyl and Neeper-Bradley 1989).  For the most
part, cresols have been negative in genotoxicity tests in vivo. Therefore, it is unlikely that parental
exposure would result in adverse childhood development or cancer development as a result of cresol
exposures to parental germ cells.
There is no information regarding pharmacokinetics of cresols in children.  A study of the metabolism of
p-cresol in human liver microsomes showed that both phase I and phase II metabolic enzymes are 
involved in the biotransformation of p-cresol and that the metabolism of p-cresol in humans and rats is 
similar (Yan et al. 2005). That study and others (Thompson et al. 1994, 1995) have provided evidence
that, at least in rats, phase I enzymes increase the liver toxicity of p-cresol in vitro, whereas conjugation 
reactions decreased the toxicity.  To the extent that some of these enzymes are developmentally regulated, 
the metabolism, and consequently the toxicity of cresols in immature humans may be different than in 
adults.  However, since the causative agent of cresols toxicity is still unknown, trying to predict how
immature enzymatic systems could affect the toxicity of cresols in developing humans would be pure
   
 















    
 
   
 











    
  
   






speculation at this time.  It is not known whether cresols can cross the placenta and there are no reports on 
levels of cresols in maternal milk.
There are no biomarkers of exposure or effect for cresols that have been validated in children or in adults
exposed as children.  No relevant studies were located regarding interactions of cresols with other
chemicals in children or adults.
No information was located regarding pediatric-specific methods for reducing peak absorption following
exposure to cresols, reducing body burden, or interfering with the mechanism of action for toxic effects. 
3.8  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The
preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as
copper, zinc, and selenium).  Biomarkers of exposure to cresols are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
   
 









    
 
   
 
   
  
  
   
 
     
 
    
 
    
   
       
 
    
   
 
   
   
  
 






tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by cresols are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Cresols 
No biomarkers that uniquely implicate exposure to cresols have been identified in humans or animals.  
Cresols are formed from the commonly found amino acid tyrosine, and occur naturally in human and 
animal tissues, fluids, and urine.  Cresols are also formed as minor metabolites of toluene, and an 
increased presence of o-cresol in the body could be due to exposure to this substance, although toluene or
hippuric acid in the urine seem to be more reliable indicators of occupational exposure to toluene than 
o-cresol (De Rosa et al. 1987; Fustinoni et al. 2007).  The use of cresols as a biomarker of exposure to 
cresol would require a considerable elevation to exceed biological background levels and potential
confounding from conversion of other environmental agents.  There is some evidence that the presence of
o-cresol in urine can be used as a biomarker for phenol exposure.  A study of workers at a coke plant
involved in the tar-distillation process found a statistically significant correlation (p<0.001) between low
concentrations of o-cresol in breathing-zone air and end-of-shift urine samples (Bieniek 1997).  Urinary
levels of o-cresol were also found to be significantly higher in the urine of workers employed in the
distillation of carbolic oil than in nonexposed workers (Bieniek 1994).
p-Cresol has been found to form adducts with DNA in in vitro systems and it has been suggested that this 
property might provide a biomarker to assess occupational exposure to toluene (Gaikwad and Bodell
2001, 2003).
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3.8.2 Biomarkers Used to Characterize Effects Caused by Cresols 
No biomarkers of effects caused by cresols have been identified in humans or animals.  Data on human 
exposure to cresols are derived mainly from cases of acute accidental or intentional exposure to high 
amounts of cresol, which usually caused external burns and corrosive necrosis of the gastrointestinal tract.  
Generally, these types of exposures also involved liver and kidney alterations as well as other nonspecific 
pathologies.  
3.9  INTERACTIONS WITH OTHER CHEMICALS
Cresols are irritant and corrosive by impairing the stratum corneum and producing coagulation necrosis
by denaturating and precipitating proteins, which explains the toxic effects at the sites of contact (i.e., 
skin, mucosal surfaces).  However, there is no information on other mechanisms of toxicity for cresols.  
Studies with liver cells in vitro suggested that metabolic activation of cresols by microsomal enzymes 
might produce toxic reactive intermediates (Thompson et al. 1994).  It is plausible that exposure to
substances that induce P-450 isozymes involved in the metabolism of cresols may increase the toxicity of
cresols.  Similar outcomes could occur by simultaneous exposure to cresols and substances that decrease 
phase II metabolic reactions.  However, there is no experimental evidence to support these assumptions.  
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to cresols than will most persons 
exposed to the same level of cresols in the environment.  Reasons may include genetic makeup, age, 
health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These 
parameters result in reduced detoxification or excretion of cresols or compromised function of organs
affected by cresols.  Populations who are at greater risk due to their unusually high exposure to cresols are
discussed in Section 6.7, Populations with Potentially High Exposures.
Some groups have been identified that might exhibit increased vulnerability to the effects of cresols.  
There is very limited evidence that individuals with glucose-6-phosphate dehydrogenase (G6PD)
deficiency may have increased susceptibility to hematological effects of cresols; the increase in 
methemoglobin formation and decrease in glutathione levels were more pronounced in blood taken from
subjects with G6PD deficiency than in blood taken from normal subjects following exposure of the blood 
to a disinfectant containing 50% cresols in vitro (Chan et al. 1971).  
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Patients with chronic renal failure constitute another group with increased susceptibility to p-cresol.  In 
these patients, the concentration of p-cresol in the blood is 10 times higher than in healthy subjects due to 
both overgrowth of intestinal bacteria responsible for p-cresol production and reduced renal clearance.  
Free serum concentrations of p-cresol were shown to predict mortality in hemodialysis patients
(Bammens et al. 2006).  It has also been suggested that p-cresol decreases endothelial proliferation and 
wound repair in uremic patients, thus contributing to the immune defect in these patients (Dou et al. 2002, 
2004).  In a prospective longitudinal study, the concentrations of p-cresol were higher in 
hypoalbuminemic individuals than in those with normal albumin, and free p-cresol was related to 
hospitalization for infection (De Smet et al. 2003b).
3.11  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to cresols.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to cresols.  When specific
exposures have occurred, poison control centers and medical toxicologists should be consulted for
medical advice.  The following texts provide specific information about treatment following exposures to 
cresols:
Ellenhorn MJ, ed.  1997.  Ellenhorn’s medical toxicology.  Diagnosis and treatment of human poisoning.  
2nd ed.  Baltimore, MD: Williams and Wilkins.
Haddad LM, Shannon MW, Winchester JF.  1998. Clinical management of poisoning and drug overdose.  
3rd ed.  Philadelphia, PA: W.B. Saunders Company.
Leikin JB, Paloucek FP.  2002.  Leikin and Paloucek’s poisoning and toxicology handbook.  3rd ed.  
Hudson, OH:  Lexi-Comp, Inc.
3.11.1 Reducing Peak Absorption Following Exposure 
For ingestion exposure, water or milk should be given if the patient is alert and has an intact gag reflex.  
Activated charcoal and a cathartic can then be administered orally or by gastric tube.  Because cresol is 
corrosive and may cause seizures, emesis should not be induced.  If the eyes have been exposed, they
should be thoroughly irrigated as soon as possible with running water or saline.  If the skin has been 
exposed, it should be flushed promptly with copious amounts of water or undiluted polyethylene glycol
   
 











     
 
  










   
















followed by thorough washing with soap or mild detergent and water (Bronstein and Currance 1988;
Haddad et al. 1998; HSDB 2008; Leikin and Paloucek 2002; Stutz and Janusz 1988). 
3.11.2 Reducing Body Burden
Procedures that might decrease the toxicity of cresols present in the bloodstream have not been identified.  
Although supporting data were not located, it is possible that elimination of cresols from the blood would 
be enhanced by alkaline diuresis, which would increase the proportion of cresols existing in the ionized 
state, thereby reducing reabsorption of cresols by the kidney tubules.
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
No specific procedures have been developed to interfere with the mechanism of action of cresols.  
Treatment of individuals intoxicated with cresols is mainly supportive.  Exposed individuals with 
evidence of central nervous system depression or seizures should be evaluated for the presence of some 
other underlying disorder.  Diazepam or phenobarbital may be administered to alleviate seizures.  
Supplemental oxygen can also be administered.  If pulmonary edema occurs, conventional therapy should 
be given.  Methylene blue may be administered for treatment of methemoglobinemia.  Additional
information regarding the treatment of individuals exposed to cresols may be obtained from Bronstein and
Currance 1988; Haddad et al. 1998; HSDB 2008; Leikin and Paloucek 2002; and Stutz and Janusz 1988.
3.12  ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of cresols is available.  Where adequate information is not
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the
initiation of a program of research designed to determine the health effects (and techniques for developing
methods to determine such health effects) of cresols.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
   
 






















     
 
 
    
   
 













that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Cresols 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
cresols are summarized in Figure 3-4.  The purpose of this figure is to illustrate the existing information 
concerning the health effects of cresols.  Each dot in the figure indicates that one or more studies provide
information associated with that particular effect.  The dot does not necessarily imply anything about the
quality of the study or studies, nor should missing information in this figure be interpreted as a “data
need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data 
Needs Related to Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989), is 
substance-specific information necessary to conduct comprehensive public health assessments.  
Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from
the scientific literature.
In the following discussion, the various forms of cresol are considered together, due to the similarity of
their effects and the levels at which these effects occur.
Cresols are irritants and have corrosive properties following exposure to high concentrations by any route
of exposure.  Therefore, the skin and mucosal membranes are targets for cresol toxicity.  The existing
information on the health effects of cresols in humans comes almost entirely from case reports of people 
who accidentally or intentionally swallowed cresol-containing substances or had these substances spilled 
on them.  The single exception was an inhalation study of mucosal irritation in humans.  Acute oral or 
dermal exposure to high amounts of cresol caused serious systemic effects and even death in humans.
A limited number of studies of inhalation exposure in animals tried to determine lethal levels or evaluated 
systemic and neurologic end points.  A much greater number of studies in animals have been conducted 
by the oral route.  Evaluation of the oral database suggests that a distinction should be made between 
studies by oral gavage and dietary studies based on differences on end points affected and threshold 
levels.  Cresols are much more toxic when administered by oral gavage than when given in the diet.  The
difference is most likely related to differences in pharmacokinetics between the two means of 
administration.  Animals exposed to cresols by gavage often showed adverse neurological signs and 
decreased weight gain associated with decreased food consumption.  Oral gavage studies evaluated 
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reproductive, developmental, and neurological end points.  Longer-term dietary studies examined 
systemic end points as well as reproductive, developmental, and carcinogenic effects.  Studies of dermal
exposure to cresols in animals generally looked at levels of lethality and irritation to the skin and eyes.  
One study of intermediate duration investigated dermal effects.  A cancer-promotion study was also 
performed using dermally applied cresols.
3.12.2 Identification of Data Needs 
Acute-Duration Exposure. Case reports of humans exposed to high doses of cresols, either orally or
dermally, have provided acute toxicity information.  Fatalities due to ingestion and dermal exposure have
been described (Bruce et al. 1976; Cason 1959; Chan et al. 1971; Green 1975; Isaacs 1922; Labram and 
Gervais 1968; Monma-Ohtaki et al. 2002).  Other effects reported in these acute high exposure scenarios
include respiratory failure (Liu et al. 1999), tachycardia and ventricular fibrillation (Labram and Gervais
1968), abdominal pain, vomiting, and corrosive lesions of the gastrointestinal tract (Hayakawa 2002;
Isaacs 1922; Jouglard et al. 1971; Kamijo et al. 2003; Wu et al. 1998; Yashiki et al. 1990), methemo­
globinemia (Chan et al. 1971; Minami et al. 1990), leukocytosis and hemolysis (Cote et al. 1984; Wu et
al. 1998), hepatocellular injury (Chan et al. 1971; Hashimoto et al. 1998; Hayakawa 2002; Kamijo et al. 
2003), renal alterations (Chan et al. 1971; Isaacs 1922; Labram and Gervais 1968; Wu et al. 1998), skin 
damage (Cason 1959; Green 1975; Herwick and Treweek 1933; Klinger and Norton 1945; Pegg and 
Campbell 1985), metabolic acidosis (Hayakawa 2002; Kamijo et al. 2003), and unconsciousness (Chan et
al. 1971; Isaacs 1922; Labram and Gervais 1968).  Many of these effects may not have been caused 
directly by cresols, but represent secondary reactions to shock caused by external and internal burns.  A
single study in volunteers reported that brief exposures to 6 mg/m3 of o-cresol in the air caused respiratory
tract irritation (Uzhdavini et al. 1972). 
Limited data on acute inhalation effects were available from only two studies (Campbell 1941; Uzhdavini
et al. 1972) in which exposure involved mixtures of vapors and aerosols that provided insufficient
information to estimate exposure levels reliably; therefore, an acute-duration inhalation MRL for cresols
was not derived.  Still, these studies provided some data on lethality of airborne cresols as well as 
information on the respiratory system (irritation), liver (fatty degeneration and necrosis), renal (tubular
degeneration), and nervous system (excitation, fatigue, convulsions).  Inhalation studies that use modern 
methodology to generate and control exposure atmospheres and that evaluate a wide range of end points 
may be considered in order to construct dose-response curves for acute inhalation exposure.  However, 
under normal circumstances, acute inhalation exposure is generally not considered hazardous due to 
   
 













   
 
 




     
   
   
 
 
   
   
     




   
    
 
     




cresols’ low vapor pressure and a distinct odor at <1 ppm (NTP 1992b).  A study of acute dermal
exposure of animals to cresols determined exposure levels that produce skin irritation and death (Vernot
et al. 1977); it is unclear what new key information would be provided by additional dermal studies.  All
acute-duration oral studies in animals administered cresols by oral gavage, a dosing mode that, as 
discussed in Section 2.3, induces different effects than those observed in dietary studies and is not
considered relevant for risk assessment.  Oral gavage studies showed reduced body weight, neurotoxicity, 
fetotoxicity, and death in exposed animals (EPA 1988b, 1988c, 1988d; TRL 1986; Tyl 1988a, 1988b).  
No acute dietary or drinking water studies were located for cresols, and for that reason, no acute-duration 
oral MRLs were derived.  Although drinking water studies would mimic exposure to contaminated water
at or near a waste site, the solubility of cresols would limit the high doses to be around 2%.  In addition, 
the odor and taste of cresols may pose potential palability problems. Therefore, acute-duration dietary
studies are needed for defining targets and generating dose-response relationships for this exposure
duration.
Intermediate-Duration Exposure. No information is available regarding humans exposed to 
cresols for an extended period of time.  One of the studies that provided acute-duration inhalation data
also provided intermediate-duration inhalation data (Uzhdavini et al. 1972).  Rodents exposed to cresols
showed adverse respiratory, cardiovascular, hepatic, renal, and neurological effects, but the methods used 
at the time to generate and monitor the exposure atmospheres were inadequate to estimate exposure 
concentrations with any precision.  Modern studies are needed to define targets of toxicity and to establish 
dose-response relationships.  It would be important to determine whether the nasal lesions observed in 
rats and mice in the dietary study conducted by NTP (1992b) also appear in animals exposed by
inhalation.  If so, the intermediate-duration oral MRL for cresols (see below) may have to be revisited 
(this also applies for chronic-duration exposure).
Oral gavage studies of intermediate duration in animals have been performed for all three cresol isomers, 
and have helped to identify the levels at which cresols produce neurological, respiratory, hepatic, renal, 
hematological, and body weight changes in orally exposed animals (EPA 1988b, 1988c, 1988d; TRL
1986).  However, gavage administration of cresols induces different effects than those observed in dietary 
studies and do not resemble human environmental exposure scenarios to cresols.  Therefore, only dietary
studies were considered for MRL derivation even though some LOAELs by gavage are lower than dietary
LOAELs.  NTP (1992b) tested the cresol isomers and a mixture of m- and p-cresol in 28-day and 13-week 
dietary studies in rats and mice.  A comprehensive number of end points were examined and the critical
effect was nasal lesions in both species exposed to p-cresol and m/p-cresol.  The data from the 13-week
   
 








    
     
  
 
   
 
    
  
   
     
   
 





   
    




      
  
  
    
  




study in rats exposed to m/p-cresol were used to derive an intermediate-duration oral MRL for cresols.  
Additional intermediate oral studies do not seem necessary at this time since the NTP (1992b) study
evaluated a comprehensive number of end points and cresols exhibited relatively little toxicity.  Only one
intermediate-duration dermal study in animals was located (Shelley 1974).  People living near waste sites
may be exposed to cresols in soil or dermally through water contaminated with cresols.  Therefore, 
additional intermediate-duration dermal exposure studies are needed. 
Chronic-Duration Exposure and Cancer. No studies of chronic duration were found in humans.  
Information regarding chronic toxicity is important because people living near hazardous waste sites 
might be exposed to cresols for many years.  A mixture of m/p-cresol was tested in male Fischer-344 rats
and female B6C3F1 mice in a 2-year toxicity and carcinogenicity bioassay sponsored by NTP (NTP
2008).  Although the study is yet to be finalized, preliminary results confirmed the presence of nasal
lesions reported in the 28-day and 13-week studies (NTP 1992b) and also observed increased incidences
of bronchiolar hyperplasia and follicular degeneration of the thyroid gland in treated mice (0, 100, 300, 
and 1,040 mg/kg/day).  The data for bronchiole hyperplasia and follicular degeneration of the thyroid
gland in female mice exposed for 2 years were used to derive a chronic-duration oral MRL for cresols.  
Additional long-term studies do not seem necessary at this time. 
No studies were located regarding the carcinogenicity of cresols in humans.  In a 2-year NTP-sponsored 
bioassay, an m/p-cresol mixture administered in the diet to male Fischer-344 rats and female B6C3F1 
mice induced a nonsignificant increase in the incidence of renal tubule adenoma in rats at 720 mg/kg/day, 
which was considered an equivocal finding of carcinogenicity by NTP (2008); no other neoplastic effects
were reported in rats.  In mice, treatment with 1,040 mg/kg/day m/p-cresol induced a significant increase
in the incidence of squamous cell papilloma in the forestomach.  Additional carcinogenicity bioassays do 
not seem necessary at this time. 
Genotoxicity. No data were located regarding the genotoxicity of cresols in humans in vivo. In vitro
studies using cultured human cells were negative for sister chromatid exchange for all three isomers 
(Cheng and Kligerman 1984) and positive for unscheduled DNA synthesis for p-cresol (Daugherty and 
Franks 1986).  Studies of the genotoxicity of cresols in animals in vivo reported negative results (Cheng
and Kligerman 1984; Ivett 1989a, 1989b, 1989c; NTP 1992b; Sernav 1989a, 1989b) with the exception of
one study (Li et al. 2005).  Results were mixed in in vitro studies using mammalian cells (Brusick 1988a, 
1988b, 1988c; Cifone 1988a, 1988b; Murli 1988; Pepper, Hamilton & Scheetz 1980, 1981), and 
uniformly negative in Salmonella assays (Douglas et al. 1980; Florin et al. 1980; Haworth et al. 1983;
   
 








   









    
  
  
   
 
   
   
 
 
    
 
   
    
    




   






Kubo et al. 2002; NTP 1992b; Pepper, Hamilton & Scheetz 1981; Pool and Lin 1982).  The positive
results obtained in some human and animal in vitro tests suggest that cresols have some ability to react
with DNA.  It is unlikely that additional tests will provide new key information regarding the genotoxicity
of cresols.
Reproductive Toxicity. There are no data available regarding the reproductive effects of cresols in 
humans.  Studies in animals do not suggest that reproductive end points are sensitive targets for cresols 
toxicity (EPA 1988b, 1988c, 1988d; Hornshaw et al. 1986; Neeper-Bradley and Tyl 1989a, 1989b; NTP
1992a, 1992b, 1992c, 2008; Tyl and Neeper-Bradley 1989).  The well-conducted dietary continuous
breeding protocol studies in mice with o-cresol and m/p-cresol found no evidence of reproductive toxicity
for o-cresol (NTP 1992a); m/p-cresol, at a dose that caused minor maternal toxicity, produced a decrease
in the number of pups/litter and increased the cumulative days to litter, but did not affect other
reproductive function end points (NTP 1992c).  In the intermediate-duration dietary studies in rats and 
mice conducted by NTP (1992b), effects were limited to mild to moderate uterine atrophy and 
lengthening of the estrous cycle, generally at the highest dose levels tested.  In the 2-year bioassay in male
rats and female mice dosed with up to 720 and 1.040 mg m/p-cresol/kg/day, respectively, there were no 
gross or microscopic alterations in the reproductive organs (NTP 2008). There is no reason to believe that
potential reproductive effects might be route-dependent.  Additional studies do not seem warranted at this
time.
Developmental Toxicity. There are no data available regarding the developmental effects of cresols 
in humans.  The developmental toxicity of cresols in animals was evaluated in a series of studies in which 
pregnant rats and rabbits were exposed by oral gavage to each cresol isomer (Neeper-Bradley and Tyl
1989a, 1989b; Tyl 1988a, 1988b; Tyl and Neeper-Bradley 1989) and in pregnant mice exposed to 
o-cresol or m/p-cresol in the diet in continuous breeding protocol studies (NTP 1992a, 1992c).  These
studies generally reported mild fetotoxicity only at maternally toxic doses.  Additional information was
provided by a comparative study that observed tremors in newborn mice exposed to 100 mg/kg/day
m-cresol on postnatal days 4–21, but none in adults exposed to up to 300 mg/kg/day for 28 days (Koizumi
et al. 2003).  The reason why this occurs is not known, but it is likely related to differences in the 
metabolic disposition of m-cresol between the two age groups.  There is no indication that potential
developmental effects of cresols could be route-dependent.  Since the data from gestation exposure
studies in animals indicate that developmental effects occur only at dose levels that affect the mother, 
further studies examining the potential developmental toxicity of cresols do not seem necessary at this
time.  
   
 









      
   
    
    
 
 
       
   
  
    
 
   
  
  
   
   
  
 
   
  
 
     
   
  
   
    
     
  





Immunotoxicity. No immunological effects were reported in case studies of human exposure.  No 
significant alterations in weight or histology of lymphoreticular organs have been observed in animals
following cresol exposure (EPA 1988b, 1988c, 1988d; Hornshaw et al. 1986; NTP 1992b, 2008).  The
information available does not suggest that the immune system is a target for cresol toxicity, but
immunocompetence has not been evaluated. 
Neurotoxicity. A common feature of oral poisoning with cresols in humans is coma (Chan et al. 1971;
Isaacs 1922; Labram and Gervais 1968).  Accidental dermal exposure of a cresol derivative was fatal to a
child (Green 1975) and produced facial paralysis in a man who spilled cresol on his face (Klinger and 
Norton 1945).  Oral gavage studies in rodents often induced adverse clinical signs indicative of
neurological impairment such as hypoactivity, excessive salivation, labored respiration, and tremors
(Neeper-Bradley and Tyl 1989a, 1989b; TRL 1986; Tyl and Neeper-Bradley 1989).  In no cases have
gross or microscopic alterations of the brain, spinal cord, or sciatic nerve been observed.  None of the
clinical signs seen in oral gavage studies have been seen in dietary studies (NTP 1992b, 2008), or if seen, 
they have occurred at much higher dose levels than in oral gavage studies. This difference is probably
related to the different disposition of cresols and metabolites between the two modes of oral dosing.  The
mechanism(s) by which cresols induce these effects is not known, but could include actions at both 
central and peripheral sites of the nervous system.  There is no reason to believe that the neurotoxic 
effects of cresols are route-dependent.  Studies aimed at elucidating these mechanisms of action would be
informative, but from the point of view of hazard identification, the nervous system is not a sensitive
target for cresols administered at environmentally relevant levels by relevant routes of exposure.  
Epidemiological and Human Dosimetry Studies. As previously mentioned, information about
the effects of cresols in humans is derived mainly from case reports of accidental or intentional ingestion 
of cresol solutions or from accidental contact of cresol with the skin.  Specific effects and references are 
mentioned under Acute-Duration Exposure. Doses were generally not available in the acute oral case 
reports, but Chan et al. (1971) estimated that roughly 2 g/kg may have caused the death of a woman.  No 
group of the general population has been identified as having being exposed exclusively or predominantly
to low levels of cresols for a long time.  Based on data from long-term dietary studies in animals, it would 
be difficult to determine what specific end points to monitor in humans exposed to cresols since cresols 
caused relatively little systemic toxicity in the animal studies; hyperplastic or metaplastic lesions in the
nasal respiratory epithelium were the most sensitive effects identified in rats and mice.  
   
 








     
 
 











     
 
    
  
 
   






      
   
   




Biomarkers of Exposure and Effect.
Exposure.  No biomarkers of exposure to cresols have been identified.  In fact, even the cresols 
themselves cannot be considered specific biomarkers for cresol exposure because they are also formed as 
breakdown products of toluene and tyrosine.  However, if toluene exposure could be ruled out, then a
high level of cresols or metabolites in the blood or urine would strongly suggest cresol exposure.  
p-Cresol was found to form adducts with DNA in in vitro systems (Gaikwad and Bodell 2001, 2003);
however, even if it does the same in vivo, identification of adducts would not necessarily indicate
exposure to cresols for the same reasons mentioned above. 
Effect.  No specific biomarkers of effect have been identified for cresols.  Since cresols are irritants and
corrosive at high concentration, their main effects are at sites of contact (i.e., skin, respiratory, and 
gastrointestinal tract).  Other effects observed in subjects exposed acutely to relatively high amounts of 
cresols (i.e., hepatic, renal, hematological, and metabolic) may be secondary to the external and internal
injuries (burns) caused by cresols.  It seems unlikely that specific biomarkers of effect will be identified
for cresols.  
Absorption, Distribution, Metabolism, and Excretion.  Case reports and a limited number of
studies in animals suggest that cresols are well absorbed by all routes of exposure, although quantitative 
data are lacking.  Only one study was located that provided information on the distribution of m- and
p-cresol in rats following an oral gavage dose (Morinaga et al. 2004).  Cresols were found to distribute
widely among tissues and no specific organ seemed to preferentially accumulate cresols.  The
intermediate-duration oral MRL for cresols is based on nasal effects in rats administered the test material
in the diet (NTP 1992b).  Since there is the possibility that the lesions may be caused by inhalation of
vapors of cresol from the food, a particularly valuable study would be to administer radiolabeled cresols
by gavage and determine whether cresol-derived radioactivity appears disproportionately in the nasal
epithelium.  
The basic metabolic reactions for cresols are known (Bray et al. 1950; Morinaga et al. 2004; Williams 
1938).  The metabolism of p-cresol has been examined in more detail in rat liver microsomes and liver
slices (Thompson et al. 1994, 1995, 1996; Yan et al. 2005).  These studies suggested that a reactive
intermediate plays a role in the toxicity of p-cresol on liver cells in vitro, but the relevance of this finding
to studies in vivo is unknown since cresols exhibited little or no liver toxicity in dietary studies in rats and 
mice (NTP 1992b).  
   
 












    





     
    
    
  




   
 
 










Lacking from the cresol database are studies comparing the pharmacokinetics of cresols administered by
oral gavage and in the diet.  This is important because the effects of cresols administered by gavage are 
different than those seen following dietary administration.  Based on information on a similar chemical, 
phenol, it is likely that the toxicity of cresols correlate with peak blood concentration rather than with 
total dose, but this has not been experimentally demonstrated for cresols.  Information on possible dose
dependency of the phase II metabolism is also lacking.  It would be valuable to know for the various
isomers which conjugation reaction, with sulfate or glutathione, predominates at low and high doses, and 
at what level each reaction might become saturated.  No PBPK models have been developed for cresols.  
Such models are needed for addressing interspecies issues related to saturable pathways associated with 
various dosing parameters such as ingestion from food or water, issues related to gavage dosing, and 
inhalation and dermal absorption.
Comparative Toxicokinetics. The limited information available suggests that the metabolism of 
cresols is similar in humans and rats based on the fact that both species excrete sulfate and glutathione
conjugation products in the urine.  In addition, a recent study showed that bioactivation patterns for
p-cresol in human and rat liver microsomes led to the same reactive intermediates and glutathione adducts 
(Yan et al. 2005).  This information is insufficient to predict whether humans and animals will exhibit
similar effects under similar exposure conditions, with the exception of portal-of-entry effects.  However,
it is unclear what practical information would provide additional comparative toxicokinetics studies given 
that cresols showed little systemic toxicity in animal studies when administered by an environmentally
relevant route of exposure (other than nasal lesions) and no reports were found on humans exposed to 
cresols for long periods of time. 
Methods for Reducing Toxic Effects. Cresols are strong irritants and corrosive at high 
concentrations and, therefore, their main effects are on surfaces with which they come in contact, such as 
the skin, and respiratory and gastrointestinal epithelia.  Cresols exhibited little systemic toxicity in a
limited number of intermediate-duration dietary studies in animals; therefore, attempts to suggest studies 
to counteract a yet unknown mechanism of action seem impractical at this time.  The treatment for high 
dermal or oral exposures to cresols is standard for chemical burns and mainly supportive.  Development
of new therapies for the treatment of skin burns will help subjects accidentally exposure to cresols and 
similar chemicals.
   
 








      
    
  
 





    






    








     
 
 







Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
There are no studies that specifically addressed exposure to cresols in children.  Data on the effects of 
cresols in adults are derived almost exclusively from cases of accidental or intentional ingestion of cresol
solutions (see above Acute-Duration Exposure for specific references).  Exposure to these high amounts 
of cresols produced corrosion at the points of contact including the skin and gastrointestinal tract.  Similar
effects would be expected in children exposed to high amounts of cresols.  There is no information on 
whether the developmental process is altered in humans exposed to cresols.  Studies in animals suggest
that fetotoxicity occurs only with doses of cresols that are also toxic to the mother (Neeper-Bradley and 
Tyl 1989a, 1989b; Tyl 1988a, 1988b; Tyl and Neeper-Bradley 1989) and further standard developmental
toxicity studies do not appear necessary at this time.  A study showed that newborn rats (exposed daily on 
postnatal days 4–21) were more sensitive to the neurological effects of bolus doses of cresols than young
rats (exposed daily for 28 days) (Koizumi et al. 2003).  This may be due to age-related differences in 
toxicokinetics.
There are no data to evaluate whether toxicokinetics of cresols in children are different from adults.  
There is no information on whether cresols can cross the placenta and there are no studies on whether
cresols can be transferred from mother to offspring through maternal milk.  Research into the
development of biomarkers of exposure for cresols would be valuable for both adults and children.  There
are no data on the interactions of cresols with other chemicals in children. There are no pediatric-specific 
methods to mitigate the effects of exposure to high amounts of cresols.  Based on the information 
available, it is reasonable to assume that the supportive methods recommended for maintaining vital
functions in adults, will also be applicable to children.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.12.3 Ongoing Studies 
No ongoing studies pertaining to cresols were identified in the Federal Research in Progress database 
(FEDRIP 2008).
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Data pertaining to the chemical identity of cresols are listed in Table 4-1.
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
The physical and chemical properties of cresols are presented in Table 4-2.













    
 
  
       
  
 










      
 
 










     
       
 
 
























       
        
 
 




4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of Cresols
o-, m-, 
Characteristics o-Cresol p-Cresol m-Cresol p-Cresol References
Chemical name o-Cresol p-Cresol m-Cresol (o, m, p)-Cresol ChemID 2008
Synonyms 2-Methylphenol; 4-Methylphenol; 3-Methylphenol Methylphenol; ChemID 2008; 
2-hydroxy­ 4-hydroxy­ 3-hydroxy­ hydroxytoluene; HSDB 2008; 
toluene; toluene; toluene; cresylic acid SANSS 1989
o-cresylic acid p-cresylic acid m-cresylic acid
Trade names No data No data No data No data
Chemical C7H8O C7H8O C7H8O C7H8O ChemID 2008
formula





CAS registry 95-48-7 106-44-5 108-39-4 1319-77-3 ChemID 2008
NIOSH GO6300000 GO6475000 GO61250000 GO5950000 SANSS 1989
RTECS
EPA F004; U052 F004; U052 F004; U052 F004; U052 HSDB 2008
hazardous
waste
DOT/UN/NA/ UN 2022; UN 2022; UN 2022; UN 2022; HSDB 2008
IMCO UN 3455; UN 3455; UN 3455; UN 3455;
shipping UN 2076; UN 2076; UN 2076; UN 2076;
IMO 6.1 IMO 6.1 IMO 6.1 IMO 6.1
HSDB 1813 1814 1815 250 HSDB 2008
NCI No data No data No data No data
CAS = Chemical Abstracts Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/Intergovernmental Maritime Consultive Organization; EPA = Environmental Protection Agency;
HSDB = Hazardous Substance Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; RTECS = Registry of Toxic Effects of Chemical Substances
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Cresols
Property o-Cresol m-Cresol p-Cresol
Mixture of o-, p-, 
and m-cresol References
Molecular weight 108.14 108.14 108.14 108.14 O’Neil et al. 2001









O’Neil et al. 2001
Physical state Solid Liquid Solid Liquid O’Neil et al. 2001
Melting point 30.944 °C 12.22 °C 34.739 °C 11–35 °C Lewis 2001;
Riddick et al. 1986 
Boiling point
1 atm 191.004 °C 202.32 °C 201.94 °C 191–203 °C Riddick et al. 1986
10 mmHg 74.9 °C 86 °C 85.7 °C No data Lewis 2001; Lide
2005
Density (20 °C) 1.047 g/mL 1.034 g/mL 1.0341 g/mL 1.030–1.038 g/mL O’Neil et al. 2001
Odor Phenol-like Phenol-like Phenol-like Phenol-like O’Neil et al. 2001
Odor threshold
Water No data 0.037 ppm No data No data Amoore and 
Hautala 1983 
Air No data 0.00028 ppm No data No data Amoore and 
Hautala 1983
Solubility
Water at 25 °C 25,950 ppm 22,700 ppm 21,520 ppm No data Yalkowsky et al.
1987

























2005; O’Neil et al.
2001
Partition coefficients
Log octanol/water 1.95 1.96 1.94 No data Hansch and Leo 
1985




25 °C 0.299 mmHg 0.138 mmHg 0.11 mmHg No data AIChE 1989,2000,
Chao et al. 1983 












    
 
  











          
      
       
  
  
     
   
  
     
 





   
 




4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2.  Physical and Chemical Properties of Cresols
Mixture of o-, p-, 

Property o-Cresol m-Cresol p-Cresol and m-cresol References
 
Henry’s law constant
atm/m3-molecule at 1.2x10-6 8.65x10-7 7.92x10-7 No data Gaffney et al. 
25 °C (calculated 1987; Hine and 




Flashpoint (closed 81 °C 85 °C 86 °C 82 °C Lewis 2001
cup)
Flammability limits 1.4% (lower) 1.1% (lower) 1.1% (lower) HSDB 2008
Conversion factors
ppm (v/v) to mg/m3	 4.50 4.50 4.50 4.50 Verschueren 1983
in air (20 °C)
 
mg/m3 to ppm (v/v) 0.22 0.22 0.22 0.22 Verschueren 1983
 




Log BCF	 1.25 1.30 1.24 No data Freitag et al. 1985;
(calculated (calculated Thomas 1982 
from Kow) from Kow)
Explosive limits No data No data No data No data
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
Prior to World War II, multimillion pound quantities of cresols were produced annually in the United 
States, and domestic production and sales of cresols have steadily increased over the past several decades.  
In 1987, the national capacity for producing cresylics (compounds relating to cresols) was 208 million 
pounds per year (CMR 2004).  More recent data indicate that the total U.S. production capacity for
cresols, xylenols, and cresylics is approximately 470 million pounds (CMR 2004).  Overall demand for
cresols, xylenols, and cresylics was 340 million pounds in 2002, 365 million pounds in 2003, and is
projected to increase to 385 million pounds by 2007 (CMR 2004).  Information regarding the production 
levels of individual isomers and specific mixtures was unavailable.  These production totals include data
on the manufacture of cresylic acid and exclude information on cresol production by coke and gas-retort 
ovens.  The commercial mixture of cresol isomers, in which the m-isomer predominates and contains
<5% phenol, is sometimes referred to as cresylic acid (Windholz et al. 1983).  However, cresylic acids
generally are composed of cresols, phenols, and xylenols; they are defined as those mixtures in which 
over 50% will boil at temperatures above 204 °C (Lewis 2001).  
Cresols are used widely by industry.  Information from the EPA's Toxic Release Inventory (TRI) on 
facilities that either manufactured or processed o-, m-, p-, or mixed isomers of cresols in 2004 is outlined
in Tables 5-1 through 5-4, respectively.  The TRI data should be used with caution since only certain 
types of facilities were required to report.  This is not an exhaustive list.  According to the 2005 Directory
of Chemical Producers (SRI 2005), cresols are currently produced by five manufacturers in New York, 
Pennsylvania, Illinois, and Texas.  Stanford Research Institute (SRI 2005) data for individual isomers and 
the mixture o-, p-, and m-isomers are included in Table 5-5. 
The oldest cresol production method used in the United States is through the recovery of fractional
distillates from coal tars.  Most domestic cresols are formed via catalytic and thermal cracking of naphtha 
fractions during petroleum distillation.  Since 1965, quantities of coal tar and petroleum isolates have
been insufficient to meet the rising demand.  Consequently, several processes for the manufacture of the
various isomers have been developed.  One General Electric facility produces o-cresol at an annual
capacity of 10,000 tons by the methylation of phenol in the presence of catalysts.  The Sherman-Williams 
Company uses the toluene sulfonation process and maintains an annual capacity for p-cresol of
15,000 tons.  The Hercules Powder Company produced p-cresol until 1972 by the cymene-cresol process.  
   
 















     
      
     
      
     
      
       
      
     
        
      
     
     
      
     
      
      
       
     
      
      
     
        
        
      
     
      
     
 
  





















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1.  Facilities that Produce, Process, or Use o-Cresol
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AL 4 0 999,999 1, 6, 9, 12, 13, 14
AR 1 1,000 9,999 12
CA 8 1,000 999,999 2, 3, 6, 7
DE 1 10,000 99,999 6
GA 4 100 99,999 2, 3, 6, 7, 8
IL 12 100 9,999,999 1, 2, 3, 4, 6, 7, 12
IN 9 100 99,999 1, 5, 7, 8, 10, 11, 12
KS 1 100 999 12
KY 11 0 999,999 2, 3, 6, 7, 8, 10, 11, 12
LA 7 1,000 9,999,999 1, 2, 3, 6, 12, 13
MI 1 1,000 9,999 7
MO 4 100 99,999 9, 12
MS 1 10,000 99,999 1, 3, 6
NE 2 1,000 99,999 12
NJ 6 1,000 999,999 6, 7, 9, 12
NY 9 1,000 999,999 1, 5, 6, 7, 13
OH 9 0 999,999 1, 3, 6, 7, 8, 12
OK 2 100 999 6, 7
PA 6 1,000 999,999 1, 4, 8, 9, 13
RI 4 1,000 99,999 6, 7, 8
SC 1 10,000 99,999 12
TN 8 100 9,999,999 2, 3, 6, 8, 9, 11, 12
TX 28 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13
UT 2 10,000 999,999 1, 3, 4, 5, 6
WI 4 1,000 999,999 6, 7
AL 4 0 999,999 1, 6, 9, 12, 13, 14
AR 1 1,000 9,999 12
aPost office state abbreviations used
bAmounts on site reported by facilities in each state
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI05 2007 (Data are from 2005)
   
 















     
     
     
     
      
      
        
     
        
     
     
     
      
     
     
     
      
       
      
       
      
     
      
       
     
     
 
  





















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-2.  Facilities that Produce, Process, or Use m-Cresol
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AR 2 100 9,999 12
CA 3 0 999,999 4, 7
FL 1 1,000 9,999 7, 8
GA 3 10,000 999,999 2, 3, 6, 7, 10, 11
IL 6 100 99,999 1, 5, 6, 10, 12, 13
IN 16 100 999,999 2, 3, 6, 7, 8, 10, 11, 12
KS 3 1,000 99,999 6, 12
KY 10 1,000 999,999 1, 2, 3, 6, 8, 10, 11, 12
LA 1 1,000 9,999 6
MA 2 1,000 99,999 6, 11
MI 2 10,000 99,999 6
MO 8 100 999,999 1, 4, 8, 9, 10, 11, 12
MS 4 100 999,999 6, 10
NC 3 0 99,999 6, 10, 11, 12
NJ 1 1,000 9,999 12
NY 6 10,000 999,999 1, 5, 6, 9, 10, 13
OH 6 100 999,999 1, 3, 5, 6, 7, 12
OK 4 100 99,999 6, 7, 10
PA 8 1,000 999,999 1, 4, 6, 8, 9, 13
RI 3 10,000 99,999 6, 7, 8
SC 4 10,000 9,999,999 6, 12
TN 9 0 9,999,999 6, 7, 8, 9, 11, 12
TX 19 0 9,999,999 1, 2, 3, 4, 5, 6, 8, 11, 12, 13, 14
WI 1 10,000 99,999 7
WV 1 100,000 999,999 6
aPost office state abbreviations used
bAmounts on site reported by facilities in each state
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI05 2007 (Data are from 2005)
   
 

















   
      
     
     
      
     
      
        
      
      
      
       
      
     
      
     
      
      
     
      
        
     
     
      
       
     
 
  





















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-3.  Facilities that Produce, Process, or Use p-Cresol
Minimum Maximum 
Number of amount on site amount on site
Statea facilities in poundsb in poundsb Activities and usesc 
AL 5 100 999,999 1, 2, 6, 12, 13, 14
AR 3 0 9,999 12
AZ 1 1,000 9,999 7
CA 3 1,000 9,999,999 1, 3, 6, 7
CT 2 10,000 999,999 6
GA 1 10,000 99,999 2, 3, 6, 7
IL 7 1,000 9,999,999 1, 3, 4, 6, 7, 10, 12
IN 13 0 999,999 2, 3, 7, 8, 10, 11, 12
KS 5 100 999,999 2, 3, 6, 8, 12
KY 9 1,000 999,999 2, 3, 6, 8, 10, 11, 12
LA 12 0 999,999 1, 2, 3, 4, 5, 6, 12
MO 9 100 999,999 1, 4, 8, 9, 10, 11, 12
MS 1 1,000 9,999 10
NC 4 1,000 99,999 6, 8, 10, 12
NE 2 1,000 99,999 12
NJ 6 1,000 999,999 2, 3, 6, 12
NY 4 100 999,999 1, 5, 6, 12, 13
OH 5 1,000 999,999 6, 12
OK 3 100 99,999 6, 7, 10
PA 8 100 999,999 1, 4, 6, 8, 9, 12, 13
RI 2 10,000 99,999 6, 8
SC 3 10,000 999,999 6, 12
TN 8 0 49,999,999 7, 8, 9, 11, 12
TX 17 0 9,999,999 1, 2, 4, 5, 6, 8, 11, 12, 13, 14
WV 1 100,000 999,999 6
aPost office state abbreviations used
bAmounts on site reported by facilities in each state
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7.  Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI05 2007 (Data are from 2005)
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-4.  Facilities that Produce, Process, or Use Cresol (Mixed Isomers)
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AL 25 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 14
AR 17 0 99,999 1, 2, 3, 5, 6, 7, 8, 9, 12, 13
CA 43 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14
CT 6 100 9,999 1, 5, 7, 10, 11
DE 5 10,000 99,999 1, 3, 5, 6, 7, 12
FL 8 0 99,999 1, 5, 7, 8, 11, 12, 13
GA 25 0 999,999 1, 2, 3, 5, 6, 7, 8, 10, 11, 12, 13
IA 1 100 999 7
ID 5 0 999 1, 5, 13
IL 36 1,000 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14
IN 47 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
KS 9 1,000 999,999 1, 4, 5, 7, 10, 12, 13
KY 27 0 9,999,999 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
LA 48 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14
MA 3 1,000 99,999 2, 3, 6, 10, 11
MD 7 0 999,999 1, 5, 12, 13
ME 2 0 99 1, 5, 13
MI 16 0 999,999 1, 4, 5, 6, 7, 12, 13
MN 6 100 99,999 1, 2, 3, 4, 5, 6, 9, 11, 12, 13
MO 24 0 999,999 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 14
MS 23 0 999,999 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14
NC 18 0 999,999 1, 2, 3, 5, 6, 7, 10, 11, 12, 13
NE 2 1,000 99,999 12
NH 6 1,000 999,999 2, 3, 7, 10, 11
NJ 17 1,000 999,999 2, 3, 4, 6, 7, 9, 12
NM 3 10,000 999,999 1, 2, 3, 7, 10, 12, 13
NV 1 10,000 99,999 12
NY 21 100 9,999,999 1, 2, 4, 5, 6, 7, 8, 9, 10, 12, 13
OH 30 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OK 6 1,000 999,999 1, 3, 4, 5, 6, 7, 9, 10, 13, 14
OR 7 0 9,999,999 1, 2, 3, 5, 7, 9, 12, 13
PA 27 0 9,999,999 1, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14
PR 1 100 999 2, 3, 4, 7, 9
RI 1 10,000 99,999 6
SC 13 0 999,999 1, 2, 3, 5, 6, 7, 12, 13
TN 14 0 999,999 1, 5, 6, 7, 9, 10, 11, 12, 13, 14
TX 68 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT 12 1,000 999,999 1, 3, 4, 5, 6, 7, 9, 10, 12, 13
   
 














     
      
      
       
      
       
      
 
  





















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-4.  Facilities that Produce, Process, or Use Cresol (Mixed Isomers)
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
VA 10 0 999,999 1, 5, 10, 11, 12
VI 1 100 999 2, 3, 4, 7, 9
WA 24 0 9,999,999 1, 2, 3, 4, 5, 7, 12, 13, 14
WI 6 0 999,999 1, 5, 6, 13
WV 12 0 9,999,999 1, 2, 3, 4, 5, 6, 8, 12, 13
WY 5 0 99,999 1, 4, 5, 6, 13
aPost office state abbreviations used
bAmounts on site reported by facilities in each state
cActivities/Uses:
1.  Produce 6.  Impurity 11.  Chemical Processing Aid
2.  Import 7. Reactant 12.  Manufacturing Aid 
3.  Onsite use/processing 8.  Formulation Component 13.  Ancillary/Other Uses
4.  Sale/Distribution 9.  Article Component 14.  Process Impurity
5.  Byproduct 10.  Repackaging
Source:  TRI05 2007 (Data are from 2005)
   
 











    








    
    





5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-5.  Current U.S. Producers of Cresol
Company Locationa Isomer
Merisol Antioxidants, LLC Oil City, Pennsylvania m-cresol





General Electric Company Selkirk, New York o-cresol
PMC Specialties Group, Inc. Chicago, Illinois o-cresol
Bell Flavors and Fragrances, Inc. Northbrook, Illinois p-cresol
Source:  Derived from SRI 2005
   
 








    
  
   
 
   
 
   
 
   
     














    
   
 
 
   
  
    




5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
This method is capable of producing p- or m-cresol from the corresponding cymene (isopropyltoluene).  
Alkaline chlorotoluene hydrolysis is used to formulate a cresol mixture with a high m-cresol content.  
However, information pertaining to domestic use of this process was unavailable (Fiege and Bayer 1987).
5.2  IMPORT/EXPORT
In 2007, 548,446 kg of cresol and cresol salts were imported from other countries netting
$1,895,164 (OSITC 2008).  The largest exporters of cresol and cresol salts to the United States were 
Spain and the United Kingdom with export amounts for 2005 of 165,040 and 822,170 kg, respectively.  
Money spent on the import of cresols and their salts to the United States has increased from $698,000 in 
2003 to $1,363,000 in 2004 and $2,754,000 in 2005 (USITC 2006).
In 2007, 26,100,350 kg of cresol and cresol salts were exported to other countries netting
$62,558,544 (OSITC 2008).  The largest importers of cresol and cresol salts from the United States were 
China, Japan, the Netherlands, and the United Kingdom with export values for 2005 of 3,200,351;
2,436,843; 6,317,298; and 6,140,655 kg, respectively.  Money from export of cresols and their salts from
the United States has increased from $29,736,000 in 2003 to $38,534,000 in 2004 and $47,280,000 in 
2005 (USITC 2006).
5.3  USE 
A considerable amount of o-cresol is used directly as either a solvent or disinfectant.  o-Cresol is also 
used as a chemical intermediate for a wide variety of products.  o-Cresol is hydrogenated to 
2-methylcyclohexanol or 2-methylcyclohexanone, which are also solvents.  Coumarin is made from the
carbonate ester of o-cresol and is a deodorizing and odor-enhancing agent that also has pharmaceutical
applications (Lewis 2001).  Alkylation of o-cresol with propene gives 3-isopropyl-6-methylphenol
(carvacrol).  Carvacrol is used as an antiseptic and in fragrances (Windholz et al. 1983).  o-Cresol also 
serves as an intermediate for the production of various antioxidants.  Several dye intermediates are 
manufactured from o-cresol.  o-Cresotinic acid, produced from o-cresol via the Kolbe synthesis, is used as
a dye, a dye intermediate, and a pharmaceutical intermediate.  Recently, an increasing proportion of
o-cresol has been devoted to the formulation of epoxy-o-cresol novolak (ECN) resins.  ECN resins are 
sealing materials for integrated circuits (silicon chips). o-Cresol is also used as an additive to phenol-
formaldehyde resins.  The manufacture of certain herbicides and pesticides, including 4-chloro-2-methyl­
phenoxyacetic acid (MCPA), 2-(4-chloro-2-methylphenoxy)-propionic acid (MCPP), γ(4-chloro­
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
2-methylphenoxy)-butyric acid (MCPB), and 4,6-dinitro-o-cresol (DNOC), is also dependent upon 
o-cresol (Fiege and Bayer 1987).
p-Cresol is used largely in the formulation of antioxidants such as 2,6-di-tert-butyl-p-cresol (BHT), 
2,6-dicyclopentyl-p-cresol, 2,2'-methylene- or 2,2'-thiodiphenols, and Tinuvin 326.  Tinuvin 326 absorbs
ultraviolet (UV) light and is added to polyethylene and polypropylene films and coatings for protection 
against photodegradation.  p-Cresol also has many applications in the fragrance and dye industries
(O’Neil et al. 2001).  Synthetic food flavors also contain p-cresol (Lewis 2001).  p-Cresol carboxylic acid 
esters and anisaldehyde are used in perfumes (Lewis 2001).  The latter is made from p-cresol methyl ether
(Fiege and Bayer 1987).
m-Cresol, either pure or mixed with p-cresol, is important in the production of contact herbicides such as
O,O-dimethyl-O-(3-methyl-4-nitrophenyl)thionophosphoric acid (fenitrothion, Follithion, and Sumithion)
and O,O-dimethyl-O-(3-methyl-4-methylthiophenyl)thionophosphoric acid ester (fenthion, Baytex, and 
Lebaycid) (Fiege and Bayer 1987).  m-Cresol is also a precursor to the pyrethroid insecticides.
Furthermore, many flavor and fragrance compounds, such as (-)-methanol and musk ambrette, are derived 
from m-cresol.  Several important antioxidants are produced from m-cresol.  m-Cresol is also used to
manufacture an explosive, 2,4,6-nitro-m-cresol.
Mixtures of m- and p-cresol often serve as disinfectants and preservatives (O’Neil et al. 2001).  Because
cresols are bactericides and fungicides, they are added to soaps as disinfectants.  Crude cresols are used as 
wood preservatives.  Tricresyl phosphate and diphenyl cresyl phosphate are produced from m- and 
p-cresol mixtures. These neutral phosphoric acid esters are used as flame-retardant plasticizers for
polyvinylchloride (PVC) and other plastics, fire-resistant hydraulic fluids, additives for lubricants, and air
filter oils.  Cresol mixtures condensed with formaldehyde are important for modifying phenolic resins.  
However, the m-isomer content is critical to the mixture because m-cresol is the most reactive of the three 
isomers.  Cresols are also used in paints and textiles.  Mixtures of cresols are used as solvents for
synthetic resin coatings such as wire enamels, metal degreasers, cutting oils, and agents to remove carbon 
deposits from combustion engines.  Other uses of cresol mixtures include ore flotation and fiber treatment
(Fiege and Bayer 1987; Windholz et al. 1983).
   
 


















5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.4  DISPOSAL
Cresols may be disposed of by landfill, land applications, biological waste water treatment, or
incineration.  In an activated sludge system, cresols exhibit a 96% reduction of the chemical oxygen 
demand and a biodegradation rate of 55 mg of oxygen/g/hour.  Cresols may be disposed of in a rotary kiln 
incinerator with a temperature range of 820–1,600 °C and a residence time of seconds.  Cresols may also 
be disposed of in a fluidized bed incinerator with a temperature range of 450–980 °C and a residence time 
of seconds (HSDB 2008).












   
 
    
  














   
  






   
 
  




6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
o-Cresol, m-cresol, p-cresol, and mixed cresols have been identified in at least 210, 22, 310, and 70 of the
1,678 hazardous waste sites that have been proposed for inclusion on the EPA National Priorities List
(NPL), respectively (HazDat 2006).  However, the number of sites evaluated for cresols is not known.  
The frequency of these sites for o-, m-, p-, and mixed cresols can be seen in Figures 6-1, 6-2, 6-3, and 6-4, 
respectively.  
Cresols are widely occurring natural and anthropogenic products.  Although cresols appear to be
ubiquitous in the environment, their concentrations probably remain low due to their rapid removal rates
in most environmental media.  In air, cresols degrade rapidly because of reactions with photochemically
produced hydroxyl radicals.  Biodegradation is the dominant mechanism responsible for the fast
breakdown of cresols in soil and water.  Nevertheless, cresols may persist in extremely oligotrophic
waters, in those with limited microbial communities, and/or those under anaerobic conditions, such as in 
some sediments and groundwater aquifers.
Based on the available information, the most common route of exposure for the general population is
inhalation.  Cresols are constantly emitted to air via automobile exhaust; consequently, people who live in 
urban and suburban settings may be constantly exposed to low levels of cresols in the atmosphere.  
Cresols are also emitted to ambient air during the combustion of coal, wood, and municipal solid waste.  
Therefore, residents near coal- and petroleum-fueled electricity-generating facilities, municipal solid 
waste incinerators, and industries with conventional furnace operations or large-scale incinerators may be
exposed to cresols in air.  People in residential areas where homes are heated with coal, oil, or wood may
also be exposed to cresols in air.  High levels of cresol exposure can result from active and passive 
inhalation of cigarette smoke (Wynder and Hoffmann 1967).  Therefore, people who smoke or live with
smokers are exposed to higher concentrations of cresol in the air.
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
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6.  POTENTIAL FOR HUMAN EXPOSURE
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
6.2.1 Air
Estimated releases of 3,313 pounds (~1.5 metric tons) of o-cresol, 41.496 pounds (~19 metric tons) of
m-cresol, 31,393 pounds (~14 metric tons) of p-cresol, and 932,106 pounds (~423 metric tons) of mixed 
isomers of cresol, to the atmosphere from 23, 28, 27, and 157 domestic manufacturing and processing
facilities in 2005, accounted for about <1, 21, 21 and 72% of the estimated total environmental releases of
o-cresol, m-cresol, p-cresol, and cresol mixed isomer from facilities required to report to the TRI (TRI05 
2007), respectively.  These releases are summarized in Tables 6-1 through 6-4.
A national emissions study conducted from 1990 to 1998 reported an estimated 11,000 tons/year released
throughout the United States for all combined isomers of cresol (EPA 2000d).  The emissions of total
cresol isomers were 6,000 and 5,000 tons/year for urban and rural locations, respectively (EPA 2000d).
Cresols are a group of widely distributed natural compounds formed as metabolites of microbial activity 
and excreted in the urine of mammals (Fiege and Bayer 1987).  Cresols occur in various plant lipid 
constituents, including oils from jasmine, cassia, Easter lily, ylang ylang, and Yucca gloriosa flowers, 
peppermint, eucalyptus, and camphor.  Oils from conifers, oaks, and sandalwood trees also contain 
cresols (Fiege and Bayer 1987).  Volatilization of natural cresols from urine and transpiration of plants
may release cresols to the air.  Cresols are also a product of combustion and can be released to the 
atmosphere from natural fires associated with lightning, spontaneous combustion, and volcanic activity
(McKnight et al. 1982).
Cresols are natural components of crude oil and coal tar, from which they are recovered as fractional
distillates.  Cresols are also produced synthetically.  The dominant anthropogenic sources for the release
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Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
AR 1 0 No data 0 0 0 0 0 0
IL 2 10 No data 0 5 250 10 255 265
KY 2 478 No data 0 0 0 478 0 478
LA 2 4 0 0 0 0 4 0 4
MO 1 10 No data 0 0 0 10 0 10
NY 3 1,000 5 0 0 0 1,005 0 1,005
OH 3 103 0 0 255 0 103 255 358
TX 7 1,695 118 182,006 10 1 182,358 1,472 183,830
WI 2 12 0 0 0 0 12 0 12
Total 23 3,313 123 182,006 270 251 183,981 1,982 185,963
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.

eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 




gClass I wells, Class II-V wells, and underground injection.

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills.





jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI05 2007 (Data are from 2005)
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Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
IL 2 10 No data 0 5 250 10 255 265
IN 6 28,159 No data 0 0 0 28,159 0 28,159
KS 1 3 No data 0 0 0 3 0 3
KY 1 785 No data 0 0 0 785 0 785
MI 1 3 No data 0 0 0 3 0 3
MO 2 270 0 0 0 0 270 0 270
MS 1 2,400 No data 0 0 0 2,400 0 2,400
NC 1 3 No data 0 0 0 3 0 3
NY 1 255 5 0 0 0 260 0 260
OH 1 1,144 0 0 500 0 1,144 500 1,644
OK 1 0 No data 0 0 0 0 0 0
SC 3 207 No data 0 0 0 207 0 207
TN 1 1,414 No data 0 0 0 1,414 0 1,414
TX 5 6,820 497 153,332 274 13 160,786 150 160,936
WV 1 23 42 0 1 0 65 1 66
Total 28 41,496 544 153,332 780 263 195,509 906 196,415
aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.

eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 




gClass I wells, Class II-V wells, and underground injection.

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills.





jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI05 2007 (Data are from 2005)
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Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
AR 1 0 No data 0 0 0 0 0 0
IL 2 10 No data 0 5 250 10 255 265
IN 6 19,942 No data 0 0 0 19,942 0 19,942
KY 1 478 No data 0 0 0 478 0 478
LA 3 4,798 0 2,282 0 0 7,080 0 7,080
MO 1 255 No data 0 0 0 255 0 255
MS 1 1,500 No data 0 0 0 1,500 0 1,500
NC 1 3 No data 0 0 0 3 0 3
NJ 1 8 0 0 23 0 31 0 31
NY 1 10 5 0 0 0 15 0 15
OH 1 0 0 0 500 0 0 500 500
OK 1 0 No data 0 0 0 0 0 0
SC 1 16 No data 0 0 0 16 0 16
TN 1 879 No data 0 0 0 879 0 879
TX 5 3,494 249 114,939 138 3 118,751 72 118,823
Total 27 31,393 254 117,221 666 253 148,960 827 149,787
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.

eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 




gClass I wells, Class II-V wells, and underground injection.

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills.





jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI05 2007 (Data are from 2005)
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6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-4.  Releases to the Environment from Facilities that Produce, Process, or
 
Use Cresol (Mixed Isomers)a
 
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
AL 7 95,823 24 0 6 0 95,853 0 95,853
AR 4 48,000 44 0 29 0 48,047 26 48,073
CA 11 424 877 0 22 0 1,301 22 1,323
DE 1 3 55,312 0 5 0 55,315 5 55,320
FL 3 47,346 7 0 18 0 47,371 0 47,371
GA 6 101,614 11 0 2 0 101,627 0 101,627
ID 1 30,000 5 0 0 0 30,005 0 30,005
IL 8 1,051 151 0 1,479 253 1,202 1,732 2,934
IN 9 13,914 0 0 193 0 13,914 193 14,107
KS 1 311 0 0 0 0 311 0 311
KY 5 103,854 0 0 0 0 103,854 0 103,854
LA 16 39,749 2,072 0 555 250 41,852 774 42,626
MD 1 35,000 No data 0 0 0 35,000 0 35,000
ME 2 73,719 14 0 1 0 73,734 0 73,734
MI 2 28,073 517 0 2 21,202 28,592 21,202 49,794
MN 1 797 No data 0 12 5 797 17 814
MO 4 510 0 0 0 0 510 0 510
MS 3 68,209 258 0 0 0 68,467 0 68,467
NC 3 41,818 9 0 343 0 41,830 340 42,170
NH 1 2,320 No data 0 0 0 2,320 0 2,320
NJ 3 1,007 14 0 480 0 1,501 0 1,501
NM 2 422 No data 0 0 529 422 529 951
NY 5 5,650 385 0 0 7 6,035 7 6,042
OH 7 557 0 0 752 18 557 770 1,327
OK 2 500 0 0 0 8,669 500 8,669 9,169
OR 1 0 No data 0 0 0 0 0 0
PA 4 9,437 3 2,400 15 3,100 9,450 5,505 14,955
SC 6 76,282 7 2 492 0 76,779 4 76,783
TN 2 21,834 20 0 5 0 21,854 5 21,859
TX 19 57,824 233 241,664 24 2 297,466 2,281 299,747
UT 3 500 500 0 6,000 0 7,000 0 7,000
VA 2 4,602 1 0 531 0 5,133 1 5,134
WA 7 19,905 256 0 6 0 20,167 0 20,167
WI 3 707 No data 0 0 0 707 0 707
WV 1 93 No data 0 0 0 93 0 93



















          
          
 










   











6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-4.  Releases to the Environment from Facilities that Produce, Process, or
 
Use Cresol (Mixed Isomers)a
 
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
WY 1 250 No data 0 0 0 250 0 250
Total 157 932,106 60,721 244,066 10,971 34,035 1,239,817 42,082 1,281,899
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number.
 
bData in TRI are maximum amounts released by each facility.
 
cPost office state abbreviations are used.
 
dNumber of reporting facilities.

eThe sum of fugitive and point source releases are included in releases to air by a given facility.
 




gClass I wells, Class II-V wells, and underground injection.

hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 

impoundments, other land disposal, other landfills.





jThe sum of all releases of the chemical to air, land, water, and underground injection wells.

kTotal amount of chemical transferred off-site, including to POTWs.
 
RF = reporting facilities; UI = underground injection
Source:  TRI05 2007 (Data are from 2005)














   
    
   
  
 
   
   
 
     
   
    
 
 
     
 
     
     
  
      











6.  POTENTIAL FOR HUMAN EXPOSURE
of cresols to the atmosphere are fugitive or accidental emissions during the manufacture, use, transport,
and storage of cresols or associated products of the coal tar and petroleum industries. 
Low levels of cresols are constantly emitted to the atmosphere in the exhaust from motor vehicle engines
using petroleum based-fuels (Fraser et al. 1998; Hampton et al. 1982; Johnson et al. 1989; Seizinger and
Dimitriades 1972).  Using data collected from 7,060 vehicles entering a tunnel in Southern California, the
emission rates (calculated as μg cresol emitted per liter of fuel consumed) of o-cresol, and m/p-cresol
were calculated as 756.6 and 4,449.1 μg/L, respectively (Fraser et al. 1998).  Cresols have been identified 
in stack emissions from municipal waste incinerators (Assmuth and Kalevi 1992; James et al. 1984; Jin et
al. 1999; Junk and Ford 1980) and in emissions from the incineration of vegetable materials (Liberti et al. 
1983).  Cresols have also been identified as a component of fly ash from coal combustion (Junk and Ford 
1980).  Therefore, coal- and petroleum-fueled electricity-generating facilities are likely to emit cresols to 
the air. The combustion of wood (Hawthorne et al. 1988, 1989; Schauer et al. 2001) and cigarettes
(Arrendale et al. 1982; Novotny et al. 1982) also emits cresols to the ambient air.  Cresols are also formed 
in the atmosphere as a result of reactions between toluene and photochemically generated hydroxy
radicals (Leone et al. 1985).  
6.2.2 Water
Estimated releases of 123 pounds (~0.6 metric tons) of o-cresol, 544 pounds (~0.2 metric tons) of
m-cresol, 254 pounds (~0.1 metric tons) of p-cresol, and 60,721 pounds (~28 metric tons) of mixed 
isomers of cresols to surface water from 23, 28, 27,and 157 domestic manufacturing and processing
facilities in 2005, accounted for about 0.06, 0.2, 0.1, and 4.7% of the estimated total environmental
releases of o-cresol, m-cresol, p-cresol, and cresol mixed isomer from facilities required to report to the
TRI (TRI05 2007), respectively.  These releases are summarized in Tables 6-1 through 6-4.
Cresols are widely distributed natural compounds.  As discussed above, they are formed as metabolites of
microbial activity and are excreted in the urine of humans (Needham et al. 1984) as well as other
mammals (Fiege and Bayer 1987).  Cresols from human urine are biodegraded at municipal sewage
treatment facilities prior to release to ambient waters.  However, for combined septic and storm sewage 
systems, cresols may be released to surface waters during periods of precipitation when influent volumes
exceed treatment plant capacities.  Also, in rural and suburban areas where septic tanks are used (o- and 
m-cresols can resist anaerobic digestion), human excrement may be a nonpoint source release of cresols to 
groundwater.











   
    
 
  
   








   
  












   
   




6.  POTENTIAL FOR HUMAN EXPOSURE
Low levels of cresols are constantly emitted in the exhaust from motor vehicle engines using
petroleum-based fuels (Hampton et al. 1982; Johnson et al. 1989; Seizinger and Dimitriades 1972).  
Therefore, waterways used for transportation and recreation are likely to receive cresols from ship and 
motorboat traffic.  Waste water effluents from coal gasification (Giabbai et al. 1985; Neufeld et al. 1985)
and liquefaction facilities (Fedorak and Hrudey 1986), shale oil production sites (Dobson et al. 1985;
Hawthorne and Sievers 1984), refineries (Cardwell et al. 1986; Snider and Manning 1982), and a poultry
processing plant (Andelman et al. 1984) also may release cresols to surface waters.
In general, cresols will degrade in surface waters very rapidly. However, cresols may persist in 
groundwater due to a lack of microbes and/or anaerobic conditions.  Cresols are largely released to 
groundwater via landfills and hazardous waste sites.  Tables 6-5 through 6-8 include monitoring data for
these sources.
Coal liquefaction and other waste water may contain elevated levels of cresols.  Effluent from coal
gasification facilities contained o-cresol at a concentration of 586 mg/L (Fedorak and Hrudey 1986).  
Waste water effluents from coal gasification facilities contained p-cresol at concentrations of 880 mg/L
(Neufeld et al. 1985) and 5.12 mg/L (Pellizzari et al. 1979).  A coal liquefaction and a shale oil waste
water effluent contained p-cresol at concentrations of 420 mg/L (Fedorak and Hrudey 1986) and 
0.779 mg/L (Pellizzari et al. 1979), respectively.  p-Cresol was emitted with the waste water of a poultry
processing plant at concentrations ranging from 0.00214 to 0.0225 mg/L (Andelman et al. 1984).  Waste
water effluents from coal gasification facilities contained m-cresol at concentrations of 950 mg/L
(Neufeld et al. 1985) and 2.67 mg/L (Pellizzari et al. 1979).  A coal liquefaction and a shale oil waste
water effluent contained m-cresol at concentrations of 1,230 mg/L (Fedorak and Hrudey 1986) and 
0.561 mg/L (Pellizzari et al. 1979), respectively.  Waste water effluents from coal gasification plants
located in North Dakota contained p- and m-cresol at a combined concentration of 1,840 mg/L (Giabbai et 
al. 1985).   
p- and m-Cresol were detected at a combined average concentration of 1.0 mg/L for three samples of
retort water from a shale oil production facility (Hawthorne and Sievers 1984).  o-Cresol was detected at
an average concentration of 1.1 mg/L for three samples of retort water from a shale oil production facility
(Hawthorne and Sievers 1984).  




















    
      
 
   








      
  
 















      
 
 









      
 
















6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-5.  Detection of o-Cresol in the Groundwater of Hazardous Waste Sites 
and Landfills
Sampling Number of Number
Type/location dates samples positive Concentration Reference
Waste sites, groundwater
Hazardous waste/ No data No data No data 2.3 mg/L Weber and 
Buffalo, New York Matsumoto 1987 
Pine tar manufacturing/ No data No data No data 3.08 mg/L Drinkwater et al.
Gainesville, Florida 1986
Wood preserving/ March 1984 19 6 0.04–7.10 mg/L Goerlitz et al.
Pensacola, Florida 1985
Coal gasification/Hoe No data 3 3 63–6,600 μg/L Stuermer et al.
Creek, Wyoming 1982
Gas works Park/Seattle, December 10 2 1–10 μg/L Turney and 
Washington 1986 Goerlitz 1990
American Creosote March 1990 No data No data 4.2 mg/L Middaugh et al.
Works Facility/ 1991
Pensacola, Florida
Coal gasification/ No data 12 8 10–77 μg/L Johansen et al.
Denmark 1997
Samara River/Ukraine 1987–1990 No data No data 1–10 μg/L Goncharuk and 
(mine water) Milyukin 1999
















Industrial effluent/ No data 4 1 418 μg/L Bethune et al.
Managua, Nicaragua 1996




















    
 
  
     
 
 












    
 
      
 
 
































6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-6.  Detection of m-Cresol in the Groundwater of Hazardous Waste Sites 
and Landfills
Sampling Number of Number
Type/location dates samples positive Concentration Reference
Waste sites, groundwater
Wood preserving/ March 1984 19 4 0.05–13.73 mg/L Goerlitz at al.
Pensacola, Florida 1985
Infiltration of waste water, groundwater
Municipal, secondary/ No data 2 1 0.02 μg/L Bedient et al.
Port Devens, 1983; Hutchins
Massachusetts et al. 1984
Samara River/Ukraine 1987–1990 No data No data 2.5–4 μg/L Goncharuk and 
(mine water) Milyukin 1999
Landfill, Groundwater
Municipal/Southington, 1982–1983 No data No data 0.6 mg/L Sawhney and 
Connecticut Kozloski 1984
Gas works Park/Seattle, December 10 1 1.5 mg/L Turney and 
Washington 1986 Goerlitz 1990
American Creosote March 1990 No data No data 2.5 mg/L Middaugh et al.
Works Facility/ 1991
Pensacola, Florida












Industrial effluent/ No data 4 1 349 μg/L Bethune et al.
Managua, Nicaragua 1996




















    
 
  
     
 
   
    
 
 














     
 
  
    
 
 
     
 
 




















6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-7.  Detection of p-Cresol in the Groundwater of Hazardous Waste Sites 
and Landfills
Sampling Number of Number
Type/location dates samples positive Concentration Reference
Waste sites, groundwater
Hazardous waste/ No data No data No data 15 mg/L Weber and 
Buffalo, New York Matsumoto 1987 
Wood preserving/ March 1984 19 3 0.02–6.17 mg/L Goerlitz et al.
Pensacola, Florida 1985
Gas Works Park/Seattle, December 10 2 0.6 and 1.6 mg/L Turney and 
Washington 1986 Goerlitz 1990




Municipal/Southington, 1982–1983 No data No data 1.5 mg/L Sawhney and 
Connecticut Kozloski 1984 
Waste sites/surface 
water













Industrial effluent/ No data 4 2 166 μg/L Bethune et al.
Managua, Nicaragua 1996
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Sampling Number of Number
Type/location dates samples positive Concentration Reference
Waste sites, groundwater
Pine tar, manufacturing/ No data No data No data 5.17 mg/L Drinkwater et al.
Gainesville, Florida 1986
Coal gasification/Hoe No data 3 3 9.6–16.000 μg/L Stuermer et al.
Creek, Wyoming 1982
Abandoned pine tar No data 11 <0.3 0.3–2,900 μg/L McCreary et al.
manufacturing plant/ 1983
Gainesville, Florida
Coal gasification/ No data 12 7 5–77 μg/L Johansen et al.
Denmark 1997
Landfill leachate/Sweden No data 3 3 34 μg/L Oman and 
Hynning 1993










    
 
     
      
  
   
    
     
     
   
    
 
   
   
  
 





    
    
 
 
     
    
 





6.  POTENTIAL FOR HUMAN EXPOSURE
6.2.3 Soil 
Estimated releases of 270 pounds (~0.1 metric tons) of o-cresol, 780 pounds (~0.4 metric tons) of
m-cresol, 666 pounds (~0.3 metric tons) of p-cresol, and 10,971 pounds (~5 metric tons) of mixed isomers
of cresol to soils from 23, 28, 27, and 157 domestic manufacturing and processing facilities in 2005, 
accounted for about 0.1, 0.4, 0.4, and 0.9% of the estimated total environmental releases of o-cresol, 
m-cresol, p-cresol, and mixed isomers respectively, from facilities required to report to the TRI (TRI05 
2007).  An additional 182,006 pounds (~83 metric tons) of o-cresol, 153,332 pounds (~70 metric tons) of 
m-cresol, 117,221 pounds (~53 metric tons) of p-cresol, and 244066 pounds (~111 metric tons) of mixed 
isomers of cresols constituting about 98, 78, 78, and 19% of the total environmental emissions for
o-cresol, m-cresol, p-cresol, and mixed isomers respectively, were released via underground injection 
(TRI05 2007).  These releases are summarized in Tables 6-1 through 6-4.
Cresols can enter soil from the same types of natural sources as described above.  In fact, microbial
activity may be an important contributor of cresols to soil.  Poultry manure reportedly contained p-cresol
at an average concentration of 11.7 mg/kg (Yasuhara 1987).  Consequently, natural cresols are constantly
released to soils via excrement, exocellular secretions, and necromass of living and former living
organisms, where they are expected to degrade rapidly (Section 6.3.2.3).  Also, rural and suburban septic
tanks and grazing animals on pasture lands may contribute relatively large amounts of cresols to soil.
Cresols are released to soil at landfills and hazardous waste sites.  In general, cresols will degrade in soil
very rapidly.  However, cresols may persist in soil under anaerobic conditions or due to the toxic effects 
of high concentrations of cresols or other associated compounds.  Tables 6-5 through 6-8 include
monitoring data for these sources.  The land application of municipal sewage sludges that contain cresols 
may also release cresols to soil (Demirjian et al. 1984, 1987).
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
The transport and partitioning of an organic compound in the environment is a function of the physical
and chemical properties of that compound and the site-specific characteristics of the environment (e.g., 
percentage soil organic matter).  Based on the environmental correlations with physical properties 
(Thomas 1982), the physical and chemical properties of the three isomeric cresols are sufficiently similar
to indicate that similar transport and partitioning processes will be important for each isomer in the
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environment.  Therefore, their potential for partitioning between the various environmental compartments
will be discussed collectively.
In the atmosphere, the vapor pressure of the isomeric cresols, 0.11±0.30 mmHg at 25.5 C (AIChE 1989, 
2000; Chao et al. 1983), suggests that these compounds will exist predominantly in the vapor phase
(Eisenreich et al. 1981) rather than being bonded to atmospheric particles.  This is consistent with 
experimental studies that found all three isomers in the gas phase of urban air samples, but they were not
present in the particulate samples collected at the same time (Cautreels and Van Cauwenberghe 1978)
when the droplets are present, gas-phase creosote will predominantly be taken up.  The relatively high 
water solubility of the cresol isomers, 21,520–25,950 mg/L (Yalkowsky et al. 1987), indicates that wet
deposition may remove them from the atmosphere.  This is confirmed by the detection of cresols in rain 
water (Section 6.4.2).  The short atmospheric residence time expected for the cresols (Section 6.3.2.1)
suggests that cresols will not be transported long distances from their initial point of release.
Calculated soil adsorption coefficients (Koc) of 17.5–117 have been determined for the three isomeric 
cresols, and compare favorably with experimentally determined values ranging from 22 to 158 (Boyd 
1982; Koch and Nagel 1988).  The estimated values were derived by regression analysis based on the
inherent hydrophobicity (octanol/water partition coefficient [Kow]) of an organic compound.  For the soils
studied in these adsorption studies, this type of regression analysis successfully predicted the potential for
the movement of cresols through soil, suggesting high to very high mobility in soil (Swann et al. 1983).
The mobility of the isomeric cresols cannot be adequately described by considering their tendency to 
partition from water.  The hydroxyl function of cresol is capable of forming relatively strong hydrogen 
bonds with active sites in the soil, and its mobility will depend on the degree in which these bonds are
formed (Artiola-Fortuny and Fuller 1982; Boyd 1982; Southworth and Keller 1986).  This was the
rationale presented to explain large values obtained in laboratory experiments, which obtained Koc values 
for isomeric cresol ranging from 115 to 3,420 in a study of three different soils (Southworth and Keller
1986).  A Koc value near 3,000 would suggest only slight mobility in soil (Swann et al. 1983).  The
amount of hydrogen bonding to sites in the soil will be strongly influenced by the pH of the surrounding
medium, the type of soil, its iron oxide content, anion exchange capacity, and amount of organic matter
present.  From the literature, one cannot make generalized trends as to which soils provide active bonding
sites for the cresol isomers.  For example, m-cresol adsorbed strongly to a high-clay-content soil
(Southworth and Keller 1986), but not to two others (Luh and Baker 1970).
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In water, the isomeric cresols may eventually volatilize to the atmosphere, but volatilization is expected to 
be a slow process.  Based on their Henry's law constants, which range from 1.2x10-6 to 
8.65x10-7 atm-m3/molecule (Gaffney et al. 1987; Hine and Mookerjee 1975), the volatilization half-life
from a model river 1 m deep, flowing at 1 m/sec, with a wind velocity of 3 m/sec can be estimated to 
range from approximately 30 to 41 days (Thomas 1982).
Experimental bioconcentration factors (BCFs) of 14.1 for o-cresol (Sabljic 1987) and 19.9 for m-cresol
(Freitag et al. 1982) indicate that the isomers of cresol will not bioconcentrate in fish and aquatic
organisms to any significant extent.  Also, cresols are not likely to bioconcentrate in humans.  Similar to 
their behavior in soil, the isomeric cresols are not expected to adsorb to sediment and suspended organic 
matter, although the potential for this process exists.
6.3.2 Transformation and Degradation
All cresol isomers can be rapidly removed from environmental media.  The dominant removal mechanism
in air appears to be oxidation by hydroxyl radical during the day and nitrate radical at night, with half-
lives on the order of a day.  In water under aerobic conditions, biodegradation will be the dominant
removal mechanism; half-lives will be on the order of a day to a week.  Under anaerobic conditions, 
biodegradation should still be important, but half-lives should be on the order of weeks to months.  In soil
under aerobic conditions, biodegradation is also important, with half-lives on the order of a week or less.
6.3.2.1  Air
Cresols degrade rapidly in air.  Removal during the day is dominated by the reaction with hydroxyl
radical (HO•), while nighttime removal is dominated by the nitrate radical.  Reaction with other oxidants 
in air (e.g., ozone) will be much slower than reactions with hydroxyl or nitrate radical (Atkinson and 
Carter 1984).
Hydroxyl radicals react with cresols by attacking the carbon bearing the hydroxyl group.  Degradation 
products from this reaction include nitrocresols and products of ring opening such as pyruvic acid, 
acetaldehyde, formaldehyde, peroxyacetylnitrate, and nitrocresol (Atkinson et al. 1980; Grosjean 1984, 
1985).  Products may vary, depending on whether the reaction takes place in the gas or particle phase
(Grosjean 1984).  Second-order rate constants for o-, p-, and m-cresol of 4.0x10-11, 4.4x10-11, and 
5.7x10-11 cm3 molecule-1 sec-1, respectively, were determined (Atkinson 1985).  Using 5x105 molecules 
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cm3 as an average tropospheric hydroxyl radical concentration (Atkinson 1985) and the reaction rate
constants presented above, the atmospheric half-lives for o-, p-, and m-cresol were calculated to be 9.63, 
8.75, and 6.76 hours, respectively.  
At night, hydroxyl radical concentrations decrease and nitrate radical concentrations increase (Platt et al. 
1984), making nitrate radical reactions more important than hydroxyl radical reactions.  Nitrate radicals 
attack cresols by removing the hydroxyl hydrogen, yielding a phenoxy radical.  The average second-order
rate constants for the reactions of o-, p-, and m-cresol and the nitrate radical are 1.01x10-11, 0.70x10-11 , 
and 1.08x10-11 cm3 molecule-1 sec-1, respectively (Atkinson et al. 1984; Carter et al. 1981).  The half-lives 
for these reactions, assuming an average night-time nitrate radical concentration of 2.4x108 molecules
cm3, are 4.8, 4.5, and 6.9 minutes for o-, m-, and p-cresols, respectively (Atkinson et al. 1984; Carter et al. 
1981).  
In addition to degradation by hydroxyl and nitrate radicals, all three cresol molecules absorb small
amounts of UV light with wavelengths above 290 nm (Sadtler 1960a, 1960b, 1966).  Therefore, direct
photolysis is also possible; however, the photolysis rate is slow compared to the rate of reaction with 
atmospheric radicals.
6.3.2.2  Water
Dilute cresols have been tested for biodegradability in numerous screening tests and sewage treatment
plant simulation tests, as well as in surface water, groundwater, estuarine water, and sea water.  Most tests 
indicate that the cresol isomers rapidly and completely degrade to simpler molecules under aerobic
conditions in fresh water.  Degradation is slower in salt water and under anaerobic conditions.  
All cresol isomers were found to degrade rapidly in biodegradation screening and sewage treatment plant
simulation studies with half-lives between <24 hours and <7 days (Alexander and Lustigman 1966;
Babeu and Vaishnav 1987; Baird et al. 1974; Chambers et al. 1963; EPA 1979; Heukelekian and Rand 
1955; Ludzack and Ettinger 1960; Lund and Rodriguez 1984; Malaney 1960; Malaney and McKinney
1966; McKinney et al. 1956; Pauli and Franke 1972; Pitter 1976; Tabak et al. 1964; Young et al. 1968).
In these studies, degradation was rapid with both acclimated and unacclimated inocula; initial
concentrations ranged from 0.5 to >500 ppm.  Degradation generally was slower at the higher
concentrations; however, under sewage treatment plant conditions, high cresol concentrations can be
degraded (e.g., Chudoba et al. [1968] reported >99% removal of starting material [4,448 ppm of p-cresol]
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in 3 days under sewage treatment plant conditions).  The available screening tests indicate that the cresols 
are readily degraded by microorganisms and activated sludge.  
Very little information is available concerning the differences in the biodegradability of the cresol
isomers.  Based on the results of one study (Visser et al. 1977), biodegradability of their isomers appears
to exist in the order:  p-cresol > o-cresol > m-cresol.  Aerobic degradation under these conditions appears
to be fast, with the initial step being the rate-limiting step.  No intermediate products have been reported 
using grab samples and the inoculum (EPA 1978; Spain and van Veld 1983).  
Aerobic biodegradation in salt water (estuarine and sea water) appears to be slower than in fresh water;
insufficient information is available to estimate anaerobic degradation in salt water.  Factors governing
biodegradation of m- and p-cresol in salt water include spatial and temporal variations (e.g., salinity and 
temperature) (Bartholomew and Pfaender 1983; Palumbo et al. 1988; Pfaender and Bartholomew 1982a, 
1982b; Spain and van Veld 1983; van Veld and Spain 1983), substrate concentration (Palumbo et al. 
1988; Spain and van Veld 1983), and the presence or absence of sediment (van Veld and Spain 1983). 
Almost no information is available for o-cresol, although one biological oxygen demand (BOD) test in 
saline water suggested rapid degradation (Takemoto et al. 1981).
In contrast to aerobic conditions, cresols do not appear to degrade rapidly in anaerobic fresh water
sediments, although very little information is available.  Horowitz et al. (1982) reported that the cresol
isomers in anoxic sediments from Wintergreen Lake in Kalamazoo County, Michigan, had degradation 
times in excess of 29 weeks.  The authors also stated that, as described above for anaerobic sludges, the 
m- and p-cresol isomers showed the most degradation, while o-cresol resisted degradation.
In anaerobic groundwater samples and groundwater samples with aquifer materials, cresol isomers 
display the same pattern of degradation p-cresol > m-cresol > o-cresol, where p-cresol is the most readily
biodegradable of the three isomers, seen in anaerobic sewage sludge experiments.  Thomas et al. (1989)
reported that o-cresol concentrations decreased, then increased, in a groundwater sample from a creosote-
contaminated site.  The authors suggested that o-cresol may be a metabolite of some other chemical
present during the multi-component study.
The degradation pathway of p-cresol in groundwater appears to proceed by oxidation of the methyl group 
to first give the corresponding benzaldehyde, then benzoic acid (Kuhn et al. 1988; Smolenski and Suflita
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1987; Suflita et al. 1988, 1989).  The hydroxybenzoic acid then can be either decarboxylated or
dehydroxylated to phenol or benzoic acid, respectively.
There are no hydrolyzable functional groups on cresol, so hydrolysis is not an important environmental
fate process.  In addition to biodegradation, chemical oxidation (including by superoxide, singlet oxygen, 
hydroxyl radical, and organic peroxy radicals) and photolysis may be removal pathways in the
environment, but do not appear to be as fast as biodegradation under most conditions.  Faust and Holgné
(1987) reported that the irradiation of water containing fulvic acid produced a transient oxidant that
oxidized o- and p-cresol.  The transient radical was suggested to be an organic peroxy species.  Irradiation 
of water without fulvic acid produced almost no degradation of p-cresol in 3 hours; the addition of fulvic
acids caused rapid disappearance with half-times of about 50 minutes (EPA 1978).  In water from
Greifensee (a polluted, eutrophic, pre-alpine Swiss lake) at pH 8, calculated half-lives for the top meter of
water (where light of the necessary wavelength is present) are 11 and 4.4 days for o- and p-cresol, 
respectively.  Singlet oxygen is also produced by solar irradiation on natural waters and can react with 
cresols.  A rate constant of 3.7x10-8 M-1 sec-1 for p-cresol reaction with singlet oxygen was produced in 
the laboratory by irradiation of water containing rose bengal (Scully and Hoigne 1987).  Using a singlet
oxygen concentration of 4x10-14 M (corresponding to the concentration in water at noon on a summer
day), these authors calculated a half-life of 500 hours. EPA (1978) studied the direct photolysis of
p-cresol in water.  In pure water and using solar irradiation in April, EPA (1978) reported half-lives of 
approximately 35 days.
While the above data indicate that oxidative and photolytic processes occur during degradation of cresols 
in water, it is difficult to estimate the half-lives for these under environmental conditions.  Since
environmental waters vary significantly in clarity (and hence, in their ability to transmit light), as well as
their concentration of fulvic substances, half-lives are expected to vary considerably.  Additionally, the
absorbance of cresols changes with the pH of the water (EPA 1978).  Thus, the amount of light absorbed 
at a specific wavelength by cresols will change with pH, as will the degradation rates.  EPA (1978)
estimated a half-life of p-cresol in environmental waters from direct photolysis of 300–400 days under
summer light conditions.  This, with the other estimates presented above, suggests that chemical oxidation 
from light-produced radicals and direct photolysis will not be a significant removal mechanism under
most environmental conditions.
In addition to oxidants generated by light, Stone (1987) reported that ferric iron [Fe(III)] and manganese
[Mn(III/IV)] oxides are capable of oxidizing p-cresol.  Fe(III) and Mn(III/IV) oxides are common species
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found in surface water particulate and soils, as well as in dust and ash.  Rate constants for p-cresol ranged 
from 10-9 to 10-6 mol/L-min for pH of 7.8–4.2, respectively.  In the environment and at low pH values, 
these species may oxidize cresols with half-lives on the order of several hours.
6.3.2.3  Sediment and Soil
Cresol degradation in soil has been reported by Medvedev and Davidov (1981a, 1981b), Namkoong et al. 
(1988), and Dobbins and Pfaender (1988).  Dobbins and Pfaender (1988) and Namkoong et al. (1988)
found that the data for cresol degradation fit first-order kinetics, but with very different rates.  Dobbins
and Pfaender (1988) found that CO2 from m-cresol degradation evolved slowly when m-cresol was
incubated in water slurries of surface and subsurface soils from a pristine location.  Degradation was 
followed by trapping radioactive carbon dioxide, and overall mass balances were performed by
comparing radioactivity remaining in the soil with the trapped CO2. In surface soils, first-order rate 
constants based on CO2 evolution were 7.55x10-5–6.31x10-4 hour-1, which yields half-lives from 46 days 
to about 1 year.
By contrast, Namkoong et al. (1988) reported a rapid degradation of all cresol isomers in surface soils
from an uncultivated grassland site.  Degradation was followed by analyzing for the parent substance, and 
first-order kinetics were followed.  o-Cresol reportedly had a half-life of about 1.6 days, while p-cresol
degraded too fast to allow measurement of a rate constant.  m-Cresol reportedly had a half-life of about
0.6 days.  Medvedev and Davidov (1981a, 1981b) reported the same relative rates for the three isomers in 
a soil from the Soviet Union but did not report absolute rates. Times to disappearance in the soil were
reportedly 16, 9, and 27 days for o-, p-, and m-cresol, respectively.  These authors were unable to detect
any secondary products from cresol metabolism.  The differences in the rates reported by Namkoong et al. 
(1988) and Dobbins and Pfaender (1988) appear to be the result of the different analytical methods used.  
Namkoong et al. (1988) used gas chromatography to determine the rate of cresol disappearance, while 
Dobbins and Pfaender (1988) used CO2 evolution to determine the rate of carbon dioxide appearance.  
Thus, based on the available information, cresols degrade rapidly in soils, possibly becoming incorporated
into soil microorganisms, but they mineralize slowly.  Indeed, Dobbins and Pfaender (1988) noted that
significant amounts of radioactivity were bound to the soil, which supports the explanation that cresols or
cresol metabolites are incorporated.
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6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to cresols depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens.  Concentrations of
cresols in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits 
of current analytical methods.  In reviewing data on cresol levels monitored or estimated in the
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
equivalent to the amount that is bioavailable.  The analytical methods available for monitoring cresols in a
variety of environmental media are detailed in Chapter 7.
6.4.1 Air
Monitoring data have not shown cresols to be widely occurring atmospheric pollutants.  A national
emissions study conducted from 1990 to 1998 reported an estimated ambient concentration average of
31.7 ng/m3 (EPA 2000d).  In an analysis of contaminants of the air in southern California in August 1987, 
background levels of p-cresol and o-cresol were found in concentrations of 0.02–0.07 and 0.09–0.30 ppb 
(Harley and Cass 1994).  The National Ambient Volatile Organic Compounds (VOCs) Database, a
compilation of published and unpublished air monitoring data from 1970 to 1987, contained very little
information on the cresols (EPA 1988e). The database contained only information for o-cresol in source-
dominated atmospheres (air surrounding a facility or known release of the chemical in question).  The
median air concentration of o-cresol at source-dominated sites is 1.62 μg/m3 for 32 samples (EPA 1988e).  
The median atmospheric concentration of o-cresol (10 samples collected at three unspecified sites in the
United States) was 1.5 μg/m3, a range of 0.5–20 μg/m3 was reported for p-cresol (62 samples collected at
11 unspecified sites in the United States), and m-cresol was not detected in any of the three samples 
studied (Kelly et al. 1994).  On September 8–9, 1993, 46.77 and 90.53 ng/m3 of o-cresol and a mixture of
p- and m-cresol, respectively, were detected in vapor-phase semivolatile organics over Southern 
California during a major photochemical smog event (Fraser et al. 1998).  Cresol was detected in the
ambient air of Upland, California; however, specific isomers were not identified (Kolber et al. 1981).  
All three isomers of cresol have been identified, but not quantified, in gas samples taken from various
municipal landfills in southern Finland (Assmuth and Kalevi 1992).  In coal gas effluent, p- and m-cresol
were found in concentrations of 11.6 and 7.09 mg/L, respectively (Jin et al. 1999).  p-Cresol was detected 
in the emissions at waste incineration plants in Germany at a concentration of 0.43 μg/m3 (Jay and 
Stieglitz 1995).  p-Cresol was indentified in the air adjacent to municipal incinerators, waste collection 
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centers, and sewage treatment plants around Southampton, England in concentrations ranging from
<0.1 to 24.5 μg/m3 (Leach et al. 1999).
In a study of air emissions from burning pine, oak, and eucalyptus, o-cresol was detected in the gas phase 
for all three samples at concentrations of 89.6, 47.7, and 37.8 mg/kg wood burned, respectively, and in the
particle phase of oak and eucalyptus at concentrations of 0.018 and 0.006 mg/kg wood burned, 
respectively.  A mixture of p- and m-cresol was detected in the gas phase for pine, oak, and eucalyptus in 
concentrations of 380, 179, and 110 mg/kg wood burned, respectively, and in the particle phase of all
three wood types at concentrations of 0.5, 0.21, and 0.055 mg/kg wood burned, respectively (Schauer et
al. 2001).  
The absence of data does not necessarily indicate a lack of cresol emissions into ambient air.  In general, 
cresols are highly reactive with hydroxyl and nitrate radicals in the day and night, respectively, and 
atmospheric half-lives for cresols are short.  Scavenging by water may further reduce the atmospheric 
residence time of cresols (see Section 6.3.2.1).
6.4.2 Water
In a national study of organic contaminants in 139 U.S. streams located in 30 states from 1999 to 2000, 
p-cresol was detected in 24.7% of the samples taken with a maximum concentration of 0.54 μg/L and a
mean concentration of 0.05 μg/L (Kolpin et al. 2002).  In a study of public groundwater at superfund 
sites, o-cresol and p-cresol were detected with maximum concentrations of 390 and 150 μg/L, 
respectively; however, neither was detected in well fields or finished water from treatment plants (Canter
and Sabatini 1994). 
o-Cresol was detected in fresh water samples from Spirit Lake, Washington, on August 7, 1980 and from
South Fork Castle Lake and Smith Creek, Washington, on September 11, 1980 at unreported 
concentrations (McKnight et al. 1982).  The presence of cresols attributed to the Mount St. Helens 
eruption on May 18, 1980 was most likely a result of incomplete combustion of plant materials
(McKnight et al. 1982).  Whether or not the cresols originated from wood fires or the actual eruption was
not clarified.  
p-Cresol was detected in surface water with a frequency of occurrence of 1.5% and with a geometric 
mean concentration of 11 μg/L for positive samples (CLPSD 1988).  p-Cresol was identified as a 
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contaminant of mixed water and sediment samples from the Tennessee River (Gordon and Goodley 1971)
at a concentration of 200 μg/L (Goodley and Gordon 1976).  p-Cresol also was detected in fresh water
samples from Spirit Lake, Washington, on August 7, 1980 at unreported concentrations (McKnight et al. 
1982).
m-Cresol was detected with a frequency of occurrence of 0.9% in surface water (CLPSD 1988).  In 
addition, m-cresol was listed as a contaminant of the St. Joseph River in the Lake Michigan Basin (Great
Lakes Water Quality Board 1983).  m-Cresol was detected in fresh water samples from Spirit Lake, 
Washington, on August 7, 1980 at unreported concentrations (McKnight et al. 1982).
Industrial effluents are a source of groundwater exposure to cresols.  While human exposure to these
waters is unlikely, it is important to note these releases to groundwater.  Unspecified isomers of cresol
were detected from one of seven sample sites along the Delaware River at a concentration of 20 μg/L.  
This was a result of industrial waste water effluent discharged by the Philadelphia Northeast Sewage 
Treatment Plant, which discharges secondary effluent into the river (Hites 1979; Sheldon and Hites 1979).
For Delaware River water from August 1976 to March 1977, the summer and winter average
concentrations of unspecified isomers of cresols that were not traceable to any source were "not detected"
and 2 μg/L, respectively; this suggested that rapid biodegradation prevents cresol detection during the
warmer months (Sheldon and Hites 1978).  
Tables 6-5 through 6-8 summarize the literature data on cresols found in groundwater and their respective
anthropogenic sources.   
Rain water at Portland, Oregon, contained o-cresol at concentrations ranging from 0.240 to 2.80 μg/L, 
with an average concentration of 1.02 μg/L for seven rainfalls between February 12, 1984 and 
April 12, 1984.  In addition to this study, combined p- and m-cresol was detected in rain in Portland, 
Oregon at concentrations >1.1 μg/L (Grosjean 1991).  Combined p- and m-cresol concentrations ranged 
from 0.380 to 2.00 μg/L, with an average concentration of >1.10 μg/L (Leuenberger et al. 1985).  
o-Cresol was detected in rain water from a rural site (Grepden, Switzerland) on April 3, 1986, at
concentrations ranging from not detected to 1.3 μg/L.  Combined p- and m-cresol concentrations ranged 
from 0.65 to 9.3 μg/L (Czuczwa et al. 1987).  Combined p-and m-cresol were detected in rain and cloud 
water in Vosges Mountains in France at concentrations ranging from 0.47 to 2.23 μg/L (Levsen et al. 
1993).  p- and m-Cresol were also detected in concentrations ranging from 0.6 to 3.6 μg/L in cloud water
samples taken from Mt. Brocken in Germany during June 1994 (Luttke et al. 1999).  p-Cresol was found 
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in snow samples from Finland, Moscow, and Siberia at concentrations 0.04, 0.004–0.06, and 0.29 μg/kg 
(Poliakova et al. 2000).  o-Cresol was found in snow samples from Finland and Moscow in concentration 
of 0.07 and 0.03 μg/kg, respectively (Poliakova et al. 2000).
Cresols are formed when various aromatic compounds are metabolized. Therefore, cresols are expected
to be in municipal waste water.  p-Cresol was detected in five of nine municipal waste water plants in 
western Virginia with concentrations ranging from 0.18 to 0.86 μg/sample (Dietrich et al. 1993).
The absence of monitoring data does not necessarily indicate a lack of cresols in the environment.  
Cresols are widely occurring natural and anthropogenic products.  However, biodegradation is probably
the dominant mechanism responsible for the rapid removal of cresols from surface waters (see 
Section 6.3.2.2).  Nevertheless, cresols may persist in extremely oligotrophic waters, in waters with 
limited microbial communities, and/or under anaerobic conditions such as in some sediments and 
groundwater aquifers.
6.4.3 Sediment and Soil
o-Cresol was detected in 3.7% of the soil samples in the Contract Laboratory Program Statistical
Database (CLPSD) (CLPSD 1988).  p- and m-Cresol were also detected with frequencies of occurrence of
4.4 and 0.9%, and geometric mean concentrations of 257 and 1,105 µg/kg for the positive samples, 
respectively (CLPSD 1988).  o-Cresol was detected at maximum concentrations of 12,000, 21,000, 
34,000, and 55,000 µg/kg in the soil of an abandoned pine tar manufacturing plant in Gainesville, Florida
at four separate sites (McCreary et al. 1983).
Cresols are an excretory product of mammals and an intermediate biotransformation product of natural
aromatics such as lignin constituents (Fiege and Bayer 1987).  Soil microorganisms are capable of 
metabolizing cresols, and any anthropogenic release of cresol, other than massive spills, is likely to be
rapidly degraded in soil (Section 6.3.2.3).
Cresols have been detected in various sediment samples.  In Roane County, Tennessee, p-cresol was
detected in two sediment samples at concentrations of 1,233 and 127 ppb.  In a study of streambed 
sediment in 20 major river basins of the United States from 1992 to1995, p-cresol was identified in 37.8%
of the sites with a maximum value of 4,800 μg/kg dry weight; however, 90% of the positive samples 
contained ≤430 μg/kg dry weight (Lopes and Furlong 2001).  o- and p-Cresol were identified, but not
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quantified, in sediment samples obtained from the Elbe River of the German Bight (Schwarzbauer et al. 
2000).
6.4.4 Other Environmental Media 
As discussed above, cresols are widely distributed natural compounds.  They are formed as metabolites of
microbial activity and are excreted in the urine of animals.  Various plant lipid constituents, including
many oils, contain cresols.  Cresols have also been detected in certain foods and beverages such as 
tomatoes, tomato ketchup, cooked asparagus, various cheeses, butter, oil, red wine, distilled spirits, raw
and roasted coffee, black tea, smoked foods, tobacco, and tobacco smoke (Fiege and Bayer 1987).  
However, very few monitoring data for cresols in food were found in the literature. p-Cresol has been 
detected in fermented soybean curds at concentrations ranging from 52.0 to 67.3 μg/kg (Chung 1999) and 
o-cresol has been detected in big eyed herring fermented fish at a mean concentration of 18.6 μg/kg (Cha
and Cadwallader 1995).
Both o-cresol and p-cresol have been detected in eggs of birds of the Selenga river estuary in Lake Baikal, 
Russia, one of the largest fresh natural water sources in the world.  Concentrations ranged from 208 to 
<10 μg/kg dry weight and from 540 to <10 μg/kg dry weight for o- and p-cresol, respectively (Lebedev et
al. 1998).
All three cresol isomers were identified as volatile emissions of fried bacon (Ho et al. 1983).  Various
brands of Scotch whiskey, whiskeys made outside of Scotland, cognac, armagnac, brandy other than 
cognac and armagnac, and white and dark rums contained cresol at concentrations of 0.01–0.20 ppm, 
0.01–0.07 ppm, trace to 0.02 ppm, trace to 0.02 ppm, trace to 0.02 ppm, and trace to 0.20 ppm, 
respectively (Lehtonen 1983).
Cresols are emitted in cigarette smoke.  The total concentration of o-cresol and combined m-cresol and 
p-cresol in cigarette smoke was reported to range from approximately 14 to 26 μg/cigarette and from
41 to 82 μg/cigarette, respectively (Wynder and Hoffmann 1967).  Depending upon the rate of ventilation, 
o-cresol was detected in cigarette smoke at levels of 7.1–37 μg/cigarette, while combined m-cresol and 
p-cresol isomers were emitted at a rate of 12.3–68 μg/cigarette (Singer et al. 2002).  The average cresol
concentration in a 45 cubic meter chamber after six cigarettes had been smoked ranged from 0.17 to 
3.9 μg/m3 depending on the brand and type of cigarette (Nelson et al. 1998).  In another study, o-, m-, and 
p-cresol were emitted from mainstream cigarette smoke at mean rates of 3.31, 2.55, and 6.36 μg/cigarette, 










    
  
   








   
 
 














   
 




6.  POTENTIAL FOR HUMAN EXPOSURE
respectively (Rustemeier et al. 2002).  Under steady-state conditions in a furnished 50 cubic meter room, 
the exposure relevant emission factors (EREFs) of o-, m-, and p-cresol were 22–41, 16–35, and 32– 
72 μg/cigarette, respectively, depending upon the ventilation of the building (Singer et al. 2003).  These
EREFs measure not only the initial exposure to environmental tobacco smoke, but also the potential for
exposure from the re-emission of chemicals from absorbing surfaces such as wallboard, carpeting, and 
other room furnishings. 
6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
Inhalation exposure is likely to be the most common route of exposure for the general population to 
cresols.  However, since cresols have a short residence time in both day- and night-time air; atmospheric 
levels are probably low despite their ubiquitous nature.
Cresols have been identified as components of automobile exhaust (Hampton et al. 1982; Johnson et al. 
1989; Seizinger and Dimitriades 1972), and may volatilize from gasoline and diesel fuels used to power
motor vehicles.  Vehicular traffic in urban and suburban settings provides a constant source of cresols to 
the atmosphere.  Hence, urban and suburban populations may be constantly exposed to atmospheric
cresols.  Cresols are also emitted to ambient air during the combustion of coal (Junk and Ford 1980), 
wood (Hawthorne et al. 1988, 1989), municipal solid waste (James et al. 1984; Junk and Ford 1980), and 
cigarettes (Arrendale et al. 1982; Novotny et al. 1982).  Therefore, residents near coal- and petroleum-
fueled electricity-generating facilities, municipal solid waste incinerators, and industries with 
conventional furnace operations or large-scale incinerators may be exposed to cresols in air.  People in 
residential areas where homes are heated with coal, oil, or wood may also be exposed to cresols in air.
Exposure to cresol may occur in atmospheres containing toluene.  Cresols are formed in the atmosphere
during photochemical reactions between toluene and photochemically generated hydroxy radicals (Leone
et al. 1985).
Cigarette smoke is also a source of cresol exposure.  One estimate indicated that an individual who 
smokes two packs of cigarettes a day may inhale 3 μg/day of total cresol (Wynder and Hoffmann 1967).  
Other estimates are somewhat higher; for instance, Nazaroff and Singer (2004) estimated that nonsmokers 
who live with a person who smokes nine cigarettes/day may inhale 2–5 μg/day of cresols through 
inhalation of second-hand smoke.
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6.  POTENTIAL FOR HUMAN EXPOSURE
Ingestion of certain foods may be as prevalent or more prevalent a route of exposure than inhalation.  
However, more quantitative data on the occurrence of cresols in food would be required to make a
comparison.  Cresols have been detected in tomatoes and tomato ketchup, cooked asparagus, various
cheeses, butter, and oil (Fiege and Bayer 1987).  Beverages such as red wine and distilled spirits 
(Lehtonen 1983), raw and roasted coffee, and black tea contain cresols (Fiege and Bayer 1987).  Fried 
(Ho et al. 1983), smoked, and barbecued foods also may contain cresols (Fiege and Bayer 1987).  For
people with groundwater wells near landfills or hazardous waste sites, drinking water may be an 
important source of exposure; individuals living near hazardous waste sites or cresol production facilities 
may also be exposed.  Quantitative information for both foods and drinking water was lacking, and the
respective average daily intakes were not calculated.
Dermal contact to cresols may occur during recreational activities at natural waterways containing either
naturally or anthropogenically generated cresols.  However, cresols are expected to degrade rapidly in 
surface water and this is not likely to be a major source of exposure.
According to the National Occupational Exposure Survey (NOES) conducted by NIOSH in the workplace
between 1981 and 1983, 10,985 (483 are female), 21,313 (16,798 are female), 5,615 (1,174 are female), 
and 132,742 (28,184 are female) workers were potentially exposed to o-, p-, m-, and the mixture of
isomers, respectively (NIOSH 1989).  The NOES database does not contain information on the frequency, 
concentration, or duration of exposure of workers to any of the chemicals listed therein.  These surveys 
provide estimates of the number of workers potentially exposed to the chemicals in the workplace.  The
most probable routes of occupational exposure are inhalation and dermal contact at places where cresols
and/or cresol-containing compounds are produced or used.
Very little information pertaining to occupational exposure to cresols was located in the literature.  
Occupational exposure to cresols has been documented in laboratories and coal gasification facilities 
(Needham et al. 1984), during paint and varnish application (Angerer and Wulf 1985), during application 
of insulation lacquers to copper wires, and in wood-preserving facilities (Nieminen and Heikkila 1986).  
During the creosote impregnation of wood, workers were exposed to cresol concentrations <0.1 mg/m3 
(Heikkila et al. 1987).  Workers of a bench scale coal conversion process were exposed to atmospheric
levels of cresols <0.1 ppm in 1981 and 1982 (Dreibelbis et al. 1985).
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6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
No data regarding environmental cresol exposure in children were found.  No reports or studies of cresol
in baby food or breast milk were found.  The most likely route of exposure to cresols for children is
through inhalation of ambient air.  Children who live in areas of high traffic or with adults who smoke are 
more likely to be exposed to cresols through inhalation.  
6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
High levels of exposure to cresols are most likely to occur in occupational settings where cresols are
either produced or used.  Intake by inhalation or dermal contact is the most probable route of high 
exposure to cresols.  Cigarette smokers or persons who reside with smokers are likely to be exposed to 
higher amounts of cresols than the nonsmoking general population
People who work at manufacturing facilities that process coal or coal tar may have an increased risk for
cresol exposure.  In a study of 76 male workers aged 22–58 years of age employed at a coke plant in 
Poland, slightly elevated levels of o-cresol and m/p-cresol were detected in the urine of employees when 
compared to a group of 34 nonoccupationally exposed individuals (Bieniek 1997).  The concentrations of
o-cresol and m/p-cresol in the urine of subjects working in the high temperature tar distillation process
were 0.54 and 18.14 mg/L, respectively, while the nonexposed control group had levels of 0.041 and 
14.38 mg/L for o-cresol and m/p-cresol, respectively (Bieniek 1997).  The time-weighted geometric mean 
concentrations of o-cresol and m/p-cresol in the breathing zone at the plant were reported as 0.09 and 
0.13 mg/m3, respectively (Bieniek 1997).   











        
   
 
   
 
    
     
     
   
    








    
 
 
   
 
 




6.  POTENTIAL FOR HUMAN EXPOSURE
Workers at gas stations, or those involved in distillation of crude tar, oil, and other plants that produce
cresols as side-products are likely to have increased exposure to cresols.  However, there are no 
monitoring data to give the exact exposure.
Cresols are metabolites of other aromatic compounds. o-Cresol is a metabolite of toluene and therefore, 
exposure to toluene may increase exposure to o-cresol.  Toluene is a major component of glue.  In a
Japanese study, people who sniffed glue as a form of intoxication had a mean value of 7.31 mg o-cresol/g
creatinine in their urine as opposed to 0.095 and 0.016 mg o-cresol/g creatinine for industrial workers and 
those who did not sniff glue (Yamazaki et al. 1992).  Workers who were occupationally exposed to 
toluene at a median concentration of 284.4 mg/m3 in workplace air had a median urinary o-cresol level of
2.1 mg/g creatinine (Angerer and Kramer 1997).  Workers at a rotogravure printing plant, who were
exposed to toluene at levels ranging from 8 to 496 mg/m3 in workplace air, had mean o-cresol urinary
excretion levels ranging from 0.080 to 2.37 mmol o-cresol/mol creatinine (0.076–2.26 mg o-cresol/g 
creatinine) (Nise 1992).  These o-cresol excretory levels were correlated with toluene exposure levels and 
smoking habits of the employees.
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of cresols is available.  Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of cresols. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed. 










    
 
     
   
 
   
 
   
 
 
       
 
     
   
 
 
      
 
   
     
    
 




         
  




6.  POTENTIAL FOR HUMAN EXPOSURE
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical and chemical properties necessary to estimate 
the fate and transport of cresols in the environment have been described for all isomers (AIChE 1989, 
2000; Amoore and Hautala 1983; Artiola-Fortuny and Fuller 1982; Boyd 1982; Chao et al. 1983; Freitag
et al. 1985; Gaffney et al. 1987; Hansch and Leo 1985; Hine and Mookerjee 1975; Lewis 2001; Lide
2005; Riddick et al. 1986; Verschueren 1983; Windholz et al. 1983; Yalkowsky et al. 1987).  Knowledge
of some of these properties was required to describe the fate and transport of cresols because adequate 
experimental data were not available.  The database was sufficient to perform the necessary estimates
(Thomas 1982).
Production, Import/Export, Use, Release, and Disposal. According to the Emergency
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this
information for 2005, became available in May of 2007.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions.
Current production volumes and demand for cresylics are available (CMR 2004; USITC 2006), as are
historical and predictive production volume information (CMR 2004; USITC 2006).  Information on the
uses of cresols is available, including the use as a chemical intermediate and wood preservative.  
Information on the release of cresols to the environment (Andelman et al. 1984; Arrendale et al. 1982;
Cardwell et al. 1986; Dobson et al. 1985; Fedorak and Hrudey 1986; Giabbai et al. 1985; Hampton et al. 
1982; Hawthorne and Sievers 1984; Hawthorne et al. 1988, 1989; James et al. 1984; Johnson et al. 1989;
Junk and Ford 1980; Leone et al. 1985; Liberti et al. 1983; Neufeld et al. 1985; Novotny et al. 1982;
Pellizzari et al. 1979; Seizinger and Dimitriades 1972; Snider and Manning 1982) from manufacturing, 
production, and use (TRI05 2007) and to the workplace, as well as their presence in foods and other
natural sources, is available (Fiege and Bayer 1987; McKnight et al. 1982; Needham et al. 1984).  
Disposal methods are also well described.  
Environmental Fate. Information concerning the partitioning of cresols in the environment is
available; cresols occur in all environmental media.  Information on the transport of cresols in 
environmental media is also available; however, the confounding influence of pH on soil transport makes 
assessing soil leaching difficult.  An extensive database is available describing the aerobic (Alexander and 
Lustigman 1966; Babeu and Vaishnav 1987; Baird et al. 1974; Chambers et al. 1963; EPA 1979;
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Heukelekian and Rand 1955; Ludzack and Ettinger 1960; Lund and Rodriguez 1984; Malaney 1960;
Malaney and McKinney 1966; McKinney et al. 1956; Pauli and Franke 1972; Pitter 1976; Tabak et al. 
1964; Young et al. 1968) and anaerobic (Battersby and Wilson 1988, 1989; Boyd et al. 1983; EPA 1981;
Fedorak and Hrudey 1984; Horowitz et al. 1982; Wang et al. 1988, 1989) degradation of cresols in water.
Data exist regarding the biodegradation of cresols in soils (Dobbins and Pfaender 1988; Medvedev and 
Davidov 1981a, 1981b; Namkoong et al. 1988).  The atmospheric fate of cresol isomers is well described 
and suggests that cresols are rapidly degraded in air (Atkinson 1985; Atkinson et al. 1980, 1984; Carter et
al. 1981; Grosjean 1984, 1985; Platt et al. 1984).  No data needs are identified at this time.
Bioavailability from Environmental Media. Case reports of people who have experienced cresol
poisoning following oral and dermal exposure indicate that all cresols can be absorbed by these routes
(Cason 1959; Chan et al. 1971; Green 1975).  However, no information is available regarding oral or
dermal absorption of cresols in water and soil matrices, or plant material.  Studies in animals have shown 
that cresols can be absorbed from contaminated air by inhalation but have not attempted to quantify this
absorption.  Studies of absorption of cresols from air, water, soil, and plant material are required to
determine the rate and extent of absorption from each of these media and comparison of the potential
hazard posed by cresols contained in each.
Food Chain Bioaccumulation. Few data are available describing the food chain bioaccumulation 
of cresols.  The available experimental data (Freitag et al. 1985) are consistent with estimated values 
obtained from regression equations which suggest that it will not bioconcentrate to any significant extent
(Thomas 1982).  Information concerning the potential for biomagnification has not been described, 
although the log Kow values are small and biomagnification is expected to be insignificant.  Therefore, no
data needs exist at this time.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of cresols in 
contaminated media at hazardous waste sites are needed so that the information obtained on levels of
cresols in the environment can be used in combination with the known body burden of cresols to assess
the potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.
Cresol levels in groundwater (Bedient et al. 1983; Drinkwater et al. 1986; Goerlitz et al. 1985; Oliveira
and Sitar 1985; Sawhney and Kozloski 1984; Stuermer et al. 1982; Weber and Matsumoto 1987) and 
surface water (CLPSD 1988; Great Lakes Water Quality Board 1983; Kolpin et al. 2002) are available.  
Data exist regarding the level of cresols in atmospheric samples including rain water and clouds (Fraser et












   
   
   
 
 
    
     
  
     
 
  
    
  
   
 
   
 




   
 
 






6.  POTENTIAL FOR HUMAN EXPOSURE
al. 1998; Grosjean 1991; Kelly et al. 1994; Leuenberger et al. 1985; Levsen et al. 1993; Luttke et al. 
1999).  Cresols have infrequently been identified in foods (Chung 1999; Fiege and Bayer 1987), as well
as in soil and sediment samples (Lopes and Furlong 2001; McCreary et al. 1983).  Continued monitoring
data in air, water, soil, and foods is necessary in order to assess the potential for human exposure from
environmental media.  Of particular value would be more quantitative data on the cresol levels in various
foods.
Exposure Levels in Humans. Cresols are naturally occurring substances that are widely distributed 
in the environment.  Humans excrete, on average, 87 mg of p-cresol per day in urine (Fiege and Bayer
1987).  Cresols may also be present as a result of the metabolic breakdown of other organic compounds, 
such as toluene (Needham et al. 1984).  As such, positive detections of cresols in human biological
samples do not necessarily indicate exposure solely to cresol.  Information concerning the number of
persons potentially exposed to cresols near waste sites and manufacturing, production, and use facilities, 
however, is not available.  High production and widespread use make the potential for human exposure
high.  A data need exists to rigorously establish cresol exposure levels in humans.  There are insufficient
data regarding body burden of cresol, partially due to the rapid metabolism and lack of bioaccumulation.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. There are limited, if any, data relating to exposures of children to cresols.
Some of the factors that would increase the risk of children exposure include living with a smoker, and 
living near gas stations, heavy traffic areas, and companies that use and/or produce cresol.  A data need 
exists to establish cresol exposure in children.  
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for cresols were located.  This substance is not
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for sub-
registries to be established.  The information that is amassed in the National Exposure Registry facilitates
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance.
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6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2008) database provided no additional information of
ongoing studies that may fill in some of the data needs identified in Section 6.8.1.
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring cresols, its metabolites, and other biomarkers of exposure and effect to 
cresols.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other
methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
7.1  BIOLOGICAL MATERIALS
Numerous methods for the determination of o-, m-, and p-cresol in urine have appeared in the literature.  
o-Cresol in urine is often measured to determine exposure to toluene or other aromatic compounds, of
which cresol is a metabolite (DeRosa et al. 1987).  The analytical methods summarized in Table 7-1 are 
sufficiently sensitive to detect the individual isomers of cresol at a concentration that may cause concern 
for human health.  Humans normally excrete 16–29 mg of p-cresol daily as a result of the breakdown of
tyrosine (Needham et al. 1984).  
The isomers of cresol are excreted in the urine as their glucuronides and sulfates (Bieniek and Wilczok
1986).  To analyze for cresols directly, they must first be separated from the biological carrier.  This is 
usually accomplished by heating a urine sample with a concentrated mineral acid for 30 minutes to 1 hour
(Angerer and Wulf 1985; DeRosa et al. 1987; Needham et al. 1984; Yoshikawa et al. 1986).  The transfer
of cresol from the aqueous hydrolysate to an organic solvent is accomplished by simple extraction with a
volatile organic solvent such as methylene chloride or ethyl ether.  Concentration of the extract by gentle 
removal of the solvent prepares the sample for the analysis stage.
The amount of cresol in the concentrated extract can then be determined by high performance liquid 
chromatography (HPLC) (DeRosa et al. 1987; Yoshikawa et al. 1986) or gas chromatography (GC)
coupled to either a flame ionization detector (FID) or a mass spectrometer detection system (Angerer and 
Wulf 1985; Needham et al. 1984).  Separation of the cresol isomers by GC is readily accomplished, and 
the use of an appropriate internal standard allows the determination of their concentrations.  Although 
   
 








   
 
       
 
     
  
 
   






    
 
 
   
 
 













   
 
 
   
 






















Table 7-1. Analytical Methods for Determining Cresols in Biological Materials
Sample 







recovery Reference Isomer 
Blood Acidification with HCl 
followed by centrifugation
at 3,000 rpm, filter to 
isolate free cresol
GC/MS 0.14 μg/mL 95.4 De Smet et al.
1998
p
Blood Deprotonization with 2 mL 
acetonitrile, vortex,
centrifugation at 1,000 rpm
GC/MS 0.016 μg/mL >95 Boatto et al.
2004
o
Urine Hydrolyze with sulfuric
acid; extract with ethyl
acetate
GC/FID No data 78–97 Needham et al.
1984
o, m, p
Urine Hydrolyze with HCl extract 
with isopropyl ether;
remove solvent; dissolve 
residue in water; add 
B-cyclodextrin
HPLC/UV 1 ppm 97–102 Yoshikawa et
al. 1986
o, m, p
Urine Acidify; steam distill;
extract with methylene 
chloride
GC/MS No data No data Angerer and 
Wulf 1985 
o
Urine Hydrolyze with sulfuric
acid; extract with CH2Cl2; 




Urine Collect sample with 
thymol; hydrolyze with 
HCl; extract with ethyl
ether
GC/FID 2 μg/mL 94% NIOSH 1994b o
Expired 
air
Breath collected in Teflon 
bag; concentration on 
Tenax GC adsorbent;
thermal desorption





FID = flame ionization detector; GC = gas chromatography; HPLC = high performance liquid chromatography;
MS = mass spectrometry; UV = ultraviolet spectroscopy
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7. ANALYTICAL METHODS
exact detection limits were not given for the above GC methods, a concentration of 10 ppm appears to be
readily determined.
Reversed-phase chromatography columns have been used for the analysis of cresols with limited success.  
A reversed-phase support has been developed that allows complete separation of the three cresol isomers 
(Bassler and Hartwick 1989).  Inclusion complexes of the cresols with ß-cyclodextrin cleanly separate the
three isomers on commercially available columns (Yoshikawa et al. 1986).  Detection limits down to 
1 ppm can be obtained by this method.
In cases involving acute cresol poisoning, cresol levels in biological tissues or blood levels are 
occasionally determined (Boatto et al. 2004).  Methods have been described that can determine the level
of free (nonprotein bound) p-cresol (De Smet et al. 1998) and o-cresol (Boatto et al. 2004) in blood.  
These methods typically involve hydrolysis with hydrochloric acid or acetonitrile to separate cresol from
proteins followed by centrifugation, solvent extraction, and analysis by GC/mass spectrometry (MS).   
The detection of cresol in the expired air of humans has been accomplished by techniques used routinely
for the analysis of other organic compounds in this sample matrix (Krotoszynski and O'Neill 1982).  In 
this technique, the subject’s breath is collected in a bag made of inert material.  The sample is then 
concentrated by pumping the expired air through a sorbent tube that collects the organic compounds.  The
organics are liberated from the adsorbent tube by thermal desorption, which flushes the components of the
mixture directly onto a GC.  The amount of each cresol isomer is quantified by comparison of the signal
strength to that of a suitable internal standard using a FID, and identification is accomplished by
interpretation of the data provided by a mass spectrometer.  No detection limits were given for this 
method.
7.2  ENVIRONMENTAL SAMPLES 
Methods for determining cresols in environmental media are summarized in Table 7-2.  Procedures for
the determination of and o- and p-cresol in water, soil, and sediment samples at hazardous waste sites are 
outlined by EPA (2005a).  The required quantitation limits for each of the isomeric cresols are 10 ppb for
water samples and 330 ppb for soil and sediment samples in this monitoring program.
For the determination of cresol in water, good laboratory practice (GLP) guidelines state that the aqueous 
sample be brought to pH 11 by the addition of sodium hydroxide (NaOH).  The basic mixture is then 
   
 









   
 
 
       
 


























      
    
  
     
   
 
  




      
   
 
 








































recovery Reference Isomer 
Air Pump air through 
adsorbent tube, desorb 
with methanol
HPLC/UV 0.3 ppt 90–110 Kuwata and 
Tanaka 1988 
o, m, p 
Air Aerodispersive 
enrichment into water
HPLC/ED No data No data Vecera and 
Janák 1987 
o 
Air Samples collected on 
solid sorbent tube.
HPLC/UV No data No data NIOSH 1994a o, m, p
Desorb with methanol
Air Sample collected on 
solid sorbent tube,
desorb with methanol
GC/FID No data No data NIOSH 1994b o, m, p
Air Ambient air drawn 
through impingers
containing 15 mL of
0.1M NaOH
HPLC/UV 1–5 ppbv >80 EPA 1986 o, m. p
Phenolates solution
adjusted to pH <4 with 
5% sulfuric acid and 
diluted with water
Water Adjust pH to 2, extract
with CH2Cl2, 





GC/MS No data No data Hites 1979 Not
specified 
Rain water None; direct injection 
onto ion exchange 
column 
HPLC/CD No data No data DOE 1985 o, m, p
Rain water Acidify, extract with
CH2Cl2, concentrate.
methylate 





1-L sample is extracted 
using a solid phase 
extraction cartridge





Samples are prepared 










Aqueous liquid waste 
or leachate is directly
injected into a reverse
phase HPLC column










   
 








   
 
 
       
 









































































Sample 	 Analytical detection Percent
matrix	 Preparation method method limit recovery Reference Isomer 
Water	 The sample is GC/MS Not Not EPA 2001 o
extracted at pH 12–13, applicable applicable Method 1625




the extract is dried over
sodium sulfate and 
concentrated to a 
volume of 1 mL
Drinking 
water
Water samples are 
collected and analyzed 





via GC/MS 42 μg/L OM100R
p-cresol
Aqueous Samples are extracted GC/MS Not Not EPA 2000c o, m, p
samples and cleaned up applicable applicable Method 8041A
(according to sample 
matrix) and the solvent
appropriately
exchanged; the 
phenols are then 
determined with or
without derivatization 
Effluent The sample is GC-MS Not Not EPA 2001b o,m,p
Water extracted at pH 12–13, (Method applicable applicable




the extract is dried over
sodium sulfate and 
concentrated to a 
volume of 1 mL
Soil, sediment Extract sample with GC/MS 330 ppb No data EPA 2005a o, p
CH2Cl2 using ultra 
sonic probe 
Bottom Wet sediment samples GC/MS 41.2 μg/Lkg 86 USGS 1995 p




Water Water samples were GC/MS 0.27 μg/L 36 USGS 2002 p
filtered using glass Method 
fiber filters; samples 0-1433-01
were extracted using 
SPE cartridges
   
 








   
 
 
       
 









   
 
  














Sample 	 Analytical detection Percent
matrix	 Preparation method method limit recovery Reference Isomer 
Sediment	 Extract rapidly stirred GC/MS No data No data Goodley and Not
sediment slurry with Gordon 1976 specified 
CH2Cl2 or ether,
concentrate
Breathing air	 Draw air through HPLC/ED 8 μg/m3 No data Nieminen and o, m, p
XAD-s adsorbent tube, Heikkila 1986 
acetonitrile desorption
CD = conductivity detector; ED = electrochemical detector; GC = gas chromatography; HPLC = high performance 
liquid chromatography; MS = mass spectrometry; SPE = solid phase extraction; UV = ultraviolet detector
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7. ANALYTICAL METHODS
extracted with methylene chloride either in a separatory funnel or a continuous liquid-liquid extractor.  
The aqueous phase is then acidified to pH 2 and reextracted with methylene chloride.  This second extract
is concentrated by evaporation and subjected to GC/mass spectrometry (MS) analysis for identification 
and quantification.
In sediment and soil samples, the isomers of cresol are determined by transferring a small portion of the
solid sample (1 g) to a vial and adding methylene chloride.  The contaminants are extracted from the
sample with the aid of an ultrasonic probe.  The methylene chloride extract is filtered, concentrated, and 
subjected to GC/MS analysis for quantitation.
No other standardized methods for the determination of the three isomers of cresol were located (EPA
1988a).  However, numerous methods for their determination have appeared in the open literature.  
Methods for the determination of cresols in ambient air (Kolber et al. 1981; Kuwata and Tanaka 1988;
Vecera and Janák 1987), breathing air (Heikkila et al. 1987; Leuenberger et al. 1985; Nieminen and 
Heikkila 1986), surface water (Goodley and Gordon 1976; Hites 1979; McKnight et al. 1982; Sheldon 
and Hites 1979), groundwater (Goerlitz et al. 1985; Hutchins et al. 1984; Sawhney and Kozloski 1984;
Stuermer et al. 1982) rain water (DOE 1985; Kawamura and Kaplan 1986; Leuenberger et al. 1985), and 
sediment samples (Goodley and Gordon 1976; Hites and Lopez-Avila 1980) are available.
The greatest difference between these methods is the procedure used in the sample preparation step.  This 
step of the analysis varies widely between experimental techniques and may involve the use of highly
specialized equipment.  After the sample preparation step, however, the consensus is that separation of the 
isomers is best accomplished by using either GC or HPLC.
Cresols degrade rapidly in the environment (see Section 6.3.2). The degradation products are also 
removed rapidly.  The products resulting from the degradation of the three isomers of cresol in the
environment are not unique to these compounds.
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of cresols is available.  Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
   
 
















    
 




    
    
 
   




    






      
    




designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of cresols. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Exposure.  There are no known biomarkers of exposure that are unique to cresols.  In addition, o-cresol
has been used as a biomarker of toluene exposure, and the isomers of cresol may appear as a result of
exposure to other aromatic compounds (Needham et al. 1984). The methods presently available are
capable of determining low levels of the cresol isomers in biological media, and background levels in the
population could be established using existing techniques (Angerer and Wulf 1985; DeRosa et al. 1987;
Krotoszynski and O'Neill 1982; Needham et al. 1984; Yoshikawa et al. 1986).  Before a complete
discussion on determining biomarkers of exposure for cresol can be undertaken, biomarkers unique to this
compound must first be established.
Effect.  Correlations of exposure and resulting biological effects are confounded by the metabolic
formation of cresol after exposure to other organic compounds.  Although the analytical methods for
determining cresol in biological materials appear to provide the necessary precision and accuracy, their
reliability in determining biomarkers of exposure and effect cannot, at this time, be ascertained.  Before a
complete discussion on determining biomarkers of effect for cresol can be undertaken, biomarkers unique
to this compound must first be established.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. Numerous methods for the determination of cresol in environmental matrices have appeared in 
the literature (DOE 1985; EPA 2005a; Goodley and Gordon 1976; Hites 1979; Kawamura and Kaplan 
1986; Kuwata and Tanaka 1988; Nieminen and Heikkila 1986; Vecera and Janák 1987).  These
procedures are capable of both identifying areas that have been contaminated with cresol and determining
   
 








   
    
   
   
 
 













   
 
    







if the contaminated areas constitute a concern for human health.  Human exposure to cresol is likely to 
occur by inhalation or ingestion of contaminated water.  Standardized methods for the determination of
the isomeric cresols exist for both of these matrices.  These methods are both reproducible and sensitive.  
In addition, acceptable methods for the determination of cresol in other environmental media have
appeared in the literature.  No data needs are identified at this time.
Although the isomeric cresols degrade readily in the environment, their degradation products (Bayly and 
Wigmore 1973; Masunaga et al. 1983, 1986) are not unique to these compounds (see Section 6.3.2).  As a
result, the determination of these intermediates cannot be accurately extrapolated back to levels of cresol
contamination in the environment.
7.3.2 Ongoing Studies 
No information regarding ongoing studies was found as a result of a search of the Federal Research in 
Progress database (FEDRIP 2008).  
The Environmental Health Laboratory Sciences Division of the National Center for Environmental
Health, Centers for Disease Control and Prevention, is developing methods for the analysis of cresols and 
other volatile organic compounds in blood.  These methods use purge and trap methodology, high-
resolution gas chromatography, and magnetic sector mass spectrometry, which give detection limits in the
low parts per trillion (ppt) range. 
The Environmental Health Laboratory Sciences Division of the National Center for Environmental
Health, Centers for Disease Control and Prevention, is developing methods for the analysis of cresols and 
other phenolic compounds in urine.  These methods use high-resolution gas chromatography and 
magnetic sector mass spectrometry, which give detection limits in the low parts per trillion (ppt) range.
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8. REGULATIONS AND ADVISORIES
 
International and national regulations and guidelines pertinent to human exposure to cresols are
summarized in Table 8-1.
ATSDR has derived an intermediate-duration oral MRL of 0.1 mg/kg/day for cresols based on an increase 
incidence of nasal lesions in male rats administered m/p-cresol in the diet for 13 weeks (NTP 1992b).  
The MRL was derived using benchmark modeling of incidence data for nasal lesions in male rats.  
Following EPA’s Benchmark Dose Guidance (EPA 2000a) to select a point of departure, a BMR of 10%
was selected for the benchmark analysis of nasal lesion incidence data in male rats in the 13-week NTP
(1992b) study.  The BMD corresponding to a BMR of 10% extra risk is 55.89 mg/kg/day; the
corresponding BMDL10 is 13.94 mg/kg/day.  An uncertainty factor of 100 (10 for interspecies 
extrapolation and 10 for human variability) was applied to the BMDL10. 
ATSDR has derived a chronic-duration oral MRL of 0.1 mg/kg/day for cresols based on increased 
incidences of bronchiole hyperplasia of the lung and follicular degeneration of the thyroid gland in female
mice administered m/p-cresol in the diet for 2 years. The MRL was derived using a LOAEL of 
100 mg/kg/day divided by an uncertainty factor of 1,000 (10 for use of a LOAEL, 10 for extrapolation 
from animals to humans, and 10 for human variability). 
EPA (IRIS 2008) has derived oral reference doses of 0.05 mg/kg/day for m- and o-cresol based on 
NOAELs of 50 mg/kg/day for decreased body weights and neurotoxicity (myoclonus, tremors, labored 
respiration) observed in Sprague-Dawley rats exposed by gavage for 90 days (TRL 1986) in an 
assessment conducted in 1989.  An uncertainty factor of 100 (10 for interspecies and 10 for intraspecies 
variability) was applied to the NOAEL. 
The EPA (IRIS 2008) has classified m-cresol, o-cresol, and p-cresol as possible human carcinogens
(Group C) based on inadequate human data and limited data in animals.  The assessment was based on an 
increased incidence of skin papillomas in mice in an initiation-promotion study and on the fact that the
cresol isomers produced positive results in genetic toxicity studies both alone and in combination.  
According to EPA’s updated criteria for assessing carcinogenicity of chemicals (EPA 2005c), cresols fall
in the category of chemicals for which there is “inadequate information to assess carcinogenic potential.”
The American Conference of Governmental Industrial Hygienists (ACGIH), International Agency for
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8.  REGULATIONS AND ADVISORIES
Table 8-1.  Regulations and Guidelines Applicable to Cresols
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification No data IARC 2004
WHO Air quality guidelines No data WHO 2000





ACGIH TLV (8-hour TWA), all isomersa 5 ppm ACGIH 2005
EPA AEGL No data EPA 2006a
Hazardous air pollutant, all isomers Yes EPA 2006c
42 USC 7412
NIOSH REL (10-hour TWA), all isomers 2.3 ppm NIOSH 2005
IDLH, all isomers 250 ppm
OSHA PEL (8-hour TWA) for general industry,
all isomersb 
5 ppm OSHA 2005c
29 CFR 1910.1000
PEL (8-hour TWA) for construction 
industry, all isomersb 
5 ppm OSHA 2005b
29 CFR 1926.55,
Appendix A
PEL (8-hour TWA) for shipyard 
industry, all isomersb 
5 ppm OSHA 2005a
29 CFR 1915.1000
b.  Water
EPA Designated as hazardous substances Yes EPA 2006b
in accordance with Section 311(b)(2)(A) 40 CFR 116.4
of the Clean Water Act, all isomers
Drinking water standards and health No data EPA 2004
advisories
Reportable quantities of hazardous Yes EPA 2006f
substances designated pursuant to 40 CFR 117.3
Section 311 of the Clean Water Act,
mixed cresols
Water quality criteria for human health No data EPA 2006e
c.  Food
FDA Bottled drinking water No data FDA 2005
21 CFR 165.110
d.  Other
ACGIH Carcinogenicity classification No data ACGIH 2005
EPA Carcinogenicity classification IRIS 2008
Cresol No data
m-Cresol Group Cc 
o-Cresol Group Cc 
p-Cresol Group Cc 
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8.  REGULATIONS AND ADVISORIES
Table 8-1.  Regulations and Guidelines Applicable to Cresols
Agency Description Information Reference
NATIONAL (cont.)
EPA RfC IRIS 2008
Cresol No datad 
m-Cresol No datad 
o-Cresol No datad 






Identification and listing of hazardous U052 EPA 2006d
waste, mixed cresols 40 CFR 261,
Appendix VIII
Superfund, emergency planning, and EPA 2006g
community right-to-know 40 CFR 302.4
Designated CERCLA hazardous Yes
substance, all isomers
Reportable quantity 100 pounds
Effective date of toxic chemical 01/01/87 EPA 2006i
release reporting, all isomers 40 CFR 372.65
Extremely hazardous substances 1,000/10,000 pounds EPA 2006h
and their threshold planning 40 CFR 355,
quantities, o-cresol only Appendix A
NTP Carcinogenicity classification No data NTP 2004
aSkin notation:  refers to the potential significant contribution to the overall exposure by the cutaneous route, including
mucous membranes and the eyes, either by contact with vapors, liquids, and solids.
bSkin designation
cGroup C:  possible human carcinogen
dThe health effects data for cresol, m-cresol, o-cresol, and p-cresol were reviewed by the U.S. EPA RfD/RfC Work
Group and determined to be inadequate for the derivation of an inhalation RfC.
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = Acute Exposure Guideline Level;
CERCLA = Comprehensive Environmetnal Response, Compensation, and Liability Act; CFR = Code of Federal
Regulations; EPA = Environmental Protection Agency; FDA = Food and Drug Administration; IARC = International
Agency for Research on Cancer; IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information 
System; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program;
OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; REL = recommended 
exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold limit values;
TWA = time-weighted average; USC = United States Code; WHO = World Health Organization













    
  
 
   
    
 
 
    
  




8.  REGULATIONS AND ADVISORIES
Research on Cancer (IARC), and the National Toxicology Program (NTP) have not classified cresols for 
human carcinogenicity (ACGIH 2005; IARC 2004; NTP 2004).
OSHA requires employers of workers who are occupationally exposed to cresol to institute engineering
controls and work practices to reduce and maintain employee exposure at or below permissible exposure
limit time-weighted average (PEL-TWA).  The employer must use engineering and work practice controls
to reduce exposures to or below an 8-hour TWA of 5 ppm for cresol and its isomers (OSHA 2006).  Both 
NIOSH and ACGIH and have established guideline values that range from 2.3 to 5 ppm for cresol and its
isomers (ACGIH 2005; NIOSH 2005).
EPA regulates cresols and its isomers under the Clean Air Act (CAA) and the Clean Water Act (CWA)
and has designated them as hazardous air pollutants (HAPs) and hazardous substances, respectively (EPA
2006b, 2006c).  EPA has established a reportable quantity (RQ) of 100 pounds (EPA 2006i).
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10.  GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response
relationship where biologically observable data are feasible.   
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure.  These may suggest potential topics for scientific research, but are not actual research studies.













   
 
 
      




   
    
 








   
 
 
   


























Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.























     
 
 
    
    
 




















    










Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors.  The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.







































     
    
   
 
    
   
  










Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
















   
 
 
     
 










   
    




       
 
     




   
  





    
 









Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past. Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.

































    
 
 








   
 
   
 
   
 




    







Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest­
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system



















    
  
    
     
  
   
 
     
 
 
   
  
 









APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure.  MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach.  They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that










   
  
   
  




   
   
    







are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-32, Atlanta, Georgia 30333.
 













   
    
   
    
   
   






   
 
   
     
      
  
  
    




   
     
   
   
 
    
   
    
  
   
      
  
  
     
 
    
   
  
   
  
 
   
CRESOLS A-3
APPENDIX A
MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Cresols 
CAS Numbers: 95-48-7, 108-39-4, 106-44-5, 1319-77-3
Date: July 2008
Profile Status: Final Draft Post-Public Comment
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute   [X] Intermediate   [ ] Chronic
Graph Key: 55
Species: Rat
Minimal Risk Level:  0.1   [X] mg/kg/day  [ ] ppm
Reference:  NTP.  1992b.  NTP report on the toxicity studies of cresols (CAS Nos.  95-48-7, 108-39-4, 
106-44-5) in F344/N rats and B6C3F1 mice (feed studies).  Research Triangle Park, NC:  National
Toxicology Program.  NIH Publication No. 92-3128.  NTP Tox 9.
Experimental design:  Groups of Fischer 344 rats (20/sex/group) were administered m/p-cresol (58.5%
m-cresol, 40.9% p-cresol) in the diet at levels of 0, 1,880, 3,750, 7,500, 15,000, or 30,000 ppm for
13 weeks (NTP 1992b).  The corresponding doses of test compound estimated by the investigators were
0, 123, 241, 486, 991, and 2,014 mg/kg/day for males and 0, 131, 254, 509, 1,024, and 2,050 mg/kg/day 
for females.  End points evaluated included clinical signs, food consumption, organ weights, clinical
chemistry and hematology, and gross and microscopic appearance of organs and tissues.  Although the
dose groups consisted of 20 rats of each sex, 10 males and 10 females were used for clinical chemistry, 
hematology, and urinalysis studies and the remaining 10 rats/sex/group were used in gross pathology, 
organ weight, and histopathological studies.   
Effect noted in study and corresponding doses: There were no deaths during the study.  Final body
weight in the 2,014/2,050 mg/kg/day males and females was reduced 17 and 12%, respectively, relative to 
controls.  Food consumption was also reduced (about 10%) in this group during the first week of the
study.  Additionally, males and females in this group exhibited rough hair coat; females also had a thin 
appearance.  Absolute and relative liver weights were significantly increased (11–12%) in males at
486 mg/kg/day and in females at 1,024 mg/kg/day.  Absolute and relative kidney weight were increased
in males at 991 mg/kg/day.  In general, hematology findings were unremarkable, although there was a
tendency to hemoconcentration at 2,014/2,050 mg/kg/day early in the study.  Clinical chemistry tests
showed an increase in serum alanine aminotransferase (ALT) in males and females exposed to 
2,014/2,050 mg/kg/day and in sorbitol dehydrogenase (SDH) in males at 2,014 mg/kg/day only on day 5.  
Bile acids in serum were increased in females at 2,050 mg/kg/day on day 90 and at 241 and 
991 mg/kg/day in males also on day 90.  There was no indication of renal injury as judged by the results
of urinalyses.  Significant histopathological changes included minimal bone marrow hypocellularity in 
males and females at 2,014/2,050 mg/kg/day, and increased colloid (minimal) in thyroid follicular cells in
females at 509 mg/kg/day and in males at 15,000 ppm (991 mg/kg/day).  An increased dose-related 
incidence and severity of hyperplasia and glandular hyperplasia of the nasal respiratory epithelium was 
observed in male and female rats.  Severity was minimal at 123/131 mg/kg/day, mild at
486/509 mg/kg/day, and moderate at 2,014/2,050 mg/kg/day.  The lesions were located at the most
anterior portions of the nasal septum, dorsal arch, and medial aspect of the nasal turbinates.  The 
hyperplasia was characterized by increased number of goblet cells and pseudogland formation due to the
infolding of the hyperplastic cells. The hyperplastic areas were associated with single cell necrosis.  The
incidences in males dosed with 0, 123, 241, 486, 991, and 2,014 mg/kg/day were 0/10, 3/10, 8/10, 10/10, 
8/10, and 10/10, respectively.  A similar trend was seen in female rats, but 3/10 control females also 
exhibited hyperplasia (3/10, 1/10, 5/10, 9/10, 8/10, and 10/10 at 0, 131, 254, 509, 1,024, and 










   
   
 
 





   
  
     
    
 
 
    
 




   
   
 







      
    
  
    
        
 
   
  
    
   
   
   
    
 




    
CRESOLS A-4
APPENDIX A
2,050 mg/kg/day, respectively).  The LOAELs for nasal lesions in male and female rats were 123 and 
254 mg/kg/day, respectively.  The NOAEL in females was 131 mg/kg/day and no NOAEL was
established in males.  
In the 28-day study with m/p-cresol in rats, the incidences of hyperplasia of the nasal respiratory
epithelium in females dosed with 0, 27, 95, 268, 886, and 2,570 mg/kg/day were 0/5, 0/5, 3/4, 5/5, 5/5, 
and 5/5, respectively.  However, data from the 13-week study are preferred for MRL derivation because 
of the longer duration and because only five rats/group were examined in the 28-day study. 
Data from the NTP (1992b) were considered adequate for analysis using the benchmark dose approach 
for MRL derivation.  Benchmark dose models in the EPA Benchmark Dose Software (BMDS)
(version 2.0) were fit to the incidence data for nasal lesions in male and female rats exposed to m/p-cresol
in the diet for 13 weeks in order to determine potential points of departure for the MRL (details of the
modeling are presented below). 
Dose and end point used for MRL derivation:  BMDL10 of 13.94 mg/kg/day for nasal lesions in male rats.
[ ] NOAEL   [ ] LOAEL   [ x ]  BMDL10 
Uncertainty Factors used in MRL derivation:
[x]  10 for extrapolation from animals to humans
[x]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Conversion from
diet to dose was done by the investigators.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information that lend support to this MRL: Almost all of the
information available on health effects from intermediate-duration oral exposure is derived from a
comprehensive study in rats and mice administered the three cresol isomers and a cresol mixture for 
28 days and 13 weeks (NTP 1992b). There are also two multigeneration reproductive studies in mice 
dosed with o-cresol (NTP 1992a) and a cresol mixture (NTP 1992c).  Evaluation of the results of these
studies indicates that the most sensitive end point was the nasal respiratory epithelium of rats and mice 
dosed with p-cresol or an m/p-cresol mixture.  No clear target of toxicity emerged for o- or m-cresol.  The 
nasal lesions occurred in rats dosed with p-cresol for 28 days (≥770 mg/kg/day), in rats exposed to 
m/p-cresol for 28 days (≥95 mg/kg/day), in mice exposed to p-cresol for 28 days (≥163 mg/kg/day), in 
mice exposed to m/p-cresol for 28 days (≥604 mg/kg/day), in rats exposed to m/p-cresol for 13 weeks 
(≥123 mg/kg/day), and in mice exposed to m/p-cresol for 13 weeks (≥472 mg/kg/day).  Other effects that 
occurred at higher doses included increases in liver and kidneys weights ( ≥240 mg/kg/day), bone marrow
hypocellularity (≥2,000 mg/kg/day), and mild uterine atrophy (≥1,000 mg/kg/day) (NTP 1992b).  Clinical
tests of liver and kidney function were generally unremarkable and gross and microscopic evaluation of
the liver and kidney showed no significant alterations (NTP 1992b).  None of the intermediate-duration 
oral gavage studies examined the nasal respiratory epithelium of the animals, and neither did the two 
multigeneration reproductive dietary studies in mice (NTP 1992a, 1992c). 
Agency Contacts (Chemical Managers): Malcolm Williams, Ph.D.; John Risher, Ph.D.; Mike Fay, Ph.D.













    
  
    
   
   
  




   
 
     
    
   
   
   
   
   
    
   
   
   
   







BENCHMARK MODELING OF NASAL RESPIRATORY LESIONS IN RATS
Benchmark dose models in the EPA Benchmark Dose Software (BMDS version 2.0) were fit to the
incidence data for nasal lesions in male and female rats exposed to m/p-cresol in the diet for 13 weeks in 
order to determine potential points of departure for the MRL.  BMDL10s (i.e., 95% lower confidence
limits on the model-estimated dose associated with a 10% extra risk for nasal lesions) calculated with the
best-fitting models for each data set (see Tables A-1, A-2, and, A-3 and Figures A-1 and A-2) were 
13.9 mg/kg/day for males and 30.8 mg/kg/day for females.  While this difference in benchmark dose may
indicate that male rats are more sensitive than females, it also can be a statistical artifact of a rather small 
sample size, only 10 rats per group.  The male rat data set was selected for determining the point of
departure for MRL derivation in order to be public health protective.  
Table A-1.  Incidence Data for Respiratory Epithelium Glandular Hyperplasia or
Hyperplasia in Rats Exposed to m/p-Cresol in the Diet for 13 Weeks
Dietary concentration (ppm) Dose (mg/kg/day) Incidence of nasal lesions












Source:  NTP 1992b











   
  
 
       
     
     
     
     
     
     
     













Table A-2.  Goodness-of-Fit Statistics and BMD10s and BMDL10s from Models
 
Fit to Incidence Data for Nasal Lesions in Male Rats 

Exposed to m/p-Cresol in the Diet for 13 Weeks
 
Model AIC X2 p valuea BMD10 (mg/kg/day) BMDL10 (mg/kg/day)
Gamma 37.3167 0.1221 24.1138 16.7698
Logistic 46.7819 0.0000 63.9362 42.8254
Log-Logisticb 36.8962 0.2605 55.8863 13.9381
Multistage 37.3167 0.1221 24.1138 16.7698
Probit 49.738 0.0002 71.306 50.8541
Log-probit 37.6831 0.2511 46.1987 26.6915
Quantal-linear 37.3167 0.1221 24.1138 16.7698
Weibull 37.3167 0.1221 24.1138 16.7698
aValues <0.1 fail to meet conventional goodness-of-fit criteria.
bBest-fitting model
AIC = Akaike’s Information Criteria; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the 
benchmark dose; p = p value from the Chi-squared test
Source:  NTP 1992b












   
  
 
        
     
     
     
     
     
     
     





    






Table A-3.  Goodness-of-Fit Statistics and BMD10s and BMDL10s from Models Fit
 
to Incidence Data for Nasal Lesions in Female Rats

Exposed to m/p-Cresol in the Diet for 13 Weeks
 
Model AIC X2 p valuea BMD10 (mg/kg/day) BMDL10 (mg/kg/day)
Gamma 61.5191 0.0477 64.2166 30.9781
Logistic 60.7552 0.0557 89.5533 60.4852
Log-Logistic 60.0961 0.0487 98.7921 28.7889
Multistageb 59.5988 0.1020 48.0244 30.7916
Probit 61.2978 0.0600 98.0573 69.3757
Log-probit 60.351 0.0591 99.9316 51.3824
Quantal-linearb 59.5988 0.1020 48.0246 30.7916
Weibull 61.5874 0.0505 52.5879 30.8181
aValues <0.1 fail to meet conventional goodness-of-fit criteria.
bBest-fitting model
AIC = Akaike’s Information Criteria; BMD = benchmark dose; BMDL = lower confidence limit (95%) on the 
benchmark dose; p = p value from the Chi-squared test
Source:  NTP 1992b




































Figure A-1.  Observed and Predicted Incidences of Nasal Lesions in Male Rats 

Exposed to m/p-Cresol in the Diet for 13 Weeks*

























*BMDs and BMDLs indicated are for a 10% extra risk and are in units of mg/kg/day.
 
Source:  NTP 1992b
 









































    
   





Figure A-2.  Observed and Predicted Incidences of Nasal Lesions in Female Rats 
Exposed to m/p-Cresol in the Diet for 13 Weeks*
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*BMDs and BMDLs Indicated are for a 10% extra risk and are in units of mg/kg/day.
Source:  NTP 1992b
BMDs and BMDLs associated with 1, 5, 10, 20, and 30% extra risk were calculated with the best-fitting
model of the male rat nasal lesion incidence data (see Table A-4).  Following EPA’s Benchmark Dose
Guidance (EPA 2000a) to select a point of departure, a benchmark response (BMR) of 10% was selected
for the benchmark analysis of nasal lesion incidence data in male rats in the 13-week NTP (1992b) study.  
The BMD corresponding to a BMR of 10% extra risk is 55.89 mg/kg/day; the corresponding BMDL10 is 
13.94 mg/kg/day (see Table A-4).  Applying an uncertainty factor of 100 (10 each for intra- and 
interspecies extrapolation) to the BMDL10 yields an intermediate-duration oral MRL of 0.1 mg/kg/day for
m/p-cresol.














     
    
    
    
    
    
     
    
    
    




      
  





















      
     
 




Table A-4.  Best-fitting Model Predictions for 1, 5, 10, 20, and 30% Extra Risk for
 
Incidence of Nasal Lesions Observed in Rats Exposed to

m/p-Cresol in the Feed for 13 Weeks
 
Best fitting model BMR (% extra risk) BMD (mg/kg/day) BMDL (mg/kg/day)










Source:  NTP 1992b
All available dichotomous models in the EPA BMDS (version 2.0) were fit to the incidence data for nasal
lesions (respiratory epithelium glandular hyperplasia or hyperplasia) in male and female rats exposed to 
m/p-cresol in the diet for 13 weeks (NTP 1992b) (Table A-1).  Predicted doses associated with 30, 20, 10, 
5, and 1% extra risks were calculated.
Male Rats
As assessed by the chi-square goodness-of-fit test, several models in the software provided adequate fits
to the data for the incidence of nasal lesions in male rats (x2 p value ≥0.1) (Table 2).  Comparing across
models, a better fit is indicated by a lower Aikake’s Information Criteria value (AIC) (EPA 2000a).  The
log-logistic model was determined to be the best-fitting model, as indicated by the AIC (Table A-2).  
Benchmark doses (BMDs and BMDLs) associated with an extra risk of 30, 20, 10, 5, and 1, calculated 
from the best fitting model, are shown in Table A-4.
The form and parameters of the log-logistic model for the male rat data are as follows:









As assessed by the chi-square goodness-of-fit test, only the quantal linear model (which was the similar to 
the 1-degree polynomial model) provided an adequate fit to the data for the incidence of nasal lesions in
female rats (x2 p value ≥0.1).  Therefore, the quantal linear model was determined to be the best-fitting
model (Table 3).  Benchmark doses (BMDs and BMDLs) associated with an extra risk of 30, 20, 10, 5, 
and 1%, calculated from the quantal linear model, are shown in Table A-4.





















The form and parameters of the quantal linear model for the female rat data are as follows:
P[response] = background + (1-background)*[1-EXP(-slope*dose)]
background = 0.318182;
slope = 0.001321;
Power = 1 (Specified)
 













   
    
   
    
    
   




   







   





    
   
  
   
 
   
 
 
   
   












MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Cresols 
CAS Numbers: 95-48-7, 108-39-4, 106-44-5, 1319-77-3
Date: July 2008
Profile Status: Final Draft Post-Public Comment
Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute   [ ] Intermediate  [X] Chronic
Graph Key: 130
Species: Mice
Minimal Risk Level:  0.1   [X] mg/kg/day  [ ] ppm
Reference:  NTP.  2008.  Toxicology and carcinogenesis studies of cresols (CAS No. 1319-77-3) in male
F344/N rats and female B6C3F1 mice (feed studies).  Research Triangle Park, NC:  National Toxicology
Program.  TR-550.  Draft technical report.
Although the report has not yet been finalized by the NTP, a draft technical report has been reviewed by
the NTP Board of Scientific Counselors Technical Reports Review Subcommittee, and a draft abstract, 
pathology tables, and survival and growth curves are available in the NTP web site 
(http://ntp.niehs.nih.gov/index.cfm?objectid=9B58ADF7-F1F6-975E-78A23152B1596409).
Experimental design:  Groups of female B6C3F1 mice (50/group) were administered m/p-cresol (60% 
m-cresol, 40% p-cresol) in the diet at levels of 0, 1,000, 3,000, or 10,000 ppm for 2 years (NTP 2008).  
The corresponding doses of test compound estimated by the investigators were approximately 0, 100, 
300, and 1,040 mg/kg/day.  End points evaluated included clinical signs, food consumption, organ 
weights, and gross and microscopic appearance of organs and tissues at termination.    
Effect noted in study and corresponding doses: Dosing with m/p-cresol did not affect survival rate.  Food 
consumption did not appear to vary significantly throughout the study.  No significant treatment-related 
clinical signs were reported.  At termination, body weight in the mid- and high-dose groups was
significantly lower than controls (11 and 24%, respectively).  Significant treatment-related, non-
neoplastic effects included:  minimal to moderate bronchiolar hyperplasia in the lung (0/50, 42/50/, 44/49, 
47/50); minimal to mild hyperplasia of the nasal respiratory epithelium (0/50, 0/50, 28/49, 21/50); mild 
follicular degeneration of the thyroid gland (7/48, 24/48, 24/49, 21/50); and increased eosinophilic foci in 
the liver (1/50, 0/50, 2/49, 12/50).  NOAELs for bronchiolar hyperplasia and thyroid follicular
degeneration were not established, and in both cases, the LOAEL was 100 mg/kg/day.
Since the incidence data indicate that bronchiolar hyperplasia of the lung and follicular degeneration of
the thyroid gland had lower thresholds than the liver or nasal effects, the former two responses were
considered for analysis using the benchmark dose approach for MRL derivation.  After inspection of the
dose response data, the use of a LOAEL/NOAEL approach for MRL derivation was considered to be
more appropriate than the use of benchmark dose analysis because of the steep increase in the response
rates between the control group and the first exposure level.
Dose and end point used for MRL derivation:  LOAEL of 100 mg/kg/day for bronchiole hyperplasia of
the lung and follicular degeneration of the thyroid gland in female mice.
[ ] NOAEL   [x] LOAEL   [ ]  BMDL10 












   
   
    
 







       
  
   
     
   
  
    







   
 




Uncertainty Factors used in MRL derivation:
[x]  10 for extrapolation from animals to humans
[x]  10 for human variability
[x]  10 for use of a LOAEL
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  Conversion from
diet to dose was done by the investigators.
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure?  No.
Other additional studies or pertinent information that lend support to this MRL: The NTP (2008) is the
only chronic-duration study with cresols available.  The NTP (2008) also tested male F-344/N rats and the
results showed that the most sensitive end point was the nasal respiratory epithelium, as in the shorter-
term studies (NTP 1992b).  Other less sensitive effects observed in rats included hyperplasia of the
transitional epithelium of the renal pelvis, squamous metaplasia in the nasal respiratory epithelium, 
inflammation of the nose, and eosinophilic foci in the liver.  The incidence of respiratory epithelium
hyperplasia of minimal to mild severity was 3/50, 17/50, 31/50, and 47/50 in the control, low-, mid-, and 
high-dose groups, respectively.  As discussed in Section 2.3, the data suggest that, over the range of doses
used in the NTP (1992b, 2008) studies, exposure beyond 13 weeks had little or no effect on the incidence
or severity of the nasal respiratory hyperplasia, indicating that the intermediate-duration MRL, which is
based on incidence data for this lesion, should be protective of nasal lesions induced by chronic-duration 
exposure.  This is supported by the fact that fitting the incidence data for nasal respiratory epithelium
hyperplasia from the 2-year study to the same BMDS model (Log-Logistic) that provided the BMDL10 
used to derive the intermediate-duration oral MRL yields a BMDL10 for chronic exposure to m/p-cresol of 
13.9017 mg/kg/day, essentially the same as the BMDL10 of 13.9381 mg/kg/day used to derive the
intermediate-duration oral MRL for m/p-cresol.    
Agency Contacts (Chemical Managers): Malcolm Williams, Ph.D.; John Risher, Ph.D.; Mike Fay, Ph.D.
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APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions:
1.	 What effects are known to occur in humans?
2.	 What effects observed in animals are likely to be of concern to humans?
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.  
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.










   




      
     
    
 
 
   
    

























   
 
  










MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2,
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study.  Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.













   







   





   
    
 
 
   
  
 
   
 
























See Sample LSE Table 3-1 (page B-6)
(1)	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981).
(7)	 System. This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8)	 NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").











   
  
    
    
   
    
 
 
    
 





     








   
 
 




   
 
 
   





   
      
    
 






(9)	 LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists.  The same health effects appear in the LSE table.
(15)	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.




















(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).























    
      



























































































































1 →	 Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Key to frequency/ NOAEL Less serious Serious (ppm)





5 6 7 8 9 10
→ Systemic ↓	 ↓ ↓ ↓ ↓ ↓
18 Rat	 13 wk Resp 3b 10 (hyperplasia)





38 Rat 18 mo 20 (CEL, multiple Wong et al. 1982
5 d/wk organs)
7 hr/d
39 Rat 89–104 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk nasal tumors)
6 hr/d
40 Mouse	 79–103 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk hemangiosarcomas)
6 hr/d
12 →	 a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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CRESOLS C-1
APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
 
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD benchmark dose
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMCO North America/Intergovernmental Maritime Dangerous Goods Code

































   
  
   
  


























DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization




Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor





















   
   
  











































mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon




























































PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell





RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization











   
  
  

















≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
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aerobic............................................................................................................................... 166, 167, 168, 180
 
alanine aminotransferase (see ALT) ..................................................................................................... 17, 80
 
ALT (see alanine aminotransferase) ............................................................................................... 17, 80, 81
 
ambient air ................................................................................................ 147, 158, 171, 172, 176, 178, 191
 






aspartate aminotransferase (see AST)......................................................................................................... 80
 




bioconcentration factor ............................................................................................................................. 166
 
biodegradation............................................................................... 9, 146, 166, 167, 168, 169, 173, 174, 181
 
biomarker .................................................................................................................................. 117, 118, 192
 
biomarkers................................................................................................. 117, 118, 119, 129, 131, 185, 192
 
blood cell count........................................................................................................................................... 79
 
body weight effects ..................................................................................................................................... 84
 
breast milk....................................................................................................................................... 5, 10, 178
 
cancer ............................................................................................................................ 90, 96, 115, 116, 124
 
carcinogen..................................................................................................................................... 91, 96, 197
 
carcinogenic .............................................................................................................. 12, 13, 21, 91, 124, 195
 




cardiovascular ......................................................................................................................... 23, 77, 92, 125
 
cardiovascular effects............................................................................................................................ 23, 77
 
chromosomal aberrations ............................................................................................................................ 99
 
clearance ........................................................................................................................... 104, 107, 110, 120
 
death........................................................ 4, 21, 22, 23, 25, 26, 27, 77, 82, 92, 102, 112, 116, 122, 125, 128
 
deoxyribonucleic acid (see DNA)............................................................................................................... 98
 
dermal effects.................................................................................................................... 23, 84, 94, 95, 124
 
developmental effects ................................................................................. 15, 25, 89, 90, 96, 116, 127, 131
 
DNA (see deoxyribonucleic acid)........................................................................... 97, 98, 99, 118, 126, 129
 
endocrine............................................................................................................................. 83, 112, 113, 114
 






gastrointestinal effects .................................................................................................................... 77, 92, 94
 
general population................................................................................................. 9, 117, 128, 147, 176, 178
 
genotoxic......................................................................................................................................... 21, 96, 99
 
genotoxicity........................................................................................................................... 96, 99, 116, 126
 
groundwater .................. 2, 3, 9, 147, 158, 159, 160, 161, 162, 163, 167, 168, 172, 173, 174, 177, 181, 191
 
half-life...................................................................................................................... 104, 117, 166, 169, 170
 
hematological effects ........................................................................................................ 78, 79, 80, 94, 119
 
hepatic effects ................................................................................................................................. 23, 80, 94
 
hydrolysis.................................................................................................................................. 144, 169, 187
 
hydroxyl radical ................................................................................................................ 147, 166, 167, 169
 










   
   
   
   
   
   
   
   
   
   
   
  
   
   
   
   
   
   
   
   
   
   
   
    
   
   
   
   
   
   
   
   
   
   





immune system ......................................................................................................................................... 128
 
immunological .................................................................................................................. 21, 24, 85, 95, 128
 
immunological effects............................................................................................................. 24, 85, 95, 128
 
Kow ............................................................................................................................................ 136, 165, 181
 
LD50........................................................................................................................................... 14, 25, 27, 92
 
lymphoreticular ................................................................................................................................... 86, 128
 




milk ....................................................................................................................................... 5, 117, 120, 131
 
musculoskeletal effects ......................................................................................................................... 80, 92
 














pharmacokinetic........................................................................................ 107, 108, 109, 115, 116, 122, 130
 
photolysis .......................................................................................................................................... 167, 169
 
placenta ............................................................................................................................................. 117, 131
 
rate constant ...................................................................................................................... 166, 167, 169, 170
 
renal effects..................................................................................................................................... 24, 82, 94
 
reproductive effects........................................................................................................... 25, 88, 89, 96, 127
 
respiratory effects............................................................................................................................ 23, 27, 92
 
salivation..................................................................................................................... 11, 26, 86, 87, 90, 128
 
solubility ................................................................................................................................... 125, 136, 165
 




thyroid................................................................................................................... 4, 12, 17, 19, 83, 126, 195
 
toxicokinetic............................................................................................................ 14, 21, 16, 101, 130, 131
 
tremors ................................................................ 11, 14, 23, 25, 85, 86, 87, 89, 90, 111, 114, 127, 128, 195
 
tumors ................................................................................................................................................... 91, 96
 
vapor phase ............................................................................................................................................... 165
 
vapor pressure ..................................................................................................................... 16, 125, 136, 165
 
volatilization ............................................................................................................................................. 166
 
 
 
 
 
 
 
 
 
 
 
 
